{
    "questions": [
        {
            "id": "5a70dfd599e2c3af26000006",
            "body": "What is Dysphoric Milk Ejection Reflex?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20443435",
                "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                "http://www.ncbi.nlm.nih.gov/pubmed/21645333"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20443435",
                    "text": "Dysphoric milk ejection reflex (D-MER) results in waves of negative emotions that last from shortly before initial milk ejection until baby starts to feed vigorously Symptoms may decrease by 3 months or they may continue throughout the breastfeeding period.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                    "text": "BACKGROUND Dysphoric milk ejection reflex (D-MER) is characterized by an abrupt dysphoria, or undesirable feeling that occurs with the MER and continues for no more than a few minutes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                    "text": "After milk ejection, the dysphoria vanishes.",
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                    "text": "The dysphoria vanished after each milk ejection.",
                    "offsetInBeginSection": 435,
                    "offsetInEndSection": 483,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                    "text": "All three women described the sudden onset of negative feelings at the initiation of each breastfeeding session.",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                    "text": "As a result, lactation professionals and other providers in the healthcare setting rarely recognize this condition.",
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 719,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21645333",
                    "text": "Dysphoric Milk Ejection Reflex (D-MER) is an abrupt emotional \"drop\" that occurs in some women just before milk release and continues for not more than a few minutes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21645333",
                    "text": "The authors suggest that an abrupt drop in dopamine may occur when milk release is triggered, resulting in a real or relative brief dopamine deficit for affected women.",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 458,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21645333",
                    "text": "Clinicians can support women with D-MER in several ways; often, simply knowing that it is a recognized phenomenon makes the condition tolerable.",
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 603,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21645333",
                    "text": "The brief negative feelings range in severity from wistfulness to self-loathing, and appear to have a physiological cause.",
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 289,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76160a83b0d9ea66000020",
            "body": "Which sequence-based algorithm for branch point prediction has been proposed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28633445"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                    "text": "Results We here propose a novel branch point prediction algorithm that utilizes information on the branch point sequence and the polypyrimidine tract.",
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 559,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                    "text": "An accurate computational model for branch point prediction is therefore an ongoing objective in human genome research.",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 406,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                    "text": "Motivation Although high-throughput sequencing methods have been proposed to identify splicing branch points in the human genome, these methods can only detect a small fraction of the branch points subject to the sequencing depth, experimental cost and the expression level of the mRNA.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 286,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                    "text": "Using experimentally validated data, we demonstrate that our proposed method outperforms existing methods.",
                    "offsetInBeginSection": 560,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                    "text": "Availability and implementation: https://github.com/zhqingit/BPP.",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 732,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                    "text": "Supplementary information Supplementary data are available at Bioinformatics online.",
                    "offsetInBeginSection": 764,
                    "offsetInEndSection": 848,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                    "text": "Contact djguo@cuhk.edu.hk.",
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 761,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9922981d1251d03b000007",
            "body": "How do circRNAs relate to tumorigenesis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28991235",
                "http://www.ncbi.nlm.nih.gov/pubmed/28933584",
                "http://www.ncbi.nlm.nih.gov/pubmed/29034621",
                "http://www.ncbi.nlm.nih.gov/pubmed/29069731",
                "http://www.ncbi.nlm.nih.gov/pubmed/29156822",
                "http://www.ncbi.nlm.nih.gov/pubmed/28279183",
                "http://www.ncbi.nlm.nih.gov/pubmed/28928231",
                "http://www.ncbi.nlm.nih.gov/pubmed/27363013",
                "http://www.ncbi.nlm.nih.gov/pubmed/27040497",
                "http://www.ncbi.nlm.nih.gov/pubmed/27158380"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584",
                    "text": "Circular RNAs (circRNAs) are a type of noncoding RNAs generated from back-splicing, which have been verified to mediate multiple tumorigenesis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621",
                    "text": "intronic circRNAs).",
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 277,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621",
                    "text": "exonic circRNAs) or introns (i.e.",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731",
                    "text": "Our study for the first time demonstrated that Myc transcription factor regulates the expression of circRNAs, adding a novel component of the Myc tumorigenic program and opening a window to investigate the function of certain circRNAs in tumorigenesis.",
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731",
                    "text": "Based on miRNA sponge mechanism, we constructed circRNAs/miRNAs network regulated by Myc, suggesting that circRNAs may widely regulate protein expression through miRNA sponge mechanism.",
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 824,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928231",
                    "text": "CircRNAs are involved in many regulatory bioprocesses of malignance, including cell cycle, tumorigenesis, invasion, metastasis, apoptosis, vascularization, through adsorbing RNA as a sponge, binding to RNA-binding protein (RBP), modulating transcription, or influencing translation.",
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27363013",
                    "text": "Accumulating evidences indicate that long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) play important roles in tumorigenesis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27363013",
                    "text": "CeRNA network inferred that lncRNA H19 and circRNA MYLK could bind competitively with miRNA-29a-3p increasing target gene DNMT3B, VEGFA and ITGB1 expressions.",
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27363013",
                    "text": "Taken together, these results suggested lncRNAs and circRNAs could implicate in the pathogenesis and development of bladder cancer.",
                    "offsetInBeginSection": 1593,
                    "offsetInEndSection": 1724,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27158380",
                    "text": "Overall, our data suggest that circRNAs play an important role in the tumorigenesis of LSCC and may serve as novel and stable biomarkers for the diagnosis and progress of LSCC.",
                    "offsetInBeginSection": 1252,
                    "offsetInEndSection": 1428,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8ee9d1fcd1d6a10c000027",
            "body": "Is there a disease or condition called Exploding Head Syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2769286",
                "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                "http://www.ncbi.nlm.nih.gov/pubmed/1896728",
                "http://www.ncbi.nlm.nih.gov/pubmed/24703829",
                "http://www.ncbi.nlm.nih.gov/pubmed/28622122",
                "http://www.ncbi.nlm.nih.gov/pubmed/20726288",
                "http://www.ncbi.nlm.nih.gov/pubmed/26252589",
                "http://www.ncbi.nlm.nih.gov/pubmed/11309216",
                "http://www.ncbi.nlm.nih.gov/pubmed/24907167"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286",
                    "text": "Fifty patients suffering from the \"exploding head syndrome\" are described.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "text": "Exploding head syndrome episodes were accompanied by clinically significant levels of fear, and a minority (2.80%) experienced it to such a degree that it was associated with clinically significant distress and/or impairment.",
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 1141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "text": "Exploding head syndrome is characterized by the perception of loud noises during sleep-wake or wake-sleep transitions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "text": "Contrary to some earlier theorizing, exploding head syndrome was found to be a relatively common experience in younger individuals.",
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896728",
                    "text": "Attention has recently been drawn to a condition termed the exploding head syndrome, which is characterized by unpleasant, even terrifying sensations of flashing lights and/or sounds during reported sleep.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622122",
                    "text": "This case report describes the first-ever diagnosis of exploding head syndrome in a patient with longstanding epilepsy and novel nocturnal events.",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 292,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726288",
                    "text": "Exploding head syndrome is a rare phenomenon but can be a significant disruption to quality of life.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252589",
                    "text": "When hypnic headache is recognized, it is eminently treatable, while exploding head syndrome is a benign condition with no reported consequences.",
                    "offsetInBeginSection": 705,
                    "offsetInEndSection": 850,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252589",
                    "text": "The rare headache disorder hypnic headache and the exploding head syndrome are also discussed.",
                    "offsetInBeginSection": 610,
                    "offsetInEndSection": 704,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167",
                    "text": "BACKGROUND Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d8a651d1251d03b00001f",
            "body": "What is the BioArchive system?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                "http://www.ncbi.nlm.nih.gov/pubmed/12513800"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "Umbilical cord blood (CB) banks usually freeze and store CB for clinical transplantation using conventional controlled-rate freezer or the automated BioArchive system.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "The experiment used 80\u00a0CB units: 40 were conventionally cryopreserved and the remainder were cryopreserved with a BioArchive.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 481,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "CBs cryopreserved with BioArchive showed significantly higher MNC and CD34+ cell viability, and CFU-GM content than those conventionally cryopreserved.",
                    "offsetInBeginSection": 1312,
                    "offsetInEndSection": 1463,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "CBs cryopreserved with BioArchive were of higher quality than conventionally cryopreserved CBs, and the cause of quality difference might be due to the difference of freezing conditions rather than the TWE effect.",
                    "offsetInBeginSection": 1644,
                    "offsetInEndSection": 1857,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "After thawing, the following measures of CB quality were compared: recovery rates of cell count, cell viability of total nucleated cells (TNCs), mononuclear cells (MNCs), and CD34+ cells, as well as colony-forming unit-granulocyte/macrophage (CFU-GM) content.",
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "Additionally, processing and storage records were reviewed to quantify the number of exposures of CB units at room temperature (transient warming event, TWE), which was analyzed in relation to CB quality.",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 946,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "MNC and CD34+ cell viability were as follows: MNC, 78.2%\u00a0\u00b1\u00a06.8% (conventional), 81.7%\u00a0\u00b1\u00a07.2% (automated); CD34+ cell, 90.6%\u00a0\u00b1\u00a06.9% (conventional), 94.7%\u00a0\u00b1\u00a03.5% (automated).",
                    "offsetInBeginSection": 947,
                    "offsetInEndSection": 1131,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513800",
                    "text": "The aim of this study was to investigate the cryobiological characteristics of placental cord blood (PCB) cryopereserved by using BioArchive auto-preserved liquid nitrogen system (BioArchive system).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513800",
                    "text": "It was concluded that the condition for cryopreservation and thawing of PCB may be harmful to mature cells, and cells with large size, such as granulocyte, but suitable to lymphocyte and monocyte, especially for the cells with small size, such as CD34(+) cells.",
                    "offsetInBeginSection": 1380,
                    "offsetInEndSection": 1641,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513800",
                    "text": "The results showed that the viability of nucleated cells post-thaw was (73.3 +/- 12.5)%, the CD34(+) cell content was (0.3 +/- 0.21)% for pre-freeze PCB and (0.45 +/- 0.36)% for post-t haw PCB.",
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 931,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a723a652dc08e987e00000a",
            "body": "Describe mechanism of action of Romosozumab.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27569204",
                "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
                "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
                "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
                "http://www.ncbi.nlm.nih.gov/pubmed/28428078"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204",
                    "text": "Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
                    "text": "Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.",
                    "offsetInBeginSection": 1091,
                    "offsetInEndSection": 1263,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
                    "text": "Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD).",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 347,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
                    "text": "Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 457,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
                    "text": "Romosozumab holds significant potential, by a novel mechanism of action, to expand our ability to treat osteoporosis.",
                    "offsetInBeginSection": 1325,
                    "offsetInEndSection": 1442,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
                    "text": "Clinical studies of romosozumab have shown that this agent is one of the most potent bone anabolic agents in development to date.",
                    "offsetInBeginSection": 597,
                    "offsetInEndSection": 726,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
                    "text": "EXPERT OPINION Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited.",
                    "offsetInBeginSection": 819,
                    "offsetInEndSection": 1025,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
                    "text": "AREAS COVERED Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials.",
                    "offsetInBeginSection": 540,
                    "offsetInEndSection": 652,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
                    "text": "Similar to preclinical animal studies with sclerostin antibodies, initial clinical studies show that romosozumab increases bone formation and bone mineral density.",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 816,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28428078",
                    "text": "Romosozumab, a humanized monoclonal sclerostin antibody under development for the treatment of osteoporosis, has a unique mechanism of action on bone-increasing bone formation and decreasing bone resorption.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76179d83b0d9ea66000021",
            "body": "Which algorithm has been proposed for efficient storage of WGS variant calls?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27085415",
                "http://www.ncbi.nlm.nih.gov/pubmed/28334390",
                "http://www.ncbi.nlm.nih.gov/pubmed/27964746"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415",
                    "text": "Together, this new selection algorithm and experimental design suggestion significantly reduce the overall cost of variant discovery through WGS experiments, making surveys for causal variants influencing disease and production even more efficient.",
                    "offsetInBeginSection": 1158,
                    "offsetInEndSection": 1406,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415",
                    "text": "We propose a new algorithm, called inverse weight selection (IWS), that preferentially selects individuals based on the cumulative presence of rare frequency haplotypes to maximize the efficiency of WGS surveys.",
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 591,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415",
                    "text": "We also suggest that future surveys focus on sequencing homozygous haplotype segments as a first pass to achieve a 50% reduction in cost with an added benefit of phasing variant calls efficiently.",
                    "offsetInBeginSection": 961,
                    "offsetInEndSection": 1157,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334390",
                    "text": "Here we introduce a new WGS variant data format implemented in the R/Bioconductor package 'SeqArray' for storing variant calls in an array-oriented manner which provides the same capabilities as VCF, but with multiple high compression options and data access using high-performance parallel computing.",
                    "offsetInBeginSection": 377,
                    "offsetInEndSection": 678,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334390",
                    "text": "When used in conjunction with R/Bioconductor packages, the SeqArray package provides users a flexible, feature-rich, high-performance programming environment for analysis of WGS variant data.",
                    "offsetInBeginSection": 1159,
                    "offsetInEndSection": 1350,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                    "text": "METHODS We developed an algorithm that analyzes the patterns of variant calls in the 178 structurally variable regions of the GRCh38 genome assembly, and infers whether a given sample is most likely to contain sequences from the primary assembly, an alternate locus, or their heterozygous combination at each of these 178 regions.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 673,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                    "text": "In WGS analysis, this results in characteristic and recognizable patterns of variant calls at positions that we term alignable scaffold-discrepant positions (ASDPs).",
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                    "text": "CONCLUSIONS Our algorithm uses the information contained in the 178 structurally variable regions of the GRCh38 genome assembly to avoid spurious variant calls in cases where samples contain an alternate locus rather than the corresponding segment of the primary assembly.",
                    "offsetInBeginSection": 1589,
                    "offsetInEndSection": 1861,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                    "text": "The new model offers opportunities to improve the technical validity of variant calling in whole-genome sequencing (WGS).",
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                    "text": "RESULTS We show that stretches of sequences that are largely but not entirely identical between the primary assembly and an alternate locus can result in multiple variant calls against regions of the primary assembly.",
                    "offsetInBeginSection": 777,
                    "offsetInEndSection": 994,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9924ea1d1251d03b000008",
            "body": "What is the association of circular RNA to breast cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28933584",
                "http://www.ncbi.nlm.nih.gov/pubmed/28744405",
                "http://www.ncbi.nlm.nih.gov/pubmed/27829232",
                "http://www.ncbi.nlm.nih.gov/pubmed/28739726",
                "http://www.ncbi.nlm.nih.gov/pubmed/28349836",
                "http://www.ncbi.nlm.nih.gov/pubmed/29109417",
                "http://www.ncbi.nlm.nih.gov/pubmed/28803498",
                "http://www.ncbi.nlm.nih.gov/pubmed/27965971",
                "http://www.ncbi.nlm.nih.gov/pubmed/29045858",
                "http://www.ncbi.nlm.nih.gov/pubmed/28484086"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405",
                    "text": "Overall, results identified a new functional circ-ABCB10 in breast cancer tumorigenesis, and reveal the important regulatory role of circ-ABCB10 through sponging miR-1271, providing a novel insight for breast cancer pathogenesis.",
                    "offsetInBeginSection": 975,
                    "offsetInEndSection": 1204,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405",
                    "text": "Circular RNA (circRNA) is a key regulator in the development and progression of human cancers, however its role in breast cancer tumorigenesis is not well understood.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405",
                    "text": "Finally, miR-1271 rescued the function of circ-ABCB10 on breast cancer cells, confirming the sponge effect of circ-ABCB10 on miR-1271.",
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 974,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28349836",
                    "text": "Circular RNA, a class of non-coding RNA, is a new group of RNAs and is related to tumorigenesis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29109417",
                    "text": "Overall, our results support the hypothesis of circular RNAs representing a novel factor in the dynamic epigenetic network of gene regulation, which involves the microRNAs, its mRNAs targets, and the circular RNAs-derived genes.",
                    "offsetInBeginSection": 937,
                    "offsetInEndSection": 1165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29109417",
                    "text": "Previous studies have demonstrated that some circular RNAs act as microRNA sponges, and are associated with cellular proliferation in cancer.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498",
                    "text": "Additionally, we discovered a regulatory role of the circ_0006528-miR-7-5p-Raf1 axis in ADM-resistant breast cancer.",
                    "offsetInBeginSection": 825,
                    "offsetInEndSection": 941,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498",
                    "text": "CONCLUSION These results revealed that circRNAs may play a role in breast cancer chemoresistance and that hsa_circ_0006528 might be a promising candidate for further functional analysis.",
                    "offsetInBeginSection": 944,
                    "offsetInEndSection": 1130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498",
                    "text": "AIM We aimed to identify circular RNAs (circRNAs) associated with breast cancer chemoresistance.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27965971",
                    "text": "Circular RNAs are nontranslated RNAs, typically nonpolyadenylated, with a resistance to exonucleases that gives them the ability to be more stable than the common linear RNA isoforms.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a95765bfcd1d6a10c000028",
            "body": "What part of what body organ controls the circadian clock?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23704227",
                "http://www.ncbi.nlm.nih.gov/pubmed/21969583",
                "http://www.ncbi.nlm.nih.gov/pubmed/21763748",
                "http://www.ncbi.nlm.nih.gov/pubmed/24013905",
                "http://www.ncbi.nlm.nih.gov/pubmed/26144255",
                "http://www.ncbi.nlm.nih.gov/pubmed/20448639",
                "http://www.ncbi.nlm.nih.gov/pubmed/11743124",
                "http://www.ncbi.nlm.nih.gov/pubmed/28779094",
                "http://www.ncbi.nlm.nih.gov/pubmed/28707700",
                "http://www.ncbi.nlm.nih.gov/pubmed/27385482"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704227",
                    "text": "Clock genes control circadian rhythms both centrally, in the suprachiasmatic nucleus of the brain and peripherally, within every organ of the body.",
                    "offsetInBeginSection": 589,
                    "offsetInEndSection": 736,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21763748",
                    "text": "humoral factors, activity and body temperature rhythms) or, trough the intrinsic renal circadian clock.",
                    "offsetInBeginSection": 1115,
                    "offsetInEndSection": 1218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24013905",
                    "text": "Furthermore, this intestinal clock controls the expression of key cell cycle regulators, such as cdc2, wee1, p21, PCNA and cdk2, but only weakly influences cyclin B1, cyclin B2 and cyclin E1 expression.",
                    "offsetInBeginSection": 620,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24013905",
                    "text": "The circadian clock controls cell proliferation in a number of healthy tissues where cell renewal and regeneration are critical for normal physiological function.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26144255",
                    "text": "We conclude that the circadian clock acts to gate auxin signalling during LR development to facilitate organ emergence.",
                    "offsetInBeginSection": 773,
                    "offsetInEndSection": 892,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11743124",
                    "text": "The rhythmic pattern of PHYA expression is not organ autonomous but depends upon the physical continuity or isolation of the rhythmic tissues, consistent with the presence of a transmitted signal that controls the overt expression of circadian rhythms without necessarily affecting the underlying clock.",
                    "offsetInBeginSection": 1230,
                    "offsetInEndSection": 1533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11743124",
                    "text": "Phytochrome A (phyA) provides light input signals to entrain the circadian clock.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 249,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28779094",
                    "text": "Deficiency of an essential clock gene Bmal1 impairs day-night variations of osmotic pressure gradient in the inner medulla, suggesting that circadian clocks in the medulla part of the kidney may regulate the circadian rhythm of cortico-medullary osmotic pressure gradient, and may contribute physiological day-night rhythm of urination.",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1352,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707700",
                    "text": "The suprachiasmatic nucleus houses the central circadian clock and is characterized by the timely regulated expression of clock genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27385482",
                    "text": "Recently, we came to appreciate that the formation and metabolic functions of BAT, a key organ for body temperature maintenance, are under an orchestrated circadian clock regulation.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 511,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa4f47cd6d6b54f7900000a",
            "body": "When is 16S rRNA Gene Sequencing used?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/14535548",
                "http://www.ncbi.nlm.nih.gov/pubmed/26770469",
                "http://www.ncbi.nlm.nih.gov/pubmed/27842515",
                "http://www.ncbi.nlm.nih.gov/pubmed/28940494",
                "http://www.ncbi.nlm.nih.gov/pubmed/25646627",
                "http://www.ncbi.nlm.nih.gov/pubmed/21240067",
                "http://www.ncbi.nlm.nih.gov/pubmed/21121044",
                "http://www.ncbi.nlm.nih.gov/pubmed/27077030",
                "http://www.ncbi.nlm.nih.gov/pubmed/18353221",
                "http://www.ncbi.nlm.nih.gov/pubmed/17037387"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26770469",
                    "text": "Together, these data present 16S rRNA gene sequencing as a novel VAP diagnosis tool that will further enable pathogen-specific treatment of VAP.",
                    "offsetInBeginSection": 1588,
                    "offsetInEndSection": 1732,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27842515",
                    "text": "A new alternative for full-length bacterial 16S rRNA gene sequencing is offered by PacBio single molecule, real-time (SMRT) technology.",
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25646627",
                    "text": "With the rapid developments in genome sequencing technologies, the focus has shifted towards the sequencing of hypervariable regions of 16S rRNA gene instead of full length gene sequencing.",
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 300,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21240067",
                    "text": "RESULTS Conventional PCR based 16S rRNA gene sequencing and the alignment of the isolate 16S rRNA gene sequence with reference sequences accurately identified 100% of clinical strains of aerobic Actinomycetes.",
                    "offsetInBeginSection": 671,
                    "offsetInEndSection": 880,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21121044",
                    "text": "16S rRNA gene sequencing has been widely used for probing the species structure of a variety of environmental bacterial communities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27077030",
                    "text": "To assess variability between laboratories in sequencing 16S rRNA, six laboratories sequenced the gene encoding the 16S rRNA from Escherichia coli O157:H7 strain EDL933 and Listeria monocytogenes serovar 4b strain NCTC11994.",
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27077030",
                    "text": "The combination of PCR amplification and 16S ribosomal RNA gene (16S rRNA) sequencing has revolutionized bacteriology by enabling rapid identification, frequently without the need for culture.",
                    "offsetInBeginSection": 217,
                    "offsetInEndSection": 409,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18353221",
                    "text": "CONCLUSION By improving the extract DNA method, selecting suitable primer, developing the gene amplification and sequencing procedure, direct 16S rRNA gene sequencing can identify the pathogens from clinical specimens.",
                    "offsetInBeginSection": 1652,
                    "offsetInEndSection": 1870,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17037387",
                    "text": "To classify mycobacteria not identified by DNA-DNA hybridization (DDH) using sequencing of rpoB and 16S rRNA gene.",
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 221,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17037387",
                    "text": "Even though sequencing of rpoB and 16S rRNA gene was utilized, it was impossible to classify M. tuberculosis complex, M. avium family, M. marinum and M. ulcerans, and M. fortitum subsp.",
                    "offsetInBeginSection": 842,
                    "offsetInEndSection": 1027,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a723cd12dc08e987e00000b",
            "body": "Can CD55 deficiency cause thrombosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22696589",
                "http://www.ncbi.nlm.nih.gov/pubmed/28657829"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696589",
                    "text": "Intra-abdominal thrombosis is a complication of paroxysmal nocturnal hemoglobinuria (PNH).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696589",
                    "text": "Data of this study indicate that the PNH defect as detected with CD55, CD59, and CD16 is not an important cause of intra-abdominal thrombosis in northwestern India.",
                    "offsetInBeginSection": 819,
                    "offsetInEndSection": 983,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696589",
                    "text": "This was due to CD55 deficiency on red blood cells and CD16 deficiency on the granulocytes.",
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 755,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696589",
                    "text": "Flowcytometry with glycosylphosphatidyl inositol-anchored proteins (GPI-AP)-CD55, -CD59, and -CD16 was performed on all patients and controls to assess the prevalence of deficiencies and PNH-type phenotype clone size.",
                    "offsetInBeginSection": 365,
                    "offsetInEndSection": 582,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22696589",
                    "text": "There is scarcity of data on cases presenting with thrombosis in whom PNH is the predisposing factor.",
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 192,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657829",
                    "text": "CONCLUSIONS CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (the CHAPLE syndrome) is caused by abnormal complement activation due to biallelic loss-of-function mutations in CD55.",
                    "offsetInBeginSection": 1242,
                    "offsetInEndSection": 1479,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657829",
                    "text": "RESULTS We identified homozygous loss-of-function mutations in the gene encoding CD55 (decay-accelerating factor), which lead to loss of protein expression.",
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 894,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657829",
                    "text": "Genetic reconstitution of CD55 or treatment with a complement-inhibitory therapeutic antibody reversed abnormal complement activation.",
                    "offsetInBeginSection": 1105,
                    "offsetInEndSection": 1239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657829",
                    "text": "Costimulatory function and cytokine modulation by CD55 were defective.",
                    "offsetInBeginSection": 1034,
                    "offsetInEndSection": 1104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657829",
                    "text": "METHODS We studied 11 patients with abdominal pain and diarrhea caused by early-onset protein-losing enteropathy with primary intestinal lymphangiectasia, edema due to hypoproteinemia, malabsorption, and less frequently, bowel inflammation, recurrent infections, and angiopathic thromboembolic disease; the disorder followed an autosomal recessive pattern of inheritance.",
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7633a89e632bc066000002",
            "body": "What is the purpose of the Tabix tool?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21208982",
                "http://www.ncbi.nlm.nih.gov/pubmed/29137598"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982",
                    "text": "Tabix is implemented as a free command-line tool as well as a library in C, Java, Perl and Python.",
                    "offsetInBeginSection": 335,
                    "offsetInEndSection": 433,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982",
                    "text": "UNLABELLED Tabix is the first generic tool that indexes position sorted files in TAB-delimited formats such as GFF, BED, PSL, SAM and SQL export, and quickly retrieves features overlapping specified regions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982",
                    "text": "Tabix features include few seek function calls per query, data compression with gzip compatibility and direct FTP/HTTP access.",
                    "offsetInBeginSection": 208,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982",
                    "text": "It is particularly useful for manually examining local genomic features on the command line and enables genome viewers to support huge data files and remote custom tracks over networks.",
                    "offsetInBeginSection": 434,
                    "offsetInEndSection": 619,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "CONCLUSIONS GFF3sort is a novel tool to sort GFF3 files for tabix indexing.",
                    "offsetInBeginSection": 942,
                    "offsetInEndSection": 1017,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "The latest version of JBrowse supports rendering sorted GFF3 files indexed by tabix, a novel strategy that is more convenient than the original conversion process.",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 310,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "RESULTS We developed GFF3sort, a script to sort GFF3 files for tabix indexing.",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "BACKGROUND The traditional method of visualizing gene annotation data in JBrowse is converting GFF3 files to JSON format, which is time-consuming.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "We anticipate that GFF3sort will be useful to help with genome annotation data processing and visualization.",
                    "offsetInBeginSection": 1018,
                    "offsetInEndSection": 1126,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "Specifically designed for JBrowse rendering, GFF3sort can properly deal with the order of features that have the same chromosome and start position, either by remembering their original orders or by conducting parent-child topology sorting.",
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 781,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9929ed1d1251d03b000009",
            "body": "What is maternal spindle transfer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27973714",
                "http://www.ncbi.nlm.nih.gov/pubmed/28429249",
                "http://www.ncbi.nlm.nih.gov/pubmed/28852557",
                "http://www.ncbi.nlm.nih.gov/pubmed/28683668",
                "http://www.ncbi.nlm.nih.gov/pubmed/29121011"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714",
                    "text": "Maternal spindle transfer is, in principle, morally permissible, but only when we have beforehand preselected a sperm and an egg for our reproductive purpose.",
                    "offsetInBeginSection": 992,
                    "offsetInEndSection": 1150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714",
                    "text": "I conclude that, according to a Habermasian perspective on prenatal genetic manipulation, maternal spindle transfer (without using a preselected sperm and egg) and pronuclear transfer are morally impermissible.",
                    "offsetInBeginSection": 781,
                    "offsetInEndSection": 991,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714",
                    "text": "I investigate, specifically, the moral permissibility of employing pronuclear transfer and maternal spindle transfer.",
                    "offsetInBeginSection": 663,
                    "offsetInEndSection": 780,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714",
                    "text": "These findings are relevant for bioconservatives, both for those who hold a Habermasian stance and for those who hold something akin to a Habermasian stance, because they answer the question: what should bioconservatives do regarding mitochondrial replacement techniques?",
                    "offsetInBeginSection": 1151,
                    "offsetInEndSection": 1422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28429249",
                    "text": "This paper examines whether there are moral differences between the mitochondrial replacement techniques that have been recently developed in order to help women afflicted by mitochondrial DNA diseases to have genetically related children\u00a0absent such conditions: maternal spindle transfer (MST) and pronuclear transfer (PNT).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28852557",
                    "text": "News about the first baby born after a mitochondrial replacement technique (MRT; specifically maternal spindle transfer) broke on September 27, 2016 and, in a matter of hours, went global.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683668",
                    "text": "In the discussions leading up to the enactment of the UK Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, it was repeatedly emphasised, by many commentators, that maternal spindle transfer (MST) and pronuclear transfer (PNT) did not give rise to children who could be considered as having three or more parents.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29121011",
                    "text": "MRT aims to avoid pathogenic mtDNA transmission between generations by maternal spindle transfer, pronuclear transfer or polar body transfer: all involve the transfer of nuclear DNA from an egg or zygote containing defective mitochondria to a corresponding egg or zygote with normal mitochondria.",
                    "offsetInBeginSection": 592,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29121011",
                    "text": "Because mitochondrial diseases are incurable, attention has focused on limiting the inheritance of pathogenic mtDNA by mitochondrial replacement therapy (MRT).",
                    "offsetInBeginSection": 432,
                    "offsetInEndSection": 591,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29121011",
                    "text": "Mitochondria are essential cytoplasmic organelles that generate energy (ATP) by oxidative phosphorylation and mediate key cellular processes such as apoptosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a96c74cfcd1d6a10c000029",
            "body": "What illness is transmitted by the Lone Star Tick, Amblyomma americanum?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                "http://www.ncbi.nlm.nih.gov/pubmed/19054615",
                "http://www.ncbi.nlm.nih.gov/pubmed/19874183",
                "http://www.ncbi.nlm.nih.gov/pubmed/18452807",
                "http://www.ncbi.nlm.nih.gov/pubmed/20380308",
                "http://www.ncbi.nlm.nih.gov/pubmed/19378409",
                "http://www.ncbi.nlm.nih.gov/pubmed/18447622",
                "http://www.ncbi.nlm.nih.gov/pubmed/27729288",
                "http://www.ncbi.nlm.nih.gov/pubmed/23637969",
                "http://www.ncbi.nlm.nih.gov/pubmed/20496596"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "Amblyomma americanum, also known as the lone star tick, is found in much of the eastern United States.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "In addition to others, species of Rickettsia, Ehrlichia, and Borrelia are all transmitted by the lone star tick.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 372,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19874183",
                    "text": "Borrelia lonestari, which has been suggested as a possible causative agent of southern tick-associated rash illness, naturally infects white-tailed deer (WTD; Odocoileus virginianus) and is transmitted by the lone star tick (Amblyomma americanum).",
                    "offsetInBeginSection": 98,
                    "offsetInEndSection": 345,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18452807",
                    "text": "Lyme-like illness (also known as southern tick-associated rash illness [STARI] or Masters disease) is vectored by the Lone Star tick (Amblyomma americanum).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20380308",
                    "text": "The lone star tick, Amblyomma americanum (Acari: Ixodidae), is commonly reported from people and animals throughout the eastern U.S. and is associated with transmission of a number of emerging diseases.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447622",
                    "text": "Amblyomma americanum, the lone star tick, comprised 99.6% of 6,502 specimens collected in suburban landscapes.",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 478,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447622",
                    "text": "Eleven of 25 lone star tick pools tested were infected with \"Rickettsia amblyommii,\" an informally named SFGR.",
                    "offsetInBeginSection": 623,
                    "offsetInEndSection": 733,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729288",
                    "text": "Monocytic ehrlichiosis in people caused by the intracellular bacterium, Ehrlichia chaffeensis, is an emerging infectious disease transmitted by the lone star tick, Amblyomma americanum.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637969",
                    "text": "Here we sought to characterize the growth characteristics and genome of Lone Star virus (LSV), an unclassified bunyavirus originally isolated from the lone star tick Amblyomma americanum.",
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 549,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20496596",
                    "text": "In this study, we evaluated Amblyomma americanum (lone star tick) in Mississippi for the presence of Ehrlichia chaffeensis, causative agent of human monocytic ehrlichiosis; Ehrlichia ewingii, causative agent of human and canine granulocytic ehrlichiosis; Borrelia lonestari, putative agent of southern tick-associated rash illness; Francisella tularensis, the agent of tularemia; and Rickettsia spp., particularly R. amblyommii, a suspected pathogen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa50086d6d6b54f7900000c",
            "body": "Which is the function of ubiquilins?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24674348",
                "http://www.ncbi.nlm.nih.gov/pubmed/19398896",
                "http://www.ncbi.nlm.nih.gov/pubmed/22628307",
                "http://www.ncbi.nlm.nih.gov/pubmed/18307982",
                "http://www.ncbi.nlm.nih.gov/pubmed/26152284",
                "http://www.ncbi.nlm.nih.gov/pubmed/27345149",
                "http://www.ncbi.nlm.nih.gov/pubmed/17603015"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674348",
                    "text": "BACKGROUND Ubiquilins are proteins that function as ubiquitin receptors in eukaryotes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896",
                    "text": "Ubiquilins (UBQLN), a family of adaptor proteins with partial homology with ubiquitin, are proposed to facilitate proteasomal degradation of ubiquitinated substrates.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896",
                    "text": "This protective function requires the essential autophagy regulators, Atg5 and Atg7.",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896",
                    "text": "The ubiquitin-associated (UBA) domain of UBQLN is required for its association with autophagosomes as well as for its prosurvival functions.Remarkably, during starvation-induced autophagy, UBQLN promotes the fusion of early autophagosomes with lysosomes.Overall, this work illustrates an important function for UBQLN in cell survival during nutrient starvation, which requires a newly recognized function for UBQLN in autophagosome maturation.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 934,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628307",
                    "text": "Ubiquilins, a family of ubiquitin-binding proteins, are involved in all protein degradation pathways.",
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18307982",
                    "text": "Our data suggest that Herp binding to ubiquilin proteins plays an important role in the ERAD pathway and that ubiquilins are specifically involved in degradation of only a subset of ubiquitinated targets, including Herp-dependent ERAD substrates.",
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1111,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18307982",
                    "text": "ER-associated protein degradation (ERAD) is a protein quality control system of ER, which eliminates misfolded proteins by proteasome-dependent degradation and ensures export of only properly folded proteins from ER.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152284",
                    "text": "Ubiquilin-2 inclusions co-localized with ubiquitin, p62/SQSTM, optineurin, and occasionally TDP-43, but were negative for \u03b1-synuclein, neurofilament, tau, and FUS.",
                    "offsetInBeginSection": 1077,
                    "offsetInEndSection": 1241,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152284",
                    "text": "UBQLN2 encodes for ubiquilin-2, a member of the ubiquitin-like protein family which facilitates delivery of ubiquitinated proteins to the proteasome for degradation.",
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 300,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345149",
                    "text": "Loss of Ubiquilins by genetic ablation or sequestration in polyglutamine aggregates leads to accumulation of non-inserted mitochondrial membrane protein precursors.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 883,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7240aa2dc08e987e00000d",
            "body": "List two human monoclonal antibodies against Clostridium difficile toxins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20089970",
                "http://www.ncbi.nlm.nih.gov/pubmed/23629713",
                "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
                "http://www.ncbi.nlm.nih.gov/pubmed/1900059",
                "http://www.ncbi.nlm.nih.gov/pubmed/16966409",
                "http://www.ncbi.nlm.nih.gov/pubmed/9237345",
                "http://www.ncbi.nlm.nih.gov/pubmed/27336843",
                "http://www.ncbi.nlm.nih.gov/pubmed/25486992",
                "http://www.ncbi.nlm.nih.gov/pubmed/1378062"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970",
                    "text": "CONCLUSIONS The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection.",
                    "offsetInBeginSection": 1561,
                    "offsetInEndSection": 1723,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970",
                    "text": "METHODS We performed a randomized, double-blind, placebo-controlled study of two neutralizing, fully human monoclonal antibodies against C. difficile toxins A (CDA1) and B (CDB1).",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 327,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713",
                    "text": "C. difficile mediates diarrhea and colitis by releasing two toxins, toxin A and toxin B.",
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713",
                    "text": "Recent studies indicated that human monoclonal antibodies (MAbs) against toxins A and B reduce their cytotoxic and secretory activities and prevent CDI in hamsters.",
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 617,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1900059",
                    "text": "The pathogenicity of Clostridium difficile is due to the production of two toxins (toxins A and B).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1900059",
                    "text": "These data show that passive immunity induced by monoclonal antibodies against toxin A was effective against pseudomembranous cecitis.",
                    "offsetInBeginSection": 826,
                    "offsetInEndSection": 960,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16966409",
                    "text": "Clostridium difficile is the leading cause of nosocomial antibiotic-associated diarrhea, and recent outbreaks of strains with increased virulence underscore the importance of identifying novel approaches to treat and prevent relapse of Clostridium difficile-associated diarrhea (CDAD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9237345",
                    "text": "A specific monoclonal antibody against toxin A from Clostridium difficile was generated that did not show thermolabile binding.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27336843",
                    "text": "This study describes the protective effects conferred by novel neutralizing anti-toxin monoclonal antibodies against C. difficile toxins and their potential as therapeutic agents in treating CDI.",
                    "offsetInBeginSection": 1358,
                    "offsetInEndSection": 1553,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1378062",
                    "text": "Five mouse monoclonal antibodies (MAbs) against Clostridium difficile toxin B have been raised and characterized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76344e9e632bc066000003",
            "body": "Which algorithms are used for compression of SAM files?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29046896",
                "http://www.ncbi.nlm.nih.gov/pubmed/22164252",
                "http://www.ncbi.nlm.nih.gov/pubmed/26026138",
                "http://www.ncbi.nlm.nih.gov/pubmed/27540265",
                "http://www.ncbi.nlm.nih.gov/pubmed/23533605"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896",
                    "text": "In this work we propose a new reference-based compressor for SAM files, which can accommodate different levels of compression, based on the specific needs of the user.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 515,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896",
                    "text": "These files are large (on the order of terabytes), which necessitates compression.",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 347,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164252",
                    "text": "In this paper, we present SAMZIP, a specialized encoding scheme, for sequence alignment data in SAM (Sequence Alignment/Map) format, which improves the compression ratio of existing compression tools available.",
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164252",
                    "text": "In recent years, some research has been done to find efficient compression algorithms to reduce the size of various sequencing data.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 319,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26026138",
                    "text": "To facilitate this effort, we propose a new lossy compressor for the quality values presented in genomic data files (e.g.",
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 352,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26026138",
                    "text": "FASTQ and SAM files), which comprise roughly half of the storage space (in the uncompressed domain).",
                    "offsetInBeginSection": 353,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540265",
                    "text": "RESULTS We describe CSAM (Compressed SAM format), a compression approach offering lossless and lossy compression for SAM files.",
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 486,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540265",
                    "text": "The structures and techniques proposed are suitable for representing SAM files, as well as supporting fast access to the compressed information.",
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 631,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533605",
                    "text": "These are compared against existing algorithms for both reference based compression (CRAM, Goby) and non-reference based compression (DSRC, BAM) and other recently published competition entries (Quip, SCALCE).",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 542,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533605",
                    "text": "Storage and transmission of the data produced by modern DNA sequencing instruments has become a major concern, which prompted the Pistoia Alliance to pose the SequenceSqueeze contest for compression of FASTQ files.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a992b371d1251d03b00000a",
            "body": "What does MetaHIT stand for?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24949196",
                "http://www.ncbi.nlm.nih.gov/pubmed/25291122",
                "http://www.ncbi.nlm.nih.gov/pubmed/24416266",
                "http://www.ncbi.nlm.nih.gov/pubmed/28357466"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24949196",
                    "text": "RESULTS IN THIS STUDY WE CONDUCTED A SYSTEMATIC COMPARISON OF THE DNA EXTRACTION METHODS USED BY THE TWO MAJOR COLLABORATIVE EFFORTS: The European MetaHIT and the American Human Microbiome Project (HMP).",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 575,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24949196",
                    "text": "While eukaryotic DNA was most efficiently extracted by the MetaHIT protocol, DNA from bacteria within the Bacteroidetes phylum was most efficiently extracted by the HMP protocol.",
                    "offsetInBeginSection": 755,
                    "offsetInEndSection": 933,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24949196",
                    "text": "Application of next generation sequencing for mapping of bacterial phylogeny and function has opened new doors to this field of research.",
                    "offsetInBeginSection": 108,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24949196",
                    "text": "CONCLUSIONS Whereas it is comforting that the inter-individual variation clearly exceeded the variation resulting from choice of extraction method, our data highlight the challenge of comparing data across studies applying different methodologies.",
                    "offsetInBeginSection": 936,
                    "offsetInEndSection": 1183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25291122",
                    "text": "Two large-scale initiatives of major funding agencies aimed at deciphering the structure and function of the human gut microbiota, namely the NIH's Human Microbiome project and the European MetaHIT project, finalized their research program in 2012.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 248,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266",
                    "text": "In this paper, we use publicly available data from the Human Microbiome Project (HMP) and MetaHIT, both surveys of healthy adults that include obese individuals, plus two smaller studies that specifically examined lean versus obese adults.",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 658,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266",
                    "text": "We conclude that there is no simple taxonomic signature of obesity in the microbiota of the human gut.",
                    "offsetInBeginSection": 1467,
                    "offsetInEndSection": 1569,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266",
                    "text": "However, human and animal-model studies have yielded conflicting results about the precise nature of associations between microbiome composition and obesity.",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266",
                    "text": "While we confirm the previously published small, but statistically significant, differences in phylum-level taxonomic composition between lean and obese individuals in several cohorts, we find no association between BMI and taxonomic composition of stool microbiomes in the larger HMP and MetaHIT datasets.",
                    "offsetInBeginSection": 944,
                    "offsetInEndSection": 1250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28357466",
                    "text": "The goals of the Human Microbiome Project and MetaHIT include comparative studies of healthy and diseased individuals.",
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 583,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a981dd0fcd1d6a10c00002e",
            "body": "Are sleep apnea and snoring associated with cardiac arrhythmias?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7774322",
                "http://www.ncbi.nlm.nih.gov/pubmed/2669355",
                "http://www.ncbi.nlm.nih.gov/pubmed/3106890",
                "http://www.ncbi.nlm.nih.gov/pubmed/1630643"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322",
                    "text": "We conclude that patients with sleep apnea as a group have higher prevalence of cardiac arrhythmias than nonapneic patients and that snoring alone, without concomitant sleep apnea, is not associated with increased frequency of cardiac arrhythmias.",
                    "offsetInBeginSection": 1446,
                    "offsetInEndSection": 1693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322",
                    "text": "We investigated the frequency of cardiac arrhythmias in patients suspected of having sleep apnea, and related them to the severity of apnea, snoring, and nocturnal hypoxemia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322",
                    "text": "We found 58 percent prevalence of arrhythmias in patients with sleep apnea (apnea/hypopnea index = AHI > 10), vs 42 percent in nonapneic controls (chi 2 = 16.7, p < 0.0001).",
                    "offsetInBeginSection": 486,
                    "offsetInEndSection": 659,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355",
                    "text": "Sleep apnea and obstructive snoring are sleep related breathing disorders (SRBD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355",
                    "text": "It becomes serious if it leads as the independent SRBD \"obstructive snoring\" to a continuous oxygen desaturation and a sleep disturbance or, if in cases of sleep apnea a postapnoic snoring is concerned.",
                    "offsetInBeginSection": 344,
                    "offsetInEndSection": 546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355",
                    "text": "In relation with other symptoms and findings associated with apnea it is always an indication for the examination for sleep apnea and obstructive snoring.",
                    "offsetInBeginSection": 1211,
                    "offsetInEndSection": 1365,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355",
                    "text": "Most frequent symptoms and findings are: hypertension, loud and irregular snoring, daytime sleepiness and nocturnal cardiac arrhythmias.",
                    "offsetInBeginSection": 1017,
                    "offsetInEndSection": 1153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3106890",
                    "text": "Severe snoring may be associated with pulmonary and systemic hypertension, secondary polycythemia, and cardiac arrhythmias.",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1630643",
                    "text": "Increasing evidence suggests that snoring and sleep apnea are associated with cerebrovascular diseases.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1630643",
                    "text": "Potential mediators among snoring, obstructive sleep apneas, and stroke include cardiac arrhythmias and other hemodynamic disturbances, increased levels of catecholamines, and disturbances in cerebral blood flow caused by sleep apneas, as well as hypoxemic periods that may potentiate atherosclerosis.",
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 999,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa80873d6d6b54f79000013",
            "body": "List ribosomal biogenesis proteins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18773413",
                "http://www.ncbi.nlm.nih.gov/pubmed/19878869",
                "http://www.ncbi.nlm.nih.gov/pubmed/28685141",
                "http://www.ncbi.nlm.nih.gov/pubmed/20554519",
                "http://www.ncbi.nlm.nih.gov/pubmed/25088252",
                "http://www.ncbi.nlm.nih.gov/pubmed/20061553",
                "http://www.ncbi.nlm.nih.gov/pubmed/23169665",
                "http://www.ncbi.nlm.nih.gov/pubmed/29143558",
                "http://www.ncbi.nlm.nih.gov/pubmed/20188109",
                "http://www.ncbi.nlm.nih.gov/pubmed/28986221"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773413",
                    "text": "One newly identified key regulator for ribosomal biogenesis and translation is the oncoprotein c-Myc, whose aberrantly excessive level and activity are highly associated with human cancers, too.",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 567,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19878869",
                    "text": "The ribosomal protein-MDM2-p53 signaling pathway provides a molecular switch that may constitute a surveillance network monitoring the integrity of ribosomal biogenesis.",
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 743,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28685141",
                    "text": "These factors include snoRNPs, nucleases, ATPases, GTPases, RNA helicases, and a vast list of proteins with no predicted enzymatic activity.",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20061553",
                    "text": "In a screen for Arabidopsis thaliana mutants affected in the trafficking of C-terminal VSD containing proteins, we isolated the ribosomal biogenesis mutant rpl4a characterized by its partial secretion of vacuolar targeted proteins and a plethora of developmental phenotypes derived from its aberrant auxin responses.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20061553",
                    "text": "We propose that the influence of auxin on ribosomal biogenesis acts as a regulatory mechanism for auxin-mediated developmental processes, and we demonstrate the involvement of this regulatory mechanism in the sorting of vacuolar targeted proteins in Arabidopsis.",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 1004,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23169665",
                    "text": "Impairment of ribosomal biogenesis can activate the p53 protein independently of DNA damage.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143558",
                    "text": "This ribosome biogenesis stress pathway activates p53 through sequestration of MDM2 by a subset of ribosomal proteins (RPs), thereby stabilizing p53.",
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 519,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143558",
                    "text": "Here, we identify human HEATR1, as a nucleolar protein which positively regulates ribosomal RNA (rRNA) synthesis.",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 633,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20188109",
                    "text": "Ribosome biogenesis is facilitated by a growing list of assembly cofactors, including helicases, GTPases, chaperones, and other proteins, but the specific functions of many of these assembly cofactors are still unclear.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28986221",
                    "text": "Unlike most ribosomal proteins, which are incorporated into pre-ribosomal particles during early steps of ribosome biogenesis in the nucleus, P-stalk proteins are attached to the 60S subunit in the cytoplasm.",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 627,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7339372dc08e987e000013",
            "body": "List drugs that are included in the Vosevi polypill.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24561141",
                "http://www.ncbi.nlm.nih.gov/pubmed/27818251",
                "http://www.ncbi.nlm.nih.gov/pubmed/20549577",
                "http://www.ncbi.nlm.nih.gov/pubmed/27538505",
                "http://www.ncbi.nlm.nih.gov/pubmed/16783994",
                "http://www.ncbi.nlm.nih.gov/pubmed/21205325",
                "http://www.ncbi.nlm.nih.gov/pubmed/28341983",
                "http://www.ncbi.nlm.nih.gov/pubmed/26390808",
                "http://www.ncbi.nlm.nih.gov/pubmed/26747390",
                "http://www.ncbi.nlm.nih.gov/pubmed/29127755"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251",
                    "text": "Polypill is a medication designed for preventing heart attacks through a combination of drugs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251",
                    "text": "This paper investigates a new methodology for the control dosage of a polypill recently reported containing hydrochlorothiazide, amlodipine, losartan and simvastatin in a 12.5/2.5/25/40 weight ratio.",
                    "offsetInBeginSection": 425,
                    "offsetInEndSection": 624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251",
                    "text": "Amlodipine, losartan and simvastatin were released from the polypill-MSN-41 system in a controlled way.",
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20549577",
                    "text": "The Indian Polycap Study (TIPS) was the first to systematically test the clinical application of the polypill; it included ramipril, hydrochlorothiazide, atenolol, aspirin, and simvastatin.",
                    "offsetInBeginSection": 455,
                    "offsetInEndSection": 644,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16783994",
                    "text": "This \"Polypill\" should be a combination of three antihypertensive drugs associated to aspirin, a statin and folic acid.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21205325",
                    "text": "CONCLUSIONS We successfully completed a Polypill feasibility trial in Sri Lanka.",
                    "offsetInBeginSection": 1806,
                    "offsetInEndSection": 1886,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26390808",
                    "text": "The polypill here represents a cardiovascular treatment regime with the incorporation of an immediate release compartment with aspirin and hydrochlorothiazide and three sustained release compartments containing pravastatin, atenolol, and ramipril.",
                    "offsetInBeginSection": 554,
                    "offsetInEndSection": 801,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26747390",
                    "text": "The Fuster-CNIC-Ferrer cardiovascular (CV) polypill has been found to be the first-in-class polypill to be approved and commercialized in Europe and Latinamerican Countries.",
                    "offsetInBeginSection": 551,
                    "offsetInEndSection": 724,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127755",
                    "text": "Right combination of drugs in the polypill might be a suitable solving of CV disease and diabetes prevention for the patients with metabolic syndrome.Key words: cardiometabolic risk - cardiovascular disease prevention - metabolic syndrome - polypill.",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1056,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127755",
                    "text": "Right now polypill (fixed combination of antihypertensives and lipid modifying drugs) are solving in the CV disease prevention.",
                    "offsetInBeginSection": 546,
                    "offsetInEndSection": 673,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7639419e632bc066000005",
            "body": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29036616"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "Results Here, we present a prediction algorithm using deep neural networks to predict protein subcellular localization relying only on sequence information.",
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 692,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "At its core, the prediction model uses a recurrent neural network that processes the entire protein sequence and an attention mechanism identifying protein regions important for the subcellular localization.",
                    "offsetInBeginSection": 693,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "Motivation The prediction of eukaryotic protein subcellular localization is a well-studied topic in bioinformatics due to its relevance in proteomics research.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "Many machine learning methods have been successfully applied in this task, but in most of them, predictions rely on annotation of homologues from knowledge databases.",
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "For novel proteins where no annotated homologues exist, and for predicting the effects of sequence variants, it is desirable to have methods for predicting protein properties from sequence information only.",
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "We demonstrate that our model achieves a good accuracy (78% for 10 categories; 92% for membrane-bound or soluble), outperforming current state-of-the-art algorithms, including those relying on homology information.",
                    "offsetInBeginSection": 1097,
                    "offsetInEndSection": 1311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "The model was trained and tested on a protein dataset extracted from one of the latest UniProt releases, in which experimentally annotated proteins follow more stringent criteria than previously.",
                    "offsetInBeginSection": 901,
                    "offsetInEndSection": 1096,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "The dataset is available at http://www.cbs.dtu.dk/services/DeepLoc/data.php.",
                    "offsetInBeginSection": 1513,
                    "offsetInEndSection": 1589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "Availability and implementation The method is available as a web server at http://www.cbs.dtu.dk/services/DeepLoc.",
                    "offsetInBeginSection": 1314,
                    "offsetInEndSection": 1428,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "Example code is available at https://github.com/JJAlmagro/subcellular_localization.",
                    "offsetInBeginSection": 1429,
                    "offsetInEndSection": 1512,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a99332a1d1251d03b00000e",
            "body": "How is Hsd17b1 associated with endometriosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15640252",
                "http://www.ncbi.nlm.nih.gov/pubmed/28405865",
                "http://www.ncbi.nlm.nih.gov/pubmed/20586553",
                "http://www.ncbi.nlm.nih.gov/pubmed/25403437",
                "http://www.ncbi.nlm.nih.gov/pubmed/22613790",
                "http://www.ncbi.nlm.nih.gov/pubmed/26261478"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252",
                    "text": "The A-allele of HSD17B1 appears to confer higher risk for endometriosis.",
                    "offsetInBeginSection": 1377,
                    "offsetInEndSection": 1449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252",
                    "text": "Here, we evaluated whether the risk and severity of endometriosis are associated with polymorphisms in estradiol-synthesizing enzyme genes: the Ser312Gly polymorphism in 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) and the Arg264Cys polymorphism in cytochrome P450, subfamily XIX (CYP19).",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 430,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28405865",
                    "text": "RESULTS Statistical analysis demonstrated that the HSD17B1 937 A>G SNP is associated with endometriosis in stages I and II.",
                    "offsetInBeginSection": 598,
                    "offsetInEndSection": 721,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28405865",
                    "text": "CONCLUSION Our genetic study demonstrated HSD17B1 937 G variant as a risk factor for infertility in women with stage I and II endometriosis in Polish Caucasian patients.",
                    "offsetInBeginSection": 1300,
                    "offsetInEndSection": 1469,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20586553",
                    "text": "RESULTS The HSD17B1 A/G SNP A allele increased overall endometriosis risk and the risk of stage I-II disease, while ESR1 longer (TA)(n) repeats only correlated with susceptibility to stage I-II endometriosis.",
                    "offsetInBeginSection": 755,
                    "offsetInEndSection": 963,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20586553",
                    "text": "CONCLUSIONS Genetic variants in ESR1, ESR2, and HSD17B1 genes could modify susceptibility to endometriosis and might influence the fertility status in endometriosis patients.",
                    "offsetInBeginSection": 1294,
                    "offsetInEndSection": 1468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22613790",
                    "text": "The findings of our study suggest that HSD17B1 and PR polymorphisms are associated with an increased risk of endometriosis.",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22613790",
                    "text": "Twenty-seven studies on the association of the cytochrome P450 subfamily 17 (CYP17), estrogen receptor gene (ER), progesterone receptor gene (PR), 17-beta-hydroxysteroid dehydrogenase type 1 gene (HSD17B1), and cytochrome P450 subfamily 19 (CYP19) polymorphisms with endometriosis risk were identified.",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 520,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22613790",
                    "text": "Further investigation into the association between CYP17, ER, PR, HSD17B1, and CYP19 polymorphisms and endometriosis risk is warranted and should include larger sample sizes.",
                    "offsetInBeginSection": 1203,
                    "offsetInEndSection": 1377,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26261478",
                    "text": "This meta-analysis suggested that HSD17B1 rs605059 polymorphisms were not associated with the risks of endometrial cancer and endometriosis.",
                    "offsetInBeginSection": 1132,
                    "offsetInEndSection": 1272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9eb008d6d6b54f79000001",
            "body": "List the continent of origin for the brown marmorated stinkbug(Halyomorpha halys)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22828257",
                "http://www.ncbi.nlm.nih.gov/pubmed/26955631",
                "http://www.ncbi.nlm.nih.gov/pubmed/25474148",
                "http://www.ncbi.nlm.nih.gov/pubmed/24871833",
                "http://www.ncbi.nlm.nih.gov/pubmed/24586332",
                "http://www.ncbi.nlm.nih.gov/pubmed/27744285",
                "http://www.ncbi.nlm.nih.gov/pubmed/23865219",
                "http://www.ncbi.nlm.nih.gov/pubmed/26463187",
                "http://www.ncbi.nlm.nih.gov/pubmed/24285660",
                "http://www.ncbi.nlm.nih.gov/pubmed/28984006"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22828257",
                    "text": "The brown marmorated stink bug, Halyomorpha halys, is native to Asia (China, Taiwan, Japan, and the Korean peninsula).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26955631",
                    "text": "The brown marmorated stink bug, Halyomorpha halys (Hemiptera: Pentatomidae), is a gregarious crop pest that has rapidly spread across the world in the last two decades.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25474148",
                    "text": "Brown marmorated stink bug, Halyomorpha halys (St\u00e5l), (Hemiptera: Pentatomidae) is an invasive polyphagous agricultural and urban nuisance pest of Asian origin that is becoming widespread in North America and Europe.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24871833",
                    "text": "The brown marmorated stink bug, Halyomorpha halys (St\u00e5l, 1855) (Hemiptera: Heteroptera: Pentatomidae) is recorded for the first time from Hungary.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586332",
                    "text": "We examined the salivary gland structure of the brown marmorated stink bug (Pentatomidae: Halyomorpha halys) and developed methods for independent collection of watery saliva and sheath saliva.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27744285",
                    "text": "Sampling soybean fields for the brown marmorated stink bug, Halyomorpha halys St\u00e5l (Hemiptera: Pentatomidae), can be challenging.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23865219",
                    "text": "Brown marmorated stink bug (Halyomorpha halys (St\u00e5l)) is an invasive agricultural and urban pest that was first detected in the United States in the late 1990s.",
                    "offsetInBeginSection": 226,
                    "offsetInEndSection": 387,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26463187",
                    "text": "The brown marmorated stink bug, Halyomorpha halys (St\u00e5l) (BMSB) is an exotic invasive insect originating in East Asia, currently causing significant damage to fruits, vegetables and other crops throughout most of the Mid-Atlantic states of the U.S.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285660",
                    "text": "We report the genome sequence of a novel iflavirus recovered from the transcriptome of a colony of the brown marmorated stink bug, Halyomorpha halys.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28984006",
                    "text": "We describe a unique microsporidian species that infects the green stink bug, Chinavia hilaris; the brown marmorated stink bug, Halyomorpha halys; the brown stink bug, Euschistus servus; and the dusky stink bug, Euschistus tristigmus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa82180d6d6b54f79000015",
            "body": "Are osteoclasts specialized in bone degradation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19372577",
                "http://www.ncbi.nlm.nih.gov/pubmed/24992711",
                "http://www.ncbi.nlm.nih.gov/pubmed/9819571",
                "http://www.ncbi.nlm.nih.gov/pubmed/8395372",
                "http://www.ncbi.nlm.nih.gov/pubmed/14702187",
                "http://www.ncbi.nlm.nih.gov/pubmed/11193210",
                "http://www.ncbi.nlm.nih.gov/pubmed/27514812",
                "http://www.ncbi.nlm.nih.gov/pubmed/22941736",
                "http://www.ncbi.nlm.nih.gov/pubmed/10968780",
                "http://www.ncbi.nlm.nih.gov/pubmed/27620531"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577",
                    "text": "Tumor cells in the bone microenvironment are able to initiate a vicious cycle of bone degradation by mobilizing osteoclasts, multinucleated cells specialized in bone degradation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992711",
                    "text": "These observations reveal that contrarily to bone resorption, the ability of osteoclasts to dissolve minerals is dispensable for the degradation of mineralized hypertrophic cartilage during endochondral bone formation.",
                    "offsetInBeginSection": 1646,
                    "offsetInEndSection": 1864,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992711",
                    "text": "Osteoclasts are specialized in mineralized tissue degradation, with the combined ability to solubilize hydroxyapatite and to degrade extracellular matrix proteins.",
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 645,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9819571",
                    "text": "Osteoclasts dissolve bone mineral by massive acid secretion and secrete specialized proteinases that degrade the organic matrix, mainly type I collagen, in this acidic milieu.",
                    "offsetInBeginSection": 692,
                    "offsetInEndSection": 867,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9819571",
                    "text": "Osteoclasts are multinucleated monocyte-macrophage derivatives that degrade bone.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14702187",
                    "text": "Osteoclasts express specialized proteins including a vacuolar-type H+-ATPase that drives HCl secretion for dissolution of bone mineral.",
                    "offsetInBeginSection": 1219,
                    "offsetInEndSection": 1354,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11193210",
                    "text": "Osteoclasts are physiological polykaryons specialized in the resorption of calcified tissue.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27514812",
                    "text": "Osteoclasts, specialized cells that degrade bone, are key components of the cellular system that regulates and maintains bone homeostasis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22941736",
                    "text": "Osteoclasts are highly specialized cells that resorb bone and contribute to bone remodeling.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27620531",
                    "text": "Skin Langerhans cells are antigen-presenting cells of the interfollicular epidermis and the upper part of the hair follicle, whereas osteoclasts are specialized bone-resorbing macrophages.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a733a672dc08e987e000014",
            "body": "Does temsirolimus improve survival of glioblastoma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                "http://www.ncbi.nlm.nih.gov/pubmed/27143690",
                "http://www.ncbi.nlm.nih.gov/pubmed/23564811",
                "http://www.ncbi.nlm.nih.gov/pubmed/24470557",
                "http://www.ncbi.nlm.nih.gov/pubmed/15998902",
                "http://www.ncbi.nlm.nih.gov/pubmed/23099651",
                "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                "http://www.ncbi.nlm.nih.gov/pubmed/28351321",
                "http://www.ncbi.nlm.nih.gov/pubmed/26786929"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                    "text": "CONCLUSIONS antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy.",
                    "offsetInBeginSection": 1438,
                    "offsetInEndSection": 1635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                    "text": "Bevacizumab did not improve overall survival.",
                    "offsetInBeginSection": 1017,
                    "offsetInEndSection": 1062,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143690",
                    "text": "CONCLUSIONS Temsirolimus was not superior to temozolomide in patients with an unmethylated MGMT promoter.",
                    "offsetInBeginSection": 1611,
                    "offsetInEndSection": 1716,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564811",
                    "text": "The combination of temsirolimus and antibodies to vascular endothelial factor (VEGF) has not yet been investigated, but with the hypothesis that temsirolimus might provide complimentary therapeutic benefit in combination with bevacizumab, we included patients with progressive GBM after bevacizumab in an open phase II study.",
                    "offsetInBeginSection": 514,
                    "offsetInEndSection": 839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998902",
                    "text": "BACKGROUND Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998902",
                    "text": "CONCLUSION Temsirolimus is well tolerated in recurrent GBM patients.",
                    "offsetInBeginSection": 1698,
                    "offsetInEndSection": 1766,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                    "text": "The addition of temsirolimus to interferon did not improve survival.",
                    "offsetInBeginSection": 1823,
                    "offsetInEndSection": 1891,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                    "text": "Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.",
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                    "text": "CONCLUSIONS As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis.",
                    "offsetInBeginSection": 1664,
                    "offsetInEndSection": 1822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28351321",
                    "text": "We recently reported that mammalian target of rapamycin inhibitors-rapamycin, temsirolimus, torin 1, and PP242-suppressed invasion and migration promoted by tumor necrosis factor-alpha and phorbol-myristate-acetate in glioblastoma cells.",
                    "offsetInBeginSection": 578,
                    "offsetInEndSection": 815,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a763b679e632bc066000006",
            "body": "Describe RIblast",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28459942"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "RIblast discovers seed regions using suffix arrays and subsequently extends seed regions based on an RNA secondary structure energy model.",
                    "offsetInBeginSection": 758,
                    "offsetInEndSection": 896,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "Availability and implementation The source code of RIblast is freely available at https://github.com/fukunagatsu/RIblast .",
                    "offsetInBeginSection": 1085,
                    "offsetInEndSection": 1207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "Results Here, we present 'RIblast', an ultrafast RNA-RNA interaction prediction method based on the seed-and-extension approach.",
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 757,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "Computational experiments indicate that RIblast achieves a level of prediction accuracy similar to those of existing programs, but at speeds over 64 times faster than existing programs.",
                    "offsetInBeginSection": 897,
                    "offsetInEndSection": 1082,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "Because experimental detections of comprehensive lncRNA-RNA interactions are difficult, computational prediction of lncRNA-RNA interactions is an indispensable technique.",
                    "offsetInBeginSection": 311,
                    "offsetInEndSection": 481,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "However, the high computational costs of existing RNA-RNA interaction prediction tools prevent their application to large-scale lncRNA datasets.",
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 626,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "One approach to understanding the functions of lncRNAs is the detection of the interacting RNA target of each lncRNA.",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 310,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "Supplementary information Supplementary data are available at Bioinformatics online.",
                    "offsetInBeginSection": 1271,
                    "offsetInEndSection": 1355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "Although more than 58\u2009000 human lncRNA genes have been discovered, most known lncRNAs are still poorly characterized.",
                    "offsetInBeginSection": 73,
                    "offsetInEndSection": 192,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                    "text": "Motivation LncRNAs play important roles in various biological processes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a991ee21d1251d03b000005",
            "body": "Are there sex differences in the transcriptome of the mouse hippocampus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28302071"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "Additionally, this analysis reveals sex differences in the transcriptome of the developing mouse hippocampus, and further clarifies the need to include both female and male mice in longitudinal studies involving molecular changes in the hippocampus.",
                    "offsetInBeginSection": 1401,
                    "offsetInEndSection": 1650,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "We also find a modest correlation between levels of mRNA and protein in the mouse hippocampus (Rho\u2009=\u20090.53).",
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "CONCLUSION This study adds to the substantial body of evidence for transcriptomic regulation in the hippocampus during postnatal development.",
                    "offsetInBeginSection": 1259,
                    "offsetInEndSection": 1400,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "To better understand the possible molecular basis for the sex-biased nature of neurological disorders, we used a developmental series of female and male mice at 1, 2, and 4 months of age to assess both mRNA and protein in the hippocampus with RNA-sequencing and mass-spectrometry, respectively.",
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "The bulk of these differentially expressed genes are changed in both sexes at one or more ages, but a total of 198 transcripts are differentially expressed between females and males at one or more ages.",
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 830,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "The number of transcripts that are differentially expressed between females and males is greater in adult animals than in younger animals.",
                    "offsetInBeginSection": 831,
                    "offsetInEndSection": 969,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "Additionally, we identify 69 transcripts that show complex and sex-specific patterns of temporal regulation through postnatal development, 8 of which are heat-shock proteins.",
                    "offsetInBeginSection": 970,
                    "offsetInEndSection": 1144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "RESULTS The transcriptomic analysis identifies 2699 genes that are differentially expressed between animals of different ages.",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 627,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "BACKGROUND A variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, major depressive disorder, dyslexia and autism, are differentially prevalent between females and males.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 203,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa0495bd6d6b54f79000002",
            "body": "What is the role of the blood-brain barrier?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24501156",
                "http://www.ncbi.nlm.nih.gov/pubmed/16120931",
                "http://www.ncbi.nlm.nih.gov/pubmed/28781208",
                "http://www.ncbi.nlm.nih.gov/pubmed/19077110",
                "http://www.ncbi.nlm.nih.gov/pubmed/21963971",
                "http://www.ncbi.nlm.nih.gov/pubmed/28369884",
                "http://www.ncbi.nlm.nih.gov/pubmed/15920760",
                "http://www.ncbi.nlm.nih.gov/pubmed/23508590",
                "http://www.ncbi.nlm.nih.gov/pubmed/8955532",
                "http://www.ncbi.nlm.nih.gov/pubmed/12742070"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156",
                    "text": "Caveolin-1 is related to the diminished expression of tight junction-associated proteins and metabolic pinocytosis vesicles when the blood-brain barrier is destroyed by outside invaders or malignant stimulus.",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 451,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156",
                    "text": "It plays an important role in physiological and pathological conditions of the blood-brain barrier and serves as a mediator in drug delivery through the blood-brain barrier.",
                    "offsetInBeginSection": 69,
                    "offsetInEndSection": 242,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28781208",
                    "text": "Blood-brain barrier pathology is recognised as a central factor in the development of many neurological disorders, but much less is known about the role of the blood-brain barrier in psychiatric disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28781208",
                    "text": "We conclude that the complex nature of blood-brain barrier dysfunction in psychosis might be relevant to many aspects of disrupted neuronal and synaptic function, increased permeability to inflammatory molecules, disrupted glutamate homoeostasis, impaired action of antipsychotics, and development of antipsychotic resistance.",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 1055,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19077110",
                    "text": "The role of inflammation and the blood-brain barrier will be discussed in cerebral palsy, schizophrenia, Parkinson's disease, Alzheimer's disease and multiple sclerosis, conditions where both inflammation and blood-brain barrier dysfunction occur either during initiation and/or progression of the disease.",
                    "offsetInBeginSection": 554,
                    "offsetInEndSection": 860,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963971",
                    "text": "Various types of transporters that exhibit substrate specificity are localized on the blood-brain barrier, and play a role in transporting substances from circulating blood and from brain interstitial fluid.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 410,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15920760",
                    "text": "In conclusion, loss of flow (flow cessation/reperfusion) independent of hypoxia-hypoglycemia plays a significant role in blood-brain barrier failure by stimulating leukocyte-mediated inflammatory mechanisms.",
                    "offsetInBeginSection": 1716,
                    "offsetInEndSection": 1923,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15920760",
                    "text": "Shear stress, hypoxia-hypoglycemia, and blood leukocytes play a significant role in blood-brain barrier failure during transient or permanent ischemia.",
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 300,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23508590",
                    "text": "Thus, the transporter protein MRP plays a role in maintaining the blood-brain barrier and modulates the activity of opioids.",
                    "offsetInBeginSection": 1449,
                    "offsetInEndSection": 1573,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12742070",
                    "text": "In situ brain perfusion in the rat, indicates that blood to brain L-[14C]glutamine transport at the blood-brain barrier is primarily mediated by a pH-dependent, Na(+)-dependent, System N transporter, but that blood to choroid plexus transport is primarily via a pH-independent System N transporter and a Na(+)-independent carrier that is not System L. Transport studies in isolated rat choroid plexuses and primary cultures of choroid plexus epithelial cells indicate that epithelial L-[14C]glutamine transport is polarized (apical uptake>basolateral) and that uptake at the apical membrane is mediated by pH dependent System N transporters (identified as SN1 and SN2 by polymerase chain reaction) and the Na(+)-independent System L. Blood-brain barrier System N transport is markedly effected by cerebral ischemia and may be a good marker of endothelial cell dysfunction.",
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 1348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa824a8fcf4565872000002",
            "body": "What is the drug Tecfidera used against?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28258191",
                "http://www.ncbi.nlm.nih.gov/pubmed/27849348",
                "http://www.ncbi.nlm.nih.gov/pubmed/23946617"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258191",
                    "text": "Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulation of the fumaric acid ester that is Food and Drug Administration approved for treatment of relapsing-remitting multiple sclerosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258191",
                    "text": "To better understand the therapeutic effects of Tecfidera and its rare side effect of progressive multifocal leukoencephalopathy, we conducted cross-sectional and longitudinal studies by immunophenotyping cells from peripheral blood (particularly T lymphocytes) derived from untreated and 4-6 and 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using multiparametric flow cytometry.",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 614,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258191",
                    "text": "Th subsets Th1 (CXCR3+), Th17 (CCR6+), and particularly those expressing both CXCR3 and CD161 were reduced most significantly, whereas the anti-inflammatory Th2 subset (CCR3+) was increased after DMF treatment.",
                    "offsetInBeginSection": 1009,
                    "offsetInEndSection": 1219,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258191",
                    "text": "Monitoring these subsets could help to evaluate the efficacy and safety of DMF treatment.",
                    "offsetInBeginSection": 1659,
                    "offsetInEndSection": 1748,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258191",
                    "text": "Our results suggest that DMF acts on specific memory and effector T cell subsets by limiting their survival, proliferation, activation, and cytokine production.",
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1658,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27849348",
                    "text": "Avonex, Tysabri, and Tecfidera have generated significant social value, a large majority of which accrues to consumers.",
                    "offsetInBeginSection": 1466,
                    "offsetInEndSection": 1585,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27849348",
                    "text": "OBJECTIVES To illustrate a more comprehensive view of value associated with medicines treating a highly severe illness and to apply these insights to estimate the costs and benefits of 3 treatments for multiple sclerosis (MS): Avonex, Tysabri, and Tecfidera.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27849348",
                    "text": "RESULTS In the baseline model, Avonex, Tysabri, and Tecfidera generated $46.2 billion of total value to consumers, almost one-third of which accrued to those without MS.",
                    "offsetInBeginSection": 843,
                    "offsetInEndSection": 1012,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27849348",
                    "text": "We used economic theory to derive the value of therapy to patients with MS and to individuals who face the risk of contracting MS in the future, under the alternative assumptions that therapies were fully insured or paid for out of pocket.",
                    "offsetInBeginSection": 317,
                    "offsetInEndSection": 556,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23946617",
                    "text": "Dimethyl fumarate capsules (Tecfidera) for multiple sclerosis, ado-trastuzumab emtansine injection (Kadcyla) for HER-2-positive breast cancer, and ospemifene tablets (Osphena) for painful intercourse in postmenopausal women.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a733d2a2dc08e987e000015",
            "body": "Is Tocilizumab effective for Giant-Cell Arteritis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28745999",
                "http://www.ncbi.nlm.nih.gov/pubmed/23650978",
                "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                "http://www.ncbi.nlm.nih.gov/pubmed/28499892",
                "http://www.ncbi.nlm.nih.gov/pubmed/27182063",
                "http://www.ncbi.nlm.nih.gov/pubmed/24854376",
                "http://www.ncbi.nlm.nih.gov/pubmed/29146018",
                "http://www.ncbi.nlm.nih.gov/pubmed/22965672",
                "http://www.ncbi.nlm.nih.gov/pubmed/21243547",
                "http://www.ncbi.nlm.nih.gov/pubmed/22284606"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999",
                    "text": "The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis.",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650978",
                    "text": "Tocilizumab is a highly effective therapeutic agent for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650978",
                    "text": "It is successful in treating diseases such as the adult-onset Still's disease, amyloidosis, giant cell arteritis, multiple myeloma, polymyalgia rheumatica, relapsing polychondritis, remitting seronegative symmetrical synovitis with pitting edema-syndrome, systemic lupus erythematosus, systemic sclerosis, and Takayasu arteritis.",
                    "offsetInBeginSection": 461,
                    "offsetInEndSection": 790,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23650978",
                    "text": "Furthermore, a large amount of case study data reveals that tocilizumab can be an effective therapy for not only rheumatoid arthritis but also for other mostly rare inflammatory rheumatic diseases.",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                    "text": "Several studies have reported that tocilizumab is effective for aortitis associated with Takayasu's arteritis and giant cell arteritis.",
                    "offsetInBeginSection": 533,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                    "text": "In conclusion, tocilizumab was effective in treating glucocorticoid- and cyclophosphamide-resistant AAV-associated aortitis.",
                    "offsetInBeginSection": 1053,
                    "offsetInEndSection": 1177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                    "text": "This is the first report demonstrating the successful treatment of AAV-associated aortitis using tocilizumab.",
                    "offsetInBeginSection": 1178,
                    "offsetInEndSection": 1287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                    "text": "It indicates that tocilizumab may be therapeutically beneficial for not only aortitis but also AAV itself.",
                    "offsetInBeginSection": 946,
                    "offsetInEndSection": 1052,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27182063",
                    "text": "CONCLUSION TCZ is effective in GCA.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22965672",
                    "text": "Herein, we present a case with giant cell arteritis resistant to oral and intravenous steroid, intravenous cyclophosphamide and mycophenolate mofetil, but successfully treated with tocilizumab.",
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 424,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76420c9e632bc066000007",
            "body": "What is MULTOVL?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23071271"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271",
                    "text": "We present the MULTOVL application suite that detects and statistically analyses multiple overlaps of genomic regions in a fast and efficient manner.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271",
                    "text": "The package supports the detection of multiple region intersections, unions and 'solitary' genomic regions.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271",
                    "text": "The significance of actually observed overlaps is estimated by comparing them with empirical null distributions generated by random shuffling of the input regions.",
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a992d981d1251d03b00000b",
            "body": "Can nanoparticles be used for afterglow imaging?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28657119",
                "http://www.ncbi.nlm.nih.gov/pubmed/29035373",
                "http://www.ncbi.nlm.nih.gov/pubmed/20798470",
                "http://www.ncbi.nlm.nih.gov/pubmed/28608898",
                "http://www.ncbi.nlm.nih.gov/pubmed/27594671"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119",
                    "text": "This study reports the design principle, synthesis, and proof-of-concept application of organic semiconducting nanoparticles (OSNs) with ultralong phosphorescence for in vivo afterglow imaging.",
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 459,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119",
                    "text": "This study not only introduces the first category of water-soluble ultralong phosphorescence organic nanoparticles but also reveals a universal design principle to prolong the lifetime of phosphorescent molecules to the level that can be effective for molecular imaging.",
                    "offsetInBeginSection": 976,
                    "offsetInEndSection": 1246,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29035373",
                    "text": "However, afterglow imaging has been limited by its reliance on inorganic nanoparticles with relatively low brightness and short-near-infrared (NIR) emission.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29035373",
                    "text": "Afterglow optical agents, which emit light long after cessation of excitation, hold promise for ultrasensitive in vivo imaging because they eliminate tissue autofluorescence.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20798470",
                    "text": "The successful observation of the afterglow from water-soluble nanoparticles may open up new applications of afterglow phosphors in biological imaging, detection and treatment.",
                    "offsetInBeginSection": 816,
                    "offsetInEndSection": 992,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28608898",
                    "text": "Until now, the afterglow emissions of most developed near infrared (NIR)-emitting persistent luminescent nanoparticles (NPLNPs) were located at approximately 700 nm, at the edge of the first tissue transparency window (from 650 to 900 nm), which resulted in relatively low tissue penetration and signal-to-noise ratio (SNR) for in vivo imaging.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 344,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28608898",
                    "text": "Herein, 5 nm ZnSn2O4:Cr,Eu (ZSO) NPLNPs with NIR afterglow emission at 800 nm are synthesized via a direct aqueous-phase synthesis method.",
                    "offsetInBeginSection": 345,
                    "offsetInEndSection": 483,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27594671",
                    "text": "However, the synthesis of water soluble afterglow nanoparticles like Sr2MgSi2O7:Eu2+, Dy3+ is a challenging issue because most afterglow materials are very complicated in composition that cannot be synthesized by simple chemical routes.",
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27594671",
                    "text": "The applications of afterglow particles for photodynamic activation and biological imaging have become a topical research area.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27594671",
                    "text": "All these results indicate the methods reported here for afterglow nanoparticle synthesis, coating and conjugation are successful, and consequently, the prepared Sr2MgSi2O7:Eu2+, Dy3+/PPIX/Folic acid nano-conjugates are promising for X-ray induced photodynamic therapy on cancer treatment.",
                    "offsetInBeginSection": 1098,
                    "offsetInEndSection": 1387,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa13fd3d6d6b54f79000003",
            "body": "List 4 drugs used to treat opioid addiction or overdose",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26495843",
                "http://www.ncbi.nlm.nih.gov/pubmed/28358791",
                "http://www.ncbi.nlm.nih.gov/pubmed/25583888",
                "http://www.ncbi.nlm.nih.gov/pubmed/26054008",
                "http://www.ncbi.nlm.nih.gov/pubmed/16953647",
                "http://www.ncbi.nlm.nih.gov/pubmed/12738346",
                "http://www.ncbi.nlm.nih.gov/pubmed/28627395",
                "http://www.ncbi.nlm.nih.gov/pubmed/23059064",
                "http://www.ncbi.nlm.nih.gov/pubmed/28219963",
                "http://www.ncbi.nlm.nih.gov/pubmed/21668757"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843",
                    "text": "10 patients (9/10 with chronic airflow obstruction) undergoing supervised injectable opioid treatment for heroin addiction received their usual prescribed dose of injectable opioid (diamorphine or methadone) (IOT), and their usual prescribed dose of oral opioid (methadone or sustained release oral morphine) after 30 minutes.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 710,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843",
                    "text": "We conclude that significant acute respiratory depression is commonly induced by opioid drugs prescribed to treat opioid addiction.",
                    "offsetInBeginSection": 1462,
                    "offsetInEndSection": 1593,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28358791",
                    "text": "Methadone is an opioid prescribed for pain management and is also provided through opioid treatment programs to treat opioid use disorders.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 342,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26054008",
                    "text": "BACKGROUND Opioid addiction and overdose is a serious problem worldwide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26054008",
                    "text": "Combined with environmental exposure, opioid overdose can cause profound hypothermia.",
                    "offsetInBeginSection": 229,
                    "offsetInEndSection": 314,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953647",
                    "text": "Buprenorphine has partial mu-opioid receptor agonist activity and is a kappa-opioid receptor antagonist; hence, it can substitute for other micro-opioid receptor agonists, yet is less apt to produce overdose reactions or dysphoria.",
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 569,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953647",
                    "text": "The introduction of a sublingual formulation combining naloxone with buprenorphine further reduces the risk of diversion to illicit intravenous use.",
                    "offsetInBeginSection": 1152,
                    "offsetInEndSection": 1300,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16953647",
                    "text": "The pharmacodynamic and pharmacokinetic profiles of buprenorphine make it unique in the armamentarium of drugs for the treatment of opioid addiction.",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 337,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28627395",
                    "text": "The foundation of the nation's opioid overdose crisis - and the totality of the nation's drug epidemic - is widespread recreational pharmacology, the use of drugs for fun or \"self-medication.\"",
                    "offsetInBeginSection": 392,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21668757",
                    "text": "OBJECTIVE To illustrate a system-level, simulation-based approach for evaluating mitigation strategies to address the dramatic rise in abuse, addiction, and overdose deaths associated with the use of pharmaceutical opioid analgesics to treat chronic pain.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa825b1fcf4565872000003",
            "body": "Are stress granules membraneous?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17209421",
                "http://www.ncbi.nlm.nih.gov/pubmed/26199455",
                "http://www.ncbi.nlm.nih.gov/pubmed/29129640",
                "http://www.ncbi.nlm.nih.gov/pubmed/19193871",
                "http://www.ncbi.nlm.nih.gov/pubmed/6581717",
                "http://www.ncbi.nlm.nih.gov/pubmed/27489304",
                "http://www.ncbi.nlm.nih.gov/pubmed/18710928",
                "http://www.ncbi.nlm.nih.gov/pubmed/24090136",
                "http://www.ncbi.nlm.nih.gov/pubmed/26777405",
                "http://www.ncbi.nlm.nih.gov/pubmed/24033457"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26199455",
                    "text": "Stress granules and P-bodies are conserved assemblies of nontranslating mRNAs in eukaryotic cells that can be related to RNA-protein aggregates found in some neurodegenerative diseases.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29129640",
                    "text": "Stress granules are mRNA-protein assemblies formed from nontranslating mRNAs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19193871",
                    "text": "Stress granules are cytoplasmic mRNA-silencing foci that form transiently during the stress response.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19193871",
                    "text": "Here, we show that Stau1 is recruited to stress granules upon induction of endoplasmic reticulum or oxidative stress as well in stress granules induced by translation initiation blockers.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 520,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6581717",
                    "text": "They consist of azurophilic granules containing membraneous lamellae.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27489304",
                    "text": "P54 DEAD box RNA helicases are components of RNA granules such as P-bodies and stress granules.",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 417,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18710928",
                    "text": "We show that specific stress stimuli induce the assembly of RNA granules in an organelle with bacterial ancestry, the chloroplast of Chlamydomonas reinhardtii.",
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 280,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090136",
                    "text": "BACKGROUND Amyotrophic lateral sclerosis (ALS)-linked fused in sarcoma/translocated in liposarcoma (FUS/TLS or FUS) is concentrated within cytoplasmic stress granules under conditions of induced stress.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26777405",
                    "text": "Moreover, multiple ATP-driven machines affect stress granules differently, with the CCT complex inhibiting stress granule assembly, while the MCM and RVB complexes promote stress granule persistence.",
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26777405",
                    "text": "Stress granules are mRNA-protein granules that form when translation initiation is limited, and they are related to pathological granules in various neurodegenerative diseases.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a733efc2dc08e987e000016",
            "body": "Describe Achenbach\u2019s syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16760737",
                "http://www.ncbi.nlm.nih.gov/pubmed/20512338",
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/835533",
                "http://www.ncbi.nlm.nih.gov/pubmed/4017281",
                "http://www.ncbi.nlm.nih.gov/pubmed/9777339",
                "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                "http://www.ncbi.nlm.nih.gov/pubmed/23565480",
                "http://www.ncbi.nlm.nih.gov/pubmed/3144988"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281",
                    "text": "), Thrombocytopenia Absent Radii Syndrome (T.A.R.",
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 210,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281",
                    "text": "Various degrees of bone marrow aplasia have been described in association with distinctive congenital anomalies such as the Fanconi Pancytopenia Syndrome (F.P.S.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4017281",
                    "text": "Syndrome) the Aase Syndrome and Diamond-Blackfan Anemia.",
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                    "text": "Authors describe the phenotype and review the literature on this syndrome.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "Although there is considerable variability, most individuals with Down syndrome have mental retardation and speech and language deficits, particularly in language production and syntax and poor speech intelligibility.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "Next, we describe language development in Down syndrome, focusing on communication behaviors in the prelinguistic period, then the development of language in children and adolescents, and finally language development in adults and the aging period.",
                    "offsetInBeginSection": 489,
                    "offsetInEndSection": 737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "We describe language development in individuals with Down syndrome across four domains: phonology, semantics, syntax, and pragmatics.",
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 871,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "This article describes research findings in the language and communication development of individuals with Down syndrome, first briefly describing the physical and cognitive phenotype of Down syndrome, and two communication related domains-hearing and oral motor skills.",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 488,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565480",
                    "text": "Also included are less well-described presentations of Wolframs syndrome.",
                    "offsetInBeginSection": 268,
                    "offsetInEndSection": 341,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565480",
                    "text": "Neuropsychiatric manifestations, depression with suicidal risk, central hypogonadism, and secondary adrenal insufficiency are among the less well-described manifestations of this syndrome.",
                    "offsetInBeginSection": 1562,
                    "offsetInEndSection": 1750,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a774e40faa1ab7d2e000007",
            "body": "Is there a link between nuclear position and DNA repair pathway choice?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25366693",
                "http://www.ncbi.nlm.nih.gov/pubmed/27266837",
                "http://www.ncbi.nlm.nih.gov/pubmed/25463437"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693",
                    "text": "Our results are consistent with a model in which nuclear position dictates the choice of DNA repair pathway, thus revealing a new level of regulation in DSB repair controlled by spatial organization of DNA within the nucleus.",
                    "offsetInBeginSection": 912,
                    "offsetInEndSection": 1137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693",
                    "text": "Nuclear organization has emerged as a key parameter in the formation of chromosomal translocations, yet little is known as to whether DNA repair can efficiently occur throughout the nucleus and whether it is affected by the location of the lesion.",
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 346,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693",
                    "text": "We demonstrate that DSBs induced at the nuclear membrane (but not at nuclear pores or nuclear interior) fail to rapidly activate the DNA damage response (DDR) and repair by homologous recombination (HR).",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 655,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693",
                    "text": "Faithful DNA repair is essential to avoid chromosomal rearrangements and promote genome integrity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693",
                    "text": "Real-time and superresolution imaging reveal that DNA DSBs within lamina-associated domains do not migrate to more permissive environments for HR, like the nuclear pores or the nuclear interior, but instead are repaired in situ by alternative end-joining.",
                    "offsetInBeginSection": 656,
                    "offsetInEndSection": 911,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27266837",
                    "text": "We aim to highlight the importance of chromatin state along with the nuclear position of the DNA lesions on the choice of DNA repair pathway and maintenance of genome integrity.",
                    "offsetInBeginSection": 544,
                    "offsetInEndSection": 721,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27266837",
                    "text": "A complex network of proteins and their modifications participate in orchestrated signaling cascades, which are induced in response to DNA damage and may determine the choice of repair pathway.",
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25463437",
                    "text": "Regulation of DNA repair pathway choice is crucial to avoid genomic instability.",
                    "offsetInBeginSection": 556,
                    "offsetInEndSection": 636,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25463437",
                    "text": "In yeast, DSBs are mobile and can scan the entire nucleus to be repaired in specialized DNA repair centers or if they are persistent, in order to associate with the nuclear pores or the nuclear envelope where they can be repaired by specialized repair pathways.",
                    "offsetInBeginSection": 637,
                    "offsetInEndSection": 898,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25463437",
                    "text": "In the third part, we discuss the mobility of heterochromatic DSBs in light of our recent data on DSB repair at the nuclear lamina, and finally, we show that DSB repair compartmentalization at the nuclear periphery is conserved from yeast to mammals, further pointing to a role for gene positioning in the outcome of DSB repair.",
                    "offsetInBeginSection": 1305,
                    "offsetInEndSection": 1633,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a992eac1d1251d03b00000c",
            "body": "Can non ubiquitinated Tomm20 promote mitophagy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27503909"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "A total of 338 new targets were identified and from these we validated glycogen synthase kinase 3\u03b2 (Gsk3\u03b2), which can phosphorylate \u03b1-synuclein, and translocase of outer mitochondrial membrane 20 (Tomm20), a mitochondrial translocase that, when ubiquitinated, promotes mitophagy, as SCFFbxo7 substrates both in vitro and in vivo Ubiquitin chain restriction analyses revealed that Fbxo7 modified Gsk3\u03b2 using K63 linkages.",
                    "offsetInBeginSection": 1131,
                    "offsetInEndSection": 1555,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "None of the PD-associated mutations in Fbxo7 impaired Tomm20 ubiquitination.",
                    "offsetInBeginSection": 1789,
                    "offsetInEndSection": 1865,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "In addition, Fbxo7 ubiquitinated Tomm20, and its levels correlated with Fbxo7 expression, indicating a stabilizing effect.",
                    "offsetInBeginSection": 1666,
                    "offsetInEndSection": 1788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "These include HURP (hepatoma up-regulated protein), whose ubiquitination results in proteasome-mediated degradation, and c-IAP1 (inhibitor of apoptosis protein 1), TNF receptor-associated factor 2 (TRAF2), and NRAGE, which are not destabilized as a result of ubiquitination.",
                    "offsetInBeginSection": 528,
                    "offsetInEndSection": 802,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "Fbxo7 is a clinically relevant F-box protein, associated with both cancer and Parkinson's disease (PD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "Point mutations within FBXO7 map within specific functional domains, including near its F-box domain and its substrate recruiting domains, suggesting that deficiencies in SCFFbxo7/PARK15 ubiquitin ligase activity are mechanistically linked to early-onset PD.",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 456,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "None of these substrates have been linked directly to PD, nor has it been determined whether they would directly engage neuronal cell death pathways.",
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 952,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "Our findings demonstrate that SCFFbxo7 has an impact directly on two proteins implicated in pathological processes leading to PD.",
                    "offsetInBeginSection": 1866,
                    "offsetInEndSection": 1995,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "Our results indicate that Fbxo7 negatively regulates Gsk3\u03b2 activity, rather than its levels or localization.",
                    "offsetInBeginSection": 1556,
                    "offsetInEndSection": 1665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                    "text": "To discover ubiquitinated substrates of SCFFbxo7 implicated more directly in PD aetiology, we conducted a high-throughput screen using protein arrays to identify new candidates.",
                    "offsetInBeginSection": 953,
                    "offsetInEndSection": 1130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa304f1d6d6b54f79000004",
            "body": "Is the consumption of chocolate associated with an increase in cardiovascular disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27493901",
                "http://www.ncbi.nlm.nih.gov/pubmed/22653982",
                "http://www.ncbi.nlm.nih.gov/pubmed/21665390",
                "http://www.ncbi.nlm.nih.gov/pubmed/21666964",
                "http://www.ncbi.nlm.nih.gov/pubmed/26076934",
                "http://www.ncbi.nlm.nih.gov/pubmed/20858571",
                "http://www.ncbi.nlm.nih.gov/pubmed/23225768",
                "http://www.ncbi.nlm.nih.gov/pubmed/21875885",
                "http://www.ncbi.nlm.nih.gov/pubmed/16390538",
                "http://www.ncbi.nlm.nih.gov/pubmed/18827977"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901",
                    "text": "BACKGROUND The consumption of chocolate and cocoa has established cardiovascular benefits.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982",
                    "text": "OBJECTIVE To model the long term effectiveness and cost effectiveness of daily dark chocolate consumption in a population with metabolic syndrome at high risk of cardiovascular disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982",
                    "text": "CONCLUSIONS The blood pressure and cholesterol lowering effects of dark chocolate consumption are beneficial in the prevention of cardiovascular events in a population with metabolic syndrome.",
                    "offsetInBeginSection": 1308,
                    "offsetInEndSection": 1500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982",
                    "text": "Daily dark chocolate consumption could be an effective cardiovascular preventive strategy in this population.",
                    "offsetInBeginSection": 1501,
                    "offsetInEndSection": 1610,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21666964",
                    "text": "Data currently available indicate that daily consumption of cocoa-rich chocolate (rich in polyphenols) may at least partially lower cardiovascular disease risk.",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23225768",
                    "text": "CONCLUSIONS High consumption of sugar-sweetened beverages and low intake of breakfast cereals, jam and honey, sweets and chocolate and nut-based spreads seem to adversely affect clustered CVD risk.",
                    "offsetInBeginSection": 2137,
                    "offsetInEndSection": 2334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21875885",
                    "text": "The highest levels of chocolate consumption were associated with a 37% reduction in cardiovascular disease (relative risk 0.63 (95% confidence interval 0.44 to 0.90)) and a 29% reduction in stroke compared with the lowest levels.",
                    "offsetInBeginSection": 1581,
                    "offsetInEndSection": 1810,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16390538",
                    "text": "BACKGROUND Consumption of chocolate has been often hypothesized to reduce the risk of cardiovascular disease (CVD) due to chocolate's high levels of stearic acid and antioxidant flavonoids.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16390538",
                    "text": "RESULTS The body of short-term randomized feeding trials suggests cocoa and chocolate may exert beneficial effects on cardiovascular risk via effects on lowering blood pressure, anti-inflammation, anti-platelet function, higher HDL, decreased LDL oxidation.",
                    "offsetInBeginSection": 857,
                    "offsetInEndSection": 1114,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18827977",
                    "text": "Accumulating evidence from the past 10 years demonstrates that moderate consumption of chocolate, especially dark chocolate, may exert protective effects against the development of cardiovascular disease.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 391,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aacd38efcf4565872000006",
            "body": "Is DNA polymerase \u03b8 involved in DNA repair?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27264557",
                "http://www.ncbi.nlm.nih.gov/pubmed/25775267",
                "http://www.ncbi.nlm.nih.gov/pubmed/28542210",
                "http://www.ncbi.nlm.nih.gov/pubmed/24989122",
                "http://www.ncbi.nlm.nih.gov/pubmed/28695890",
                "http://www.ncbi.nlm.nih.gov/pubmed/26514729",
                "http://www.ncbi.nlm.nih.gov/pubmed/26484154",
                "http://www.ncbi.nlm.nih.gov/pubmed/28668117"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557",
                    "text": "DNA polymerase theta (pol \u03b8) is encoded in the genomes of many eukaryotes, though not in fungi.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25775267",
                    "text": "DNA polymerase \u03b8 protects against genomic instability via an alternative end-joining repair pathway for DNA double-strand breaks.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28542210",
                    "text": "One of these proteins, DNA Polymerase \u03b8 (Pol \u03b8), coordinates a mutagenic DSB repair pathway named microhomology-mediated end joining (MMEJ) and is also a critical component for bypass or repair of ICLs in several organisms.",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28542210",
                    "text": "Together, our data illustrate the functional importance of the helicase-like domain of Pol \u03b8 and suggest that its tethering to the polymerase domain is important for its multiple functions in DNA repair and damage tolerance.",
                    "offsetInBeginSection": 1512,
                    "offsetInEndSection": 1737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24989122",
                    "text": "Although DNA polymerase \u03b8 (Pol \u03b8) is known to carry out translesion synthesis and has been implicated in DNA repair, its physiological function under normal growth conditions remains unclear.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28695890",
                    "text": "Here we show that DNA polymerase \u03b8, despite its minor role in chromosomal DNA repair, substantially contributes to random integration, and that cells lacking both DNA polymerase \u03b8 and DNA ligase IV, which is essential for non-homologous end joining (NHEJ), exhibit 100% efficiency of spontaneous gene targeting by virtue of undetectable levels of random integration.",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28695890",
                    "text": "Thus, DNA polymerase \u03b8-mediated end joining is the sole homology-independent repair route in the absence of NHEJ and, intriguingly, their combined absence reveals rare Alu-Alu recombination events utilizing a stretch of homology.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 866,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26514729",
                    "text": "DNA polymerase theta (Pol \u03b8) is an error-prone A-family polymerase that is highly conserved among multicellular eukaryotes and plays multiple roles in DNA repair and the regulation of genome integrity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26484154",
                    "text": "The physiological function of the human DNA polymerase \u03b8 (pol \u03b8) is still unclear despite its in vitro translesion synthesis capacity during DNA damage repair process.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28668117",
                    "text": "DNA polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene in mammalian genomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7341fe2dc08e987e000018",
            "body": "What is the link between lithium use during pregnancy and Ebstein anomaly?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18982835",
                "http://www.ncbi.nlm.nih.gov/pubmed/8031346",
                "http://www.ncbi.nlm.nih.gov/pubmed/2743779",
                "http://www.ncbi.nlm.nih.gov/pubmed/28591541",
                "http://www.ncbi.nlm.nih.gov/pubmed/6518066",
                "http://www.ncbi.nlm.nih.gov/pubmed/1346886",
                "http://www.ncbi.nlm.nih.gov/pubmed/16611133",
                "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
                "http://www.ncbi.nlm.nih.gov/pubmed/24781368",
                "http://www.ncbi.nlm.nih.gov/pubmed/15702702"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8031346",
                    "text": "DATA EXTRACTION AND SYNTHESIS In the 1970s a very strong association was suggested between maternal lithium treatment during pregnancy and Ebstein's anomaly of the heart in the offspring.",
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 613,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2743779",
                    "text": "Some studies suggest that lithium might be involved as a teratogen increasing the incidence of Ebstein's anomaly in the offspring of female patients with manio-depressive psychosis and lithium-administered during pregnancy.",
                    "offsetInBeginSection": 74,
                    "offsetInEndSection": 297,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28591541",
                    "text": "BACKGROUND There has been concern that exposure to lithium early in pregnancy may be associated with a marked increase in the risk of Ebstein's anomaly (a right ventricular outflow tract obstruction defect) in infants and overall congenital cardiac defects, but data are conflicting and limited.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28591541",
                    "text": "CONCLUSIONS Maternal use of lithium during the first trimester was associated with an increased risk of cardiac malformations, including Ebstein's anomaly; the magnitude of this effect was smaller than had been previously postulated.",
                    "offsetInBeginSection": 1719,
                    "offsetInEndSection": 1952,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1346886",
                    "text": "In-utero exposure to lithium during the first trimester of pregnancy might be associated with an increased risk of cardiac malformations, especially the rare Ebstein's anomaly.",
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1346886",
                    "text": "Lithium carbonate is an effective drug for prophylaxis and treatment of major affective disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16611133",
                    "text": "There is a possibility that, in particular, lithium may be associated with the Ebstein anomaly but present evidence cannot definitely affirm or deny this association.",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12114921",
                    "text": "Reported neonatal problems with maternal lithium therapy include Ebstein's anomaly, poor respiratory effort and cyanosis, rhythm disturbances, nephrogenic diabetes insipidus, thyroid dysfunction, hypoglycemia, hypotonia and lethargy, hyperbilirubinemia, and large-for-gestational-age infants.",
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24781368",
                    "text": "CONCLUSIONS Lithium treatment in pregnancy is associated with a higher rate of cardiovascular anomalies.",
                    "offsetInBeginSection": 1708,
                    "offsetInEndSection": 1812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
                    "text": "A profound ultrasound screening of the organs should be performed in case of lithium exposition, whereas newer studies showed no increase in risk for Ebstein anomaly.",
                    "offsetInBeginSection": 1154,
                    "offsetInEndSection": 1320,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a774fdcfaa1ab7d2e000008",
            "body": "Which protein is regulated by Tudor interacting repair regulator (TIRR)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28241136"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "Here we identify an uncharacterized protein, Tudor interacting repair regulator (TIRR), that directly binds the tandem Tudor domain and masks its H4K20me2 binding motif.",
                    "offsetInBeginSection": 424,
                    "offsetInEndSection": 593,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "Upon DNA damage, the protein kinase ataxia-telangiectasia mutated (ATM) phosphorylates 53BP1 and recruits RAP1-interacting factor 1 (RIF1) to dissociate the 53BP1-TIRR complex.",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "P53-binding protein 1 (53BP1) is a multi-functional double-strand break repair protein that is essential for class switch recombination in B lymphocytes and for sensitizing BRCA1-deficient tumours to poly-ADP-ribose polymerase-1 (PARP) inhibitors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "Central to all 53BP1 activities is its recruitment to double-strand breaks via the interaction of the tandem Tudor domain with dimethylated lysine 20 of histone H4 (H4K20me2).",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "These findings identify TIRR as a new factor that influences double-strand break repair using a unique mechanism of masking the histone methyl-lysine binding function of 53BP1.",
                    "offsetInBeginSection": 1024,
                    "offsetInEndSection": 1200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "Depletion of TIRR destabilizes 53BP1 in the nuclear-soluble fraction and alters the double-strand break-induced protein complex centring 53BP1.",
                    "offsetInBeginSection": 880,
                    "offsetInEndSection": 1023,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "However, overexpression of TIRR impedes 53BP1 function by blocking its localization to double-strand breaks.",
                    "offsetInBeginSection": 771,
                    "offsetInEndSection": 879,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9931cd1d1251d03b00000d",
            "body": "Does SARM1 deletion cause neurodegeneration?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28978465",
                "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                "http://www.ncbi.nlm.nih.gov/pubmed/26686637",
                "http://www.ncbi.nlm.nih.gov/pubmed/28485482",
                "http://www.ncbi.nlm.nih.gov/pubmed/24993772"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978465",
                    "text": "We therefore propose Sarm1 deletion as a more reliable tool than WldS for investigating Wallerian-like mechanisms in disease models and suggest that SARM1 blockade may have greater therapeutic potential than WLDS-related strategies.",
                    "offsetInBeginSection": 822,
                    "offsetInEndSection": 1054,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978465",
                    "text": "While Sarm1 deletion or WldS can rescue perinatal lethality and widespread Wallerian-like axonopathy in young NMNAT2-deficient mice, we report that an absence of SARM1 enables these mice to survive into old age with no overt phenotype, whereas those rescued by WldS invariantly develop a progressive neuromuscular defect in their hindlimbs from around 3\u00a0months of age.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 821,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                    "text": "Hence, genetic deletion of SARM1 blocks the development of vincristine-induced peripheral polyneuropathy in mice.",
                    "offsetInBeginSection": 1936,
                    "offsetInEndSection": 2049,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                    "text": "We suggest that targeting SARM1 or its downstream effectors may be a viable therapeutic option to prevent vincristine-induced peripheral polyneuropathy and possibly other peripheral polyneuropathies.",
                    "offsetInBeginSection": 2506,
                    "offsetInEndSection": 2705,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                    "text": "Our results reveal that subacute/chronic axon loss induced by vincristine occurs via a SARM1 mediated axonal destruction pathway, and that blocking this pathway prevents the development of vincristine-induced peripheral polyneuropathy.",
                    "offsetInBeginSection": 2050,
                    "offsetInEndSection": 2285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                    "text": "Here we evaluate if genetic deletion of SARM1 decreases axonal degeneration in a mouse model of neuropathy induced by the chemotherapeutic agent vincristine.",
                    "offsetInBeginSection": 813,
                    "offsetInEndSection": 970,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                    "text": "This finding fuels hope that inhibition of SARM1 or its downstream components can be used therapeutically in patients threatened by axonal loss.",
                    "offsetInBeginSection": 451,
                    "offsetInEndSection": 595,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                    "text": "Recently, we and others discovered that genetic deletion of SARM1 (sterile alpha and TIR motif containing protein 1) dramatically protects axons from degeneration after axotomy in mice.",
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28485482",
                    "text": "Although several studies in mouse models of peripheral neuropathy showed prevention of axon degeneration in the slow Wallerian degeneration (Wlds) mouse, the role of a recently identified player in Wallerian degeneration, Sarm1, has not been explored extensively.",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 401,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24993772",
                    "text": "However, recent reports have indicated that neurons express the key players of innate immunity, including Toll-like receptors (TLRs) and their adaptor proteins (Sarm1, Myd88, and Trif), and may produce cytokines in response to pathogen infection.",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 441,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa55b65d6d6b54f7900000e",
            "body": "Please list 6 symptoms of Scarlet fever.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11086489",
                "http://www.ncbi.nlm.nih.gov/pubmed/1919136",
                "http://www.ncbi.nlm.nih.gov/pubmed/29081840",
                "http://www.ncbi.nlm.nih.gov/pubmed/26585817",
                "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                "http://www.ncbi.nlm.nih.gov/pubmed/2772682",
                "http://www.ncbi.nlm.nih.gov/pubmed/3619689",
                "http://www.ncbi.nlm.nih.gov/pubmed/3284506",
                "http://www.ncbi.nlm.nih.gov/pubmed/28468073",
                "http://www.ncbi.nlm.nih.gov/pubmed/19871154"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11086489",
                    "text": "A further 6 children, outside of this class, had complaints of scarlet fever, impetigo or pharyngitis.",
                    "offsetInBeginSection": 711,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136",
                    "text": "Reinfection or relapse cases of scarlet fever were found in 6.7% (642/9,585).",
                    "offsetInBeginSection": 1542,
                    "offsetInEndSection": 1619,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136",
                    "text": "6.",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 610,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                    "text": "Scarlatinal antistreptococcic serum affords some degree of protection against virulent scarlet fever streptococci but has no protective power against hemolytic streptococci from other diseases.",
                    "offsetInBeginSection": 987,
                    "offsetInEndSection": 1180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                    "text": "6.",
                    "offsetInBeginSection": 867,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2772682",
                    "text": "The severity of symptoms and the demonstration of scarlet fever developing from infection with this organism supports antibiotic treatment of patients with group C streptococcal pharyngitis.",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3284506",
                    "text": "An extra- and intra-hepatic bile duct dilatation has been observed in a child in the course of scarlet fever.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28468073",
                    "text": "The ratio between numbers of scarlet fever cases and streptococcal infection was 1 \u2236 38.17.",
                    "offsetInBeginSection": 1315,
                    "offsetInEndSection": 1408,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19871154",
                    "text": "The scarlet fever toxin-antitoxin reaction is discussed in relation to other flocculation reactions.",
                    "offsetInBeginSection": 1033,
                    "offsetInEndSection": 1133,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19871154",
                    "text": "6.",
                    "offsetInBeginSection": 1030,
                    "offsetInEndSection": 1032,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aacd83ffcf4565872000008",
            "body": "What is PARP inhibitor (PARPi) resistance?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23103855",
                "http://www.ncbi.nlm.nih.gov/pubmed/28255272",
                "http://www.ncbi.nlm.nih.gov/pubmed/28973445",
                "http://www.ncbi.nlm.nih.gov/pubmed/28588062",
                "http://www.ncbi.nlm.nih.gov/pubmed/28069876",
                "http://www.ncbi.nlm.nih.gov/pubmed/28242626",
                "http://www.ncbi.nlm.nih.gov/pubmed/27454289",
                "http://www.ncbi.nlm.nih.gov/pubmed/23165508",
                "http://www.ncbi.nlm.nih.gov/pubmed/26984416",
                "http://www.ncbi.nlm.nih.gov/pubmed/28450426"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855",
                    "text": "Importantly, PARPi resistance was minimized by long-term treatment with the novel PARP inhibitor AZD2461, which is a poor P-glycoprotein substrate.",
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 842,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855",
                    "text": "We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-glycoprotein drug efflux transporter.",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255272",
                    "text": "Therefore, the concept to block PARP enzymes by PARP inhibitor (PARPi) was appreciated in cancer treatment.",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 360,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28588062",
                    "text": "High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 323,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28069876",
                    "text": "Olaparib is an FDA-approved PARP inhibitor (PARPi) that has shown promise as a synthetic lethal treatment approach for BRCA-mutant castration-resistant prostate cancer (CRPC) in clinical use.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28242626",
                    "text": "ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms.",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 938,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454289",
                    "text": "Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454289",
                    "text": "Ectopic overexpression of Rdd-BRCA1 promoted partial PARPi and cisplatin resistance.",
                    "offsetInBeginSection": 1264,
                    "offsetInEndSection": 1348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26984416",
                    "text": "Demonstration of anti-cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 649,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450426",
                    "text": "Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7347a02dc08e987e00001b",
            "body": "Gallbladder carriage is a well recognised means of spread of which bacteria?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24349565",
                "http://www.ncbi.nlm.nih.gov/pubmed/28018582",
                "http://www.ncbi.nlm.nih.gov/pubmed/23171127",
                "http://www.ncbi.nlm.nih.gov/pubmed/27131005",
                "http://www.ncbi.nlm.nih.gov/pubmed/28096978",
                "http://www.ncbi.nlm.nih.gov/pubmed/25206941"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565",
                    "text": "Salmonella Typhi asymptomatic chronic carriage represents a challenge for the diagnosis and prevention of typhoid fever in endemic areas.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349565",
                    "text": "Gallbladder carriage has been demonstrated to be mediated by biofilm formation on gallstones and by intracellular persistence in the gallbladder epithelium of mice.",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 380,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28018582",
                    "text": "BACKGROUND Asymptomatic carriage has been recognised as an important risk factor for infection caused by antibiotic resistant bacteria.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28018582",
                    "text": "We investigated the faecal carriage rates of ESBL-, AmpC-producing and ciprofloxacin non-susceptible Escherichia coli and Klebsiella spp.",
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 432,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23171127",
                    "text": "Because intestinal carriage is a key factor in the epidemiology of ESBL-producing Enterobacteriaceae, the study of the prevalence of these resistant bacteria and risk factors in young children is of particular interest.",
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 647,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23171127",
                    "text": "The fecal flora of children in the community can represent a reservoir for ESBLs genes which are located on highly transmissible plasmids and the spread of these genes among bacterial pathogens is concerning.",
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                    "text": "DESIGN We screened for the presence of aerobic and anaerobic ESBL-producing bacteria and bla CTX-M in supragingival plaque samples from healthy human adults with culture-verified fecal carriage of CTX-M-producing Escherichia coli.",
                    "offsetInBeginSection": 726,
                    "offsetInEndSection": 956,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                    "text": "Enterobacteriaceae are commonly found in the gastrointestinal tract and long-term intestinal carriage is considered important for the spread of ESBL and as a source of clinical infections.",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                    "text": "OBJECTIVE To investigate possible carriage of ESBL-producing bacteria in supragingival plaque of known fecal carriers of these bacteria.",
                    "offsetInBeginSection": 587,
                    "offsetInEndSection": 723,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                    "text": "Oral biofilm such as supragingival plaque is known to contain numerous antibiotic resistance determinants and may also represent a poorly investigated site for ESBL carriage and further spread.",
                    "offsetInBeginSection": 391,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a775182faa1ab7d2e000009",
            "body": "What is the role of tankyrases in response to Double Strand Breaks (DSBs)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26845027"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027",
                    "text": "The Mediator of DNA damage Checkpoint protein 1 (MDC1) is essential for spreading of the DDR signaling on chromatin surrounding Double Strand Breaks (DSBs) by acting as a scaffold for PI3K kinases and for ubiquitin ligases.",
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 402,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027",
                    "text": "DNA lesions are sensed by a network of proteins that trigger the DNA damage response (DDR), a signaling cascade that acts to delay cell cycle progression and initiate DNA repair.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027",
                    "text": "We find that TNKSs are recruited to DNA lesions by MDC1 and regulate DNA end resection and BRCA1A complex stabilization at lesions leading to efficient DSB repair by HR and proper checkpoint activation.",
                    "offsetInBeginSection": 627,
                    "offsetInEndSection": 829,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027",
                    "text": "MDC1 also plays a role both in Non-Homologous End Joining (NHEJ) and Homologous Recombination (HR) repair pathways.",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 518,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027",
                    "text": "Here we identify two novel binding partners of MDC1, the poly (ADP-ribose) Polymerases (PARPs) TNKS1 and 2.",
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 626,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9ac4161d1251d03b000010",
            "body": "Does MC1R palmitoylation reduce pigmentation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28869973"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "Here we demonstrate a potential MC1R-targeted intervention strategy in mice to rescue loss-of-function MC1R in MC1R RHC variants for therapeutic benefit by activating MC1R protein palmitoylation.",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "Using C57BL/6J-Mc1re/eJ mice, in which endogenous MC1R is prematurely terminated, expressing Mc1r RHC variants, we show that pharmacological activation of palmitoylation rescues the defects of Mc1r RHC variants and prevents melanomagenesis.",
                    "offsetInBeginSection": 1206,
                    "offsetInEndSection": 1446,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "The results highlight a central role for MC1R palmitoylation in pigmentation and protection against melanoma.",
                    "offsetInBeginSection": 1447,
                    "offsetInEndSection": 1556,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "MC1R palmitoylation, primarily mediated by the protein-acyl transferase ZDHHC13, is essential for activating MC1R signalling, which triggers increased pigmentation, ultraviolet-B-induced G1-like cell cycle arrest and control of senescence and melanomagenesis in vitro and in vivo.",
                    "offsetInBeginSection": 925,
                    "offsetInEndSection": 1205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "Individuals carrying MC1R variants, especially those associated with red hair colour, fair skin and poor tanning ability (denoted as RHC variants), are associated with higher risk of melanoma.",
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 495,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "The melanocortin-1 receptor (MC1R), a G-protein-coupled receptor, has a crucial role in human and mouse pigmentation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "However, how MC1R activity is modulated by ultraviolet irradiation, why individuals with red hair are more prone to developing melanoma, and whether the activity of RHC variants might be restored for therapeutic benefit are unknown.",
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 728,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "Activation of MC1R in melanocytes by \u03b1-melanocyte-stimulating hormone (\u03b1-MSH) stimulates cAMP signalling and melanin production and enhances DNA repair after ultraviolet irradiation.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 302,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a96c886fcd1d6a10c00002a",
            "body": "A bite from the Lone Star Tick Amblyomma americanum, can cause the victim to become allergic to red meat, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                "http://www.ncbi.nlm.nih.gov/pubmed/24690977",
                "http://www.ncbi.nlm.nih.gov/pubmed/25108787",
                "http://www.ncbi.nlm.nih.gov/pubmed/9722725",
                "http://www.ncbi.nlm.nih.gov/pubmed/21940418",
                "http://www.ncbi.nlm.nih.gov/pubmed/17848069"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "Amblyomma americanum, also known as the lone star tick, is found in much of the eastern United States.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "In addition to others, species of Rickettsia, Ehrlichia, and Borrelia are all transmitted by the lone star tick.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 372,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "Recently described conditions such as Southern tick-associated rash illness and anaphylaxis to red meat following tick bites have been attributed to the lone star tick.",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 541,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "Today, A americanum remains an important vector for tick-borne illness.",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 259,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24690977",
                    "text": "A link has been discovered between the bite of the Lone Star Tick (Amblyomma americanum) and the development of sensitivity to galactose-\u03b1-1,3-galactose.",
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 513,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787",
                    "text": "The Lone Star tick, Amblyomma americanum Linnaeus 1758 (Acari; Ixodidae), causes considerable production losses to the southern U.S. cattle industry due to reduced weight, infertility, secondary infections at bite wound sites, damaged hides, and potentially death, as these ticks tend to infest livestock in large numbers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 322,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787",
                    "text": "Increased expression of IGHG1, IL6, IL1\u03b1, and IL1RN in bovine tick bite-site biopsies suggests that Th2 differentiation may be important for the local bovine response to A. americanum ticks.",
                    "offsetInBeginSection": 1357,
                    "offsetInEndSection": 1548,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9722725",
                    "text": "OBJECTIVE To differentiate cases of physician-diagnosed erythema migrans and erythema migrans-like rashes associated with Lone Star tick (Amblyomma americanum) bites.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21940418",
                    "text": "The EM-like eruptions, which were of unknown etiology, often followed the bite of the Lone Star tick (Amblyomma americanum) and the rash is called STARI (southern tick-associated rash illness).",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 387,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17848069",
                    "text": "Two infectious diseases, and one presumably infectious disease, each vectored by or associated with the bite of the lone star tick (Amblyomma americanum), were identified and characterized by clinicians and scientists in the United States during the 1980s and 1990s.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 266,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aad547efcf456587200000b",
            "body": "What is the \"protein inference problem\"?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26935399",
                "http://www.ncbi.nlm.nih.gov/pubmed/23385215",
                "http://www.ncbi.nlm.nih.gov/pubmed/22954624",
                "http://www.ncbi.nlm.nih.gov/pubmed/17990506",
                "http://www.ncbi.nlm.nih.gov/pubmed/19645593",
                "http://www.ncbi.nlm.nih.gov/pubmed/22626983",
                "http://www.ncbi.nlm.nih.gov/pubmed/22331862",
                "http://www.ncbi.nlm.nih.gov/pubmed/24407311"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399",
                    "text": "In fact, the protein inference problem can be regarded as a special protein quantification problem in the sense that truly present proteins are those proteins whose abundance values are not zero.",
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 628,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399",
                    "text": "Thus, we argue that the protein inference problem can be viewed as a special protein quantification problem in which one protein is considered to be present if its abundance is not zero.",
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399",
                    "text": "This demonstrates that it is plausible to model the protein inference problem as a special protein quantification task, which opens the door of devising more effective protein inference algorithms from a quantification perspective.",
                    "offsetInBeginSection": 1638,
                    "offsetInEndSection": 1869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23385215",
                    "text": "Based on the concept of peptide detectability, we formulate the protein inference problem as a constrained Lasso regression problem, which can be solved very efficiently through a coordinate descent procedure.",
                    "offsetInBeginSection": 451,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22954624",
                    "text": "Based on this simple fact, the protein inference problem is formulated as an optimization problem: minimize the number of proteins with non-zero probabilities under the constraint that the difference between the calculated peptide probability and the peptide probability generated from peptide identification algorithms should be less than some threshold.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 1129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22954624",
                    "text": "Experimental results show that our method is competitive with the state-of-the-art protein inference algorithms.",
                    "offsetInBeginSection": 1402,
                    "offsetInEndSection": 1514,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17990506",
                    "text": "A major challenge in shotgun proteomics has been the assignment of identified peptides to the proteins from which they originate, referred to as the protein inference problem.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19645593",
                    "text": "The protein inference problem represents a major challenge in shotgun proteomics.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22626983",
                    "text": "SIR has in addition two visualization tools that facilitate further exploration of the protein inference problem.",
                    "offsetInBeginSection": 1197,
                    "offsetInEndSection": 1310,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22331862",
                    "text": "The problem of identifying the proteins in a complex mixture using tandem mass spectrometry can be framed as an inference problem on a graph that connects peptides to proteins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a736f0c3b9d13c708000007",
            "body": "What is included in the Mentzer index?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24818016",
                "http://www.ncbi.nlm.nih.gov/pubmed/18192142",
                "http://www.ncbi.nlm.nih.gov/pubmed/19579993",
                "http://www.ncbi.nlm.nih.gov/pubmed/25806419",
                "http://www.ncbi.nlm.nih.gov/pubmed/6185967",
                "http://www.ncbi.nlm.nih.gov/pubmed/24388269",
                "http://www.ncbi.nlm.nih.gov/pubmed/24139948",
                "http://www.ncbi.nlm.nih.gov/pubmed/28706390"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016",
                    "text": "The patient groups were evaluated according to red blood cell (RBC) count; red blood distribution width index; the Mentzer, Shine and Lal, England and Fraser, Srivastava and Bevington, Green and King, Ricerca, Sirdah, and Ehsani indices; mean density of hemoglobin/liter of blood; and mean cell density of hemoglobin.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 953,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016",
                    "text": "The Mentzer index provided the highest reliabilities for differentiating \u03b2 -TT from IDA.",
                    "offsetInBeginSection": 1245,
                    "offsetInEndSection": 1334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016",
                    "text": "The Mentzer index was the most reliable index, as it had the highest sensitivity (98.7%), specificity (82.3%), and Youden's index (81%) for detecting \u03b2 -TT; this was followed by the Ehsani index (94.8%, 73.5%, and 68.3%, resp.)",
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1191,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579993",
                    "text": "The best discrimination index according to Youden's criteria was Mentzer (Youden's index = 90.1) followed by the new index (Youden's index = 85.5).",
                    "offsetInBeginSection": 676,
                    "offsetInEndSection": 823,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579993",
                    "text": "Sensitivity, specificity and Youden's index were compared between the proposed index and four other indices, namely England-Fraser, Mentzer, Srivastava and RBC count.",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 534,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25806419",
                    "text": "Here, we demonstrate that in our population the Mentzer Index separates individuals with \u03b2-thal minor from those without \u03b2-thal minor, regardless of their iron status.",
                    "offsetInBeginSection": 576,
                    "offsetInEndSection": 745,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24388269",
                    "text": "METHODS The oral manifestations and mean red blood cell (RBC) count, corpuscular cell volume, RBC distribution width, Mentzer index, and Green and King index as well as blood concentrations of hemoglobin, iron, total iron binding capacity, vitamin B12, folic acid, and homocysteine in 75 IDA patients and in 150 age- and sex-matched healthy controls were measured and compared.",
                    "offsetInBeginSection": 220,
                    "offsetInEndSection": 597,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139948",
                    "text": "METHODS The oral manifestations and mean red blood cell count, corpuscular cell volume, red blood cell distribution width, Mentzer index, and Green and King index as well as blood concentrations of hemoglobin, iron, total iron binding capacity, vitamin B12, folic acid, and homocysteine in 65 TT patients and in 130 age- and sex-matched healthy controls were measured and compared.",
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 595,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139948",
                    "text": "Moreover, TT patients had significantly lower mean hemoglobin level, corpuscular cell volume, Mentzer index, and Green and King index (p < 0.001 for all) as well as significantly higher mean red blood cell count and red blood cell distribution width (p < 0.001 for both) than healthy controls.",
                    "offsetInBeginSection": 950,
                    "offsetInEndSection": 1243,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28706390",
                    "text": "Youden index of the Mentzer index (MI) was the highest (69.0) and S and L, the lowest (13.2) indicating MI to be the most efficient and the S and L, the least in differentiating the two entities.",
                    "offsetInBeginSection": 868,
                    "offsetInEndSection": 1063,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a804f71faa1ab7d2e00001d",
            "body": "Which algorithm is used for detection of long repeat expansions?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28887402"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                    "text": "Identifying large expansions of short tandem repeats (STRs), such as those that cause amyotrophic lateral sclerosis (ALS) and fragile X syndrome, is challenging for short-read whole-genome sequencing (WGS) data.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                    "text": "We applied our algorithm to WGS data from 3001 ALS patients who have been tested for the presence of the C9orf72 repeat expansion with repeat-primed PCR (RP-PCR).",
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 671,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                    "text": "Thus, ExpansionHunter can be used to accurately detect known pathogenic repeat expansions and provides researchers with a tool that can be used to identify new pathogenic repeat expansions.",
                    "offsetInBeginSection": 1360,
                    "offsetInEndSection": 1549,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                    "text": "We further applied our algorithm to a set of 152 samples in which every sample had one of eight different pathogenic repeat expansions, including those associated with fragile X syndrome, Friedreich's ataxia, and Huntington's disease, and correctly flagged all but one of the known repeat expansions.",
                    "offsetInBeginSection": 1059,
                    "offsetInEndSection": 1359,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                    "text": "We developed a software tool called ExpansionHunter that, using PCR-free WGS short-read data, can genotype repeats at the locus of interest, even if the expanded repeat is larger than the read length.",
                    "offsetInBeginSection": 308,
                    "offsetInEndSection": 508,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                    "text": "Additionally, 99.9% (2786/2789, 95% CI [0.997, 1.00]) of the wild-type samples were correctly classified as wild type by this method with the remaining three samples identified as possible expansions.",
                    "offsetInBeginSection": 858,
                    "offsetInEndSection": 1058,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                    "text": "Compared against this truth data, ExpansionHunter correctly classified all (212/212, 95% CI [0.98, 1.00]) of the expanded samples as either expansions (208) or potential expansions (4).",
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 857,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                    "text": "A solution to this problem is an important step toward integrating WGS into precision medicine.",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 307,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9ac4e81d1251d03b000011",
            "body": "Which brain tumors does neuroligin-3 promote?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25913192",
                "http://www.ncbi.nlm.nih.gov/pubmed/16300891",
                "http://www.ncbi.nlm.nih.gov/pubmed/28959975",
                "http://www.ncbi.nlm.nih.gov/pubmed/26032268",
                "http://www.ncbi.nlm.nih.gov/pubmed/18555979",
                "http://www.ncbi.nlm.nih.gov/pubmed/25957677",
                "http://www.ncbi.nlm.nih.gov/pubmed/24854097",
                "http://www.ncbi.nlm.nih.gov/pubmed/23248271"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913192",
                    "text": "The synaptic protein neuroligin-3 (NLGN3) was identified as the leading candidate mitogen, and soluble NLGN3 was sufficient and necessary to promote robust HGG cell proliferation.",
                    "offsetInBeginSection": 572,
                    "offsetInEndSection": 751,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891",
                    "text": "This study indicates that synaptogenetic processes in brain and retina use different molecular machineries, whereby the neuroligins might represent the more distinctly regulated part of the neurexin-neuroligin complexes.",
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1266,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891",
                    "text": "Therefore, we studied the expression patterns of neurexin-1 (Nx-1) and neuroligin-1 and -3 during embryonic development of the chick retina and brain by reverse-transcriptase polymerase chain reaction (RT-PCR) and in situ hybridization (ISH).",
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 563,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28959975",
                    "text": "An important mechanism that mediates this neural regulation of brain cancer is activity-dependent cleavage and secretion of the synaptic adhesion molecule neuroligin-3 (NLGN3), which promotes glioma proliferation through the PI3K-mTOR pathway.",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 848,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268",
                    "text": "published in Cell has identified Neuroligin-3 (NLGN3) as a mitogen promoting high-grade glioma growth.",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 329,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18555979",
                    "text": "Recent studies reported that sequence polymorphisms in neuroligin-3 (NLGN3) and neuroligin-4 (NLGN4) genes have been linked to autism spectrum disorders indicating neuroligin genes as candidate targets in brain disorders.",
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25957677",
                    "text": "demonstrate that this also occurs in the brain, identifying neuronal activity-induced secretion of neuroligin-3 as a novel mechanism promoting glioma proliferation.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24854097",
                    "text": "In this study, we characterized the expression of a gene involved in synaptogenesis and plasticity (neuroligin-3) and one that codes for the rate-limiting enzyme in dopamine biosynthesis (tyrosine hydroxylase; TH1) in the female Xiphophorus nigrensis (northern swordtail) brain as related to mate preference behavior.",
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 726,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24854097",
                    "text": "Analysis of TH and neuroligin-3 expression across different brain regions showed that expression patterns varied with the male social environment only for neuroligin-3, where the density of correlated expression between brain regions was positively associated with mate choice contexts that involved a greater number of courting male phenotypes (LS and LL).",
                    "offsetInBeginSection": 1373,
                    "offsetInEndSection": 1730,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248271",
                    "text": "Likewise, coexpression of both MDGA1 and neuroligin-2 reduced the synaptogenic capacity of neuroligin-2 in an artificial synapse-formation assay by abolishing the ability of neuroligin-2 to form an adhesion complex with neurexins.",
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1225,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a96f40cfcd1d6a10c00002b",
            "body": "What is calciphylaxis",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10764004",
                "http://www.ncbi.nlm.nih.gov/pubmed/27321367",
                "http://www.ncbi.nlm.nih.gov/pubmed/20019019",
                "http://www.ncbi.nlm.nih.gov/pubmed/24096524",
                "http://www.ncbi.nlm.nih.gov/pubmed/23430392",
                "http://www.ncbi.nlm.nih.gov/pubmed/23663061",
                "http://www.ncbi.nlm.nih.gov/pubmed/16108246",
                "http://www.ncbi.nlm.nih.gov/pubmed/26779700",
                "http://www.ncbi.nlm.nih.gov/pubmed/29053546",
                "http://www.ncbi.nlm.nih.gov/pubmed/21324820"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004",
                    "text": "Key Words: Calciphylaxis, parathyroid hormone, parathyroidectomy, skin necrosis, chronic renal failure.",
                    "offsetInBeginSection": 2001,
                    "offsetInEndSection": 2104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004",
                    "text": "OBJECTIVE Calciphylaxis, a rare disorder typically affecting renal failure patients, results in vascular calcification with subsequent skin necrosis, gangrene, and often death from sepsis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27321367",
                    "text": "WHAT IS NEW AND CONCLUSION Previously only few cases of solely warfarin-induced calciphylaxis have been described.",
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27321367",
                    "text": "WHAT IS KNOWN AND OBJECTIVE Calciphylaxis is a rare and potentially life-threatening cause of skin necrosis and is poorly recognized by clinicians in non-uraemic patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019019",
                    "text": "Although calciphylaxis is most frequently associated with end-stage renal disease (ESRD) and secondary hyperparathyroidism, it has been reported infrequently among patients on warfarin.",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663061",
                    "text": "Calciphylaxis is a metastatic calcification-induced vasculopathy that results in the occlusion of small blood vessels.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663061",
                    "text": "Although calciphylaxis is normally associated with end-stage renal disease, calciphylaxis from non-uremic origin occurs as well.",
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26779700",
                    "text": "Calciphylaxis is characterized by calcification in the medium and small vessel arterioles and can be a life-threatening complication often associated with chronic kidney disease (CKD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26779700",
                    "text": "There is no definitive evidence to support the belief current epidemic rates of obesity, diabetes, (diabesity), and chronic renal disease will predispose more patients to the development of calciphylaxis.",
                    "offsetInBeginSection": 1006,
                    "offsetInEndSection": 1210,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21324820",
                    "text": "A multidisciplinary approach involving early diagnosis, aggressive medical management, operative debridement, and parathyroidectomy has the best chance of improving survival in calciphylaxis.",
                    "offsetInBeginSection": 1580,
                    "offsetInEndSection": 1771,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d79ca1d1251d03b00001d",
            "body": "Is the gene CDKN2A nevogenic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10620111",
                "http://www.ncbi.nlm.nih.gov/pubmed/15304099",
                "http://www.ncbi.nlm.nih.gov/pubmed/28830827",
                "http://www.ncbi.nlm.nih.gov/pubmed/12406345"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10620111",
                    "text": "1), supporting the view that CDKN2A is nevogenic.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 651,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10620111",
                    "text": "We have correlated the atypical mole syndrome phenotype and gene carrier status in five families with germline CDKN2A mutations and shown that family members with the atypical mole syndrome were three times more likely to be mutant gene carriers than their relatives who did not have the atypical mole syndrome (odds ratio 3.4; confidence interval 1.0-11.",
                    "offsetInBeginSection": 246,
                    "offsetInEndSection": 601,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10620111",
                    "text": "Those family members who also have the atypical mole syndrome are commonly targeted for screening in the belief that they are more likely to be mutant gene carriers.",
                    "offsetInBeginSection": 80,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15304099",
                    "text": "Continued accumulation of nevi in mutation carriers supports a nevogenic role for this CDKN2A mutation.",
                    "offsetInBeginSection": 1154,
                    "offsetInEndSection": 1257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830827",
                    "text": "Our results support the hypothesis that unidentified nevogenic genes are co-inherited with CDKN2A and may influence carcinogenesis.",
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830827",
                    "text": "Germline mutations in CDKN2A are frequently identified among melanoma kindreds and are associated with increased atypical nevus counts.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12406345",
                    "text": "Rare germline mutations in CDKN2A predispose to melanoma and appear to be nevogenic, although the correlation between nevus phenotype and mutation status is poor.",
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12406345",
                    "text": "Ala148Thr is a G to A missense polymorphism of CDKN2A, which is found in 4%-6% of the general population.",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 664,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12406345",
                    "text": "It is plausible that more common CDKN2A variants may influence both melanoma susceptibility and nevus susceptibility.",
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 558,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12406345",
                    "text": "Melanocytic nevi are the most potent risk factors for melanoma yet identified.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7373f63b9d13c708000008",
            "body": "Which disease is treated with Fexinidazole?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
                "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
                "http://www.ncbi.nlm.nih.gov/pubmed/22539226",
                "http://www.ncbi.nlm.nih.gov/pubmed/24841257",
                "http://www.ncbi.nlm.nih.gov/pubmed/21200426",
                "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
                "http://www.ncbi.nlm.nih.gov/pubmed/28552771"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
                    "text": "CONCLUSIONS Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi.",
                    "offsetInBeginSection": 1832,
                    "offsetInEndSection": 2005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
                    "text": "Fexinidazole, a 2-subsituted 5-nitroimidazole drug candidate rediscovered following extensive compound mining by the Drugs for Neglected Diseases initiative and currently in Phase I clinical study for the treatment of human African trypanosomiasis, was evaluated in experimental models of acute and chronic CD caused by different strains of Trypanosoma cruzi.",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 649,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
                    "text": "Here, we report that fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis.",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 359,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
                    "text": "These findings illustrate the potential of fexinidazole as an oral drug therapy for treating visceral leishmaniasis.",
                    "offsetInBeginSection": 1547,
                    "offsetInEndSection": 1663,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539226",
                    "text": "Fexinidazole, a 2-substituted 5-nitroimidazole rediscovered by the Drugs for Neglected Diseases initiative (DNDi) after extensive compound mining of public and pharmaceutical company databases, has the potential to become a short-course, safe and effective oral treatment, curing both acute and chronic HAT.",
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24841257",
                    "text": "Fexinidazole metabolites were effective in treating T. cruzi in a mouse model of acute infection, with cure rates superior to those achieved with either fexinidazole itself or benznidazole.",
                    "offsetInBeginSection": 1540,
                    "offsetInEndSection": 1729,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21200426",
                    "text": "Fexinidazole is the first new clinical drug candidate with the potential for treating advanced-stage sleeping sickness in thirty years.",
                    "offsetInBeginSection": 3566,
                    "offsetInEndSection": 3701,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
                    "text": "Therefore, we aimed to assess the safety and efficacy of an oral regimen of fexinidazole (a 2-substituted 5-nitroimidazole with proven trypanocidal activity) versus nifurtimox eflornithine combination therapy in patients with late-stage g-HAT.",
                    "offsetInBeginSection": 451,
                    "offsetInEndSection": 694,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
                    "text": "INTERPRETATION Our findings show that oral fexinidazole is effective and safe for the treatment of T b gambiense infection compared with nifurtimox eflornithine combination therapy in late-stage HAT patients.",
                    "offsetInBeginSection": 3213,
                    "offsetInEndSection": 3421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
                    "text": "In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.",
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 357,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8056a2faa1ab7d2e00001f",
            "body": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                "http://www.ncbi.nlm.nih.gov/pubmed/28806134"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                    "text": "Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins.",
                    "offsetInBeginSection": 901,
                    "offsetInEndSection": 1110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                    "text": "These proteins are referred to as LIR-containing proteins (LIRCPs).",
                    "offsetInBeginSection": 1111,
                    "offsetInEndSection": 1178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                    "text": "Given the need for the identification of LIRCPs in various organisms, we developed the iLIR database ( https://ilir.warwick.ac.uk ) as a freely available web resource, listing all the putative canonical LIRCPs identified in silico in the proteomes of 8 model organisms using the iLIR server, combined with a Gene Ontology (GO) term analysis.",
                    "offsetInBeginSection": 1330,
                    "offsetInEndSection": 1671,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                    "text": "Additionally, a curated text-mining analysis of the literature permitted us to identify novel putative LICRPs in mammals that have not previously been associated with autophagy.",
                    "offsetInBeginSection": 1672,
                    "offsetInEndSection": 1849,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                    "text": "In the past few years it has been revealed that Atg8-interacting proteins include not only receptors but also components of the core autophagic machinery, proteins associated with vesicles and their transport, and specific proteins that are selectively degraded by autophagy.",
                    "offsetInBeginSection": 625,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                    "text": "Atg8-family proteins are the best-studied proteins of the core autophagic machinery.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134",
                    "text": "Here, we have developed the iLIR@viral database ( http://ilir.uk/virus/ ) as a freely accessible web resource listing all the putative canonical LIR motifs identified in viral proteins.",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 929,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134",
                    "text": "Additionally, we used a curated text-mining analysis of the literature to identify novel putative LIR motif-containing proteins (LIRCPs) in viruses.",
                    "offsetInBeginSection": 930,
                    "offsetInEndSection": 1078,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134",
                    "text": "So far, only one viral protein has been experimentally shown to have a functional LIR motif, leaving open a vast field for investigation.",
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 743,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134",
                    "text": "Such interactions are usually mediated through LC3-interacting region (LIR) motifs.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 605,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9ac6821d1251d03b000012",
            "body": "How does neuronal activity affect neuroligin-3?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25913192",
                "http://www.ncbi.nlm.nih.gov/pubmed/26032268",
                "http://www.ncbi.nlm.nih.gov/pubmed/27725662",
                "http://www.ncbi.nlm.nih.gov/pubmed/28959975",
                "http://www.ncbi.nlm.nih.gov/pubmed/15150161",
                "http://www.ncbi.nlm.nih.gov/pubmed/16300891",
                "http://www.ncbi.nlm.nih.gov/pubmed/28067903",
                "http://www.ncbi.nlm.nih.gov/pubmed/19406211",
                "http://www.ncbi.nlm.nih.gov/pubmed/15152050",
                "http://www.ncbi.nlm.nih.gov/pubmed/24619977"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268",
                    "text": "published in Cell has identified Neuroligin-3 (NLGN3) as a mitogen promoting high-grade glioma growth.",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 329,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662",
                    "text": "Strikingly, developmentally early conditional knockout of cerebellin-1 only modestly impaired synaptic transmission, whereas in contrast to the individual single knockouts, developmentally early conditional double knockout of both cerebellin-1 and neuroligin-3 severely decreased synaptic transmission.",
                    "offsetInBeginSection": 1216,
                    "offsetInEndSection": 1518,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662",
                    "text": "Mutations in neuroligin-3 predispose to autism, but how such mutations affect synaptic function remains incompletely understood.",
                    "offsetInBeginSection": 89,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28959975",
                    "text": "An important mechanism that mediates this neural regulation of brain cancer is activity-dependent cleavage and secretion of the synaptic adhesion molecule neuroligin-3 (NLGN3), which promotes glioma proliferation through the PI3K-mTOR pathway.",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 848,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15150161",
                    "text": "Our findings suggest that the previously identified mutations in neuroligin genes are likely to be relevant for the neuro-developmental defects in autism-spectrum disorders and mental retardation since they impair the function of a synaptic cell adhesion molecule.",
                    "offsetInBeginSection": 982,
                    "offsetInEndSection": 1246,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903",
                    "text": "As a result, the neuroligin-3 deletion altered network activity by reducing gamma oscillations and sharp wave ripples, changes associated with a decrease in extinction of contextual fear memories.",
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 865,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903",
                    "text": "Here we show that conditional deletion of the postsynaptic cell adhesion molecule neuroligin-3 in parvalbumin interneurons causes a decrease in NMDA-receptor-mediated postsynaptic currents and an increase in presynaptic glutamate release probability by selectively impairing the inhibition of glutamate release by presynaptic Group III metabotropic glutamate receptors.",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903",
                    "text": "These results demonstrate that neuroligin-3 specifies the properties of excitatory synapses on parvalbumin-containing interneurons by a retrograde trans-synaptic mechanism and suggest a molecular pathway whereby neuroligin-3 mutations contribute to neuropsychiatric disorders.",
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19406211",
                    "text": "The neuroligin (NL) gene family codes for brain specific cell adhesion molecules that play an important role in synaptic connectivity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24619977",
                    "text": "While some of these genes reach genome-wide significance, others, such as the R451C point mutation in the synaptic cell adhesion molecule neuroligin-3, appear to be rare.",
                    "offsetInBeginSection": 77,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9700adfcd1d6a10c00002c",
            "body": "Sclerostin regulates what process?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23737439",
                "http://www.ncbi.nlm.nih.gov/pubmed/28571484",
                "http://www.ncbi.nlm.nih.gov/pubmed/28081119",
                "http://www.ncbi.nlm.nih.gov/pubmed/25030653",
                "http://www.ncbi.nlm.nih.gov/pubmed/21890009",
                "http://www.ncbi.nlm.nih.gov/pubmed/12702725",
                "http://www.ncbi.nlm.nih.gov/pubmed/24151757",
                "http://www.ncbi.nlm.nih.gov/pubmed/20043874",
                "http://www.ncbi.nlm.nih.gov/pubmed/22082361",
                "http://www.ncbi.nlm.nih.gov/pubmed/21312267"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439",
                    "text": "We found that sclerostin upregulated osteocyte expression of carbonic anhydrase 2 (CA2/Car2), cathepsin K (CTSK/Ctsk), and tartrate-resistant acid phosphatase (ACP5/Acp5).",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 807,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439",
                    "text": "Knockdown in MLO-Y4 cells of each of the putative sclerostin receptors, Lrp4, Lrp5 and Lrp6, using siRNA, inhibited the sclerostin induction of Car2, Catk and Acp5 mRNA, as well as pHo and calcium release.",
                    "offsetInBeginSection": 1496,
                    "offsetInEndSection": 1701,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439",
                    "text": "The osteocyte product sclerostin is emerging as an important paracrine regulator of bone mass.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28571484",
                    "text": "In humans, the SOST gene encodes sclerostin, an inhibitor of bone growth and remodeling, which also negatively regulates the bone repair process.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28081119",
                    "text": "Sclerostin secreted by osteocytes is mechanosensory and important in bone remodeling.",
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25030653",
                    "text": "Therefore, adaptive bone remodeling occurring at a distinct bone compartment is orchestrated by altered sclerostin levels, which regulate the expression of the other osteocyte-specific proteins, such as RANKL, OPG, and proteins encoded by \"mineralization-related genes\" (DMP1, PHEX, and probably FGF23).",
                    "offsetInBeginSection": 1104,
                    "offsetInEndSection": 1407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25030653",
                    "text": "For example, under specific terms, sclerostin regulates differential RANKL and OPG production, and creates a dynamic RANKL/OPG ratio, leading either to bone formation or resorption.",
                    "offsetInBeginSection": 1408,
                    "offsetInEndSection": 1589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21890009",
                    "text": "Sclerostin is a secreted inhibitor of Wnt signaling and plays an essential role in the regulation of bone mass.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20043874",
                    "text": "Sclerostin, a secreted glycoprotein, regulates osteoblast function.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22082361",
                    "text": "Sclerostin, an osteocyte-expressed negative regulator of bone formation, is one of the inhibitors of Wnt signaling that is a critical pathway in the correct process of osteoblast differentiation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d7caa1d1251d03b00001e",
            "body": "What is Alzheimers disease resilience?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                "http://www.ncbi.nlm.nih.gov/pubmed/28299413",
                "http://www.ncbi.nlm.nih.gov/pubmed/27815399",
                "http://www.ncbi.nlm.nih.gov/pubmed/29124107",
                "http://www.ncbi.nlm.nih.gov/pubmed/23127468",
                "http://www.ncbi.nlm.nih.gov/pubmed/18728949",
                "http://www.ncbi.nlm.nih.gov/pubmed/28025282"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                    "text": "The following terminology was applied: Alzheimer resilience, brain resilience, metabolic resilience, cardiovascular resilience, mitochondrial resilience and exercise resilience.",
                    "offsetInBeginSection": 1114,
                    "offsetInEndSection": 1291,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                    "text": "CONCLUSION knowing that disturbances in brain, neuroendocrine, vascular and mitochondria metabolism are important events in neurodegeneration and dementia development, the ability of exercise to trigger adaptive mechanisms might represent an important non-pharmacological strategy to improve resilience to AD.",
                    "offsetInBeginSection": 1609,
                    "offsetInEndSection": 1918,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                    "text": "Five papers defined Alzheimer's resilience, 15 papers brain resilience, five cardiovascular resilience, one metabolic resilience, 11 mitochondrial resilience, and 7 exercise resilience.",
                    "offsetInBeginSection": 1339,
                    "offsetInEndSection": 1524,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                    "text": "BACKGROUND Although Alzheimer's disease (AD) is a neurodegenerative pathology characterized by accumulation of \u03b2-amyloid plaques and neurofibrillary tangles at cerebral level, recent studies highlighted that AD might be the result of many altered physiological processes occurring at whole-organism level.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28299413",
                    "text": "However, unlike other conditions (e.g., Alzheimer's disease and coronary artery disease), resilience to trauma is not a disease but an adaptive response to trauma.",
                    "offsetInBeginSection": 1452,
                    "offsetInEndSection": 1615,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28299413",
                    "text": "We found a significantly higher resilience in participants with apoE genotype containing the E2 allele (E2/2, E2/3) as compared to participants with the E4 allele (E4/4, E4/3).",
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 800,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815399",
                    "text": "Furthermore, resilience metrics interacted with biomarker status such that biomarker-positive individuals with low resilience showed the greatest risk of subsequent decline.",
                    "offsetInBeginSection": 1265,
                    "offsetInEndSection": 1438,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18728949",
                    "text": "Social support positively influenced resilience, and caregivers with high family support had the highest probability of elevated resilience.",
                    "offsetInBeginSection": 964,
                    "offsetInEndSection": 1104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025282",
                    "text": "Objectives Apolipoprotein E (APOE) \u025b4 and Clusterin (CLU) C alleles are risk factors for Alzheimer's disease (AD) and episodic memory (EM) decline.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025282",
                    "text": "Results For both sexes, younger age, higher education, stronger grip, and everyday novel cognitive activity predicted memory resilience.",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 905,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7376e33b9d13c708000009",
            "body": "Describe Vanishing lung syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26259424",
                "http://www.ncbi.nlm.nih.gov/pubmed/25322795",
                "http://www.ncbi.nlm.nih.gov/pubmed/22564798",
                "http://www.ncbi.nlm.nih.gov/pubmed/28219569",
                "http://www.ncbi.nlm.nih.gov/pubmed/22937434",
                "http://www.ncbi.nlm.nih.gov/pubmed/28975065",
                "http://www.ncbi.nlm.nih.gov/pubmed/24511405",
                "http://www.ncbi.nlm.nih.gov/pubmed/7272201",
                "http://www.ncbi.nlm.nih.gov/pubmed/25618882",
                "http://www.ncbi.nlm.nih.gov/pubmed/24977015"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424",
                    "text": "Vanishing lung syndrome (VLS) is a rare radiological syndrome in which the lungs appear to be disappearing on X-ray.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424",
                    "text": "Eventually, his CT chest revealed the diagnosis of giant bullous disease/vanishing lung syndrome.",
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 792,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795",
                    "text": "The present study suggests that vanishing lung syndrome may be associated with autosomal dominant and recessive genetic inheritance.",
                    "offsetInBeginSection": 1316,
                    "offsetInEndSection": 1448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795",
                    "text": "Vanishing lung syndrome, also known as idiopathic giant bullous emphysema, is a rare disease characterized by giant emphysematous bullae.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219569",
                    "text": "Vanishing lung syndrome is a clinical presentation of giant bullous emphysema associated with significant morbidity and mortality.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219569",
                    "text": "We present a case of a 50-year-old white woman with vanishing lung syndrome who presented with a spontaneous secondary pneumothorax and an uncontrolled bronchopleural fistula.",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937434",
                    "text": "We describe here a rare case of Idiopathic Bullous Emphysema/Vanishing Lung Syndrome (VLS) in a 33-year-old male patient with a history of marijuana abuse who presents to the hospital with pleuritic chest pain thought to be due to pneumothorax based on the chest radiograph.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 274,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28975065",
                    "text": "A small number of case reports have described a pathological entity called vanishing lung syndrome (VLS), which is a rare bullous lung disease usually caused by tobacco smoking.",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24511405",
                    "text": "Vanishing lung syndrome (VLS) is a rare and distinct clinical syndrome that usually affects young men.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
                    "text": "Giant bullous emphysema (GBE), known as 'vanishing lung syndrome', usually occurs in association with chronic obstructive pulmonary disease (COPD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a80dbaafaa1ab7d2e000026",
            "body": "Are there ways of joint Bayesian inference of risk variants?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27407109"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "In simulation, RiVIERA promising power in detecting causal variants and causal annotations, the multi-trait joint inference further improved the detection power.",
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 697,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "Here, we introduce a new Bayesian model RiVIERA (Risk Variant Inference using Epigenomic Reference Annotations) for inference of driver variants from summary statistics across multiple traits using hundreds of epigenomic annotations.",
                    "offsetInBeginSection": 302,
                    "offsetInEndSection": 535,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "This is partly remedied by prioritization of disease-associated variants that overlap GWAS-enriched epigenomic annotations.",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 301,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "Genome wide association studies (GWAS) provide a powerful approach for uncovering disease-associated variants in human, but fine-mapping the causal variants remains a challenge.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "RiVIERA identified meaningful tissue-specific enrichments for enhancer regions defined by H3K4me1 and H3K27ac for Blood T-Cell specifically in the nine autoimmune diseases and Brain-specific enhancer activities exclusively in Schizophrenia.",
                    "offsetInBeginSection": 1003,
                    "offsetInEndSection": 1243,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "Moreover, the variants from the 95% credible sets exhibited high conservation and enrichments for GTEx whole-blood eQTLs located within transcription-factor-binding-sites and DNA-hypersensitive-sites.",
                    "offsetInBeginSection": 1244,
                    "offsetInEndSection": 1444,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "Furthermore, joint modeling the nine immune traits by simultaneously inferring and exploiting the underlying epigenomic correlation between traits further improved the functional enrichments compared to single-trait models.",
                    "offsetInBeginSection": 1445,
                    "offsetInEndSection": 1668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "We applied RiVIERA to model the existing GWAS summary statistics of 9 autoimmune diseases and Schizophrenia by jointly harnessing the potential causal enrichments among 848 tissue-specific epigenomics annotations from ENCODE/Roadmap consortium covering 127 cell/tissue types and 8 major epigenomic marks.",
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 1002,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9ac7ba1d1251d03b000013",
            "body": "What does intepirdine target?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28253832"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "Studies have shown that the current treatments for AD, cholinesterase inhibitors (ChEI's) and NMDA receptor antagonists, have limited efficacy.",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "Expert opinion: If current Phase-3 trials are positive, 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.",
                    "offsetInBeginSection": 1152,
                    "offsetInEndSection": 1385,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "The 5-HT-6 receptor antagonists Idalopirdine and Intepirdine have shown the most progress in current clinical trials and warrant consideration as emerging treatments for AD.",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 710,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "Characterized by neuronal cell death accompanied by the accumulation of neurofibrillary tangles and neuritic plaques, AD results in devastating clinical symptomatology with a lasting psychosocial and financial impact.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "Areas covered: This review discusses 5-HT6 antagonists currently in clinical trials as potential treatments for AD symptomatology and how 5-HT6 physiology may play a positive role in alleviating AD symptom pathophysiology.",
                    "offsetInBeginSection": 711,
                    "offsetInEndSection": 933,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "A literature search using PubMed was conducted using the terms Idalopirdine, Intepirdine, 5-HT-6 antagonist, and AD as keywords.",
                    "offsetInBeginSection": 934,
                    "offsetInEndSection": 1062,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "Alzheimer's disease (AD) is a major neuropsychiatric disorder affecting more than 5 million Americans over age 65.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "Clinicaltrials.gov and Alzforum were also used to obtain information on clinical trials.",
                    "offsetInBeginSection": 1063,
                    "offsetInEndSection": 1151,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "By the year 2050, AD is expected to affect over 30 million.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a981bcffcd1d6a10c00002d",
            "body": "List 3 symptoms of Wernicke encephalopathy.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15141340",
                "http://www.ncbi.nlm.nih.gov/pubmed/25539041",
                "http://www.ncbi.nlm.nih.gov/pubmed/16219837",
                "http://www.ncbi.nlm.nih.gov/pubmed/24293308",
                "http://www.ncbi.nlm.nih.gov/pubmed/27399058",
                "http://www.ncbi.nlm.nih.gov/pubmed/25856744",
                "http://www.ncbi.nlm.nih.gov/pubmed/17039990",
                "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
                "http://www.ncbi.nlm.nih.gov/pubmed/23696407",
                "http://www.ncbi.nlm.nih.gov/pubmed/26653343"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340",
                    "text": "Wernicke encephalopathy, a potentially reversible condition, may be unrecognized in terminally ill cancer patients.",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 284,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340",
                    "text": "Although Wernicke encephalopathy has been reported in the oncological literature, only one terminally ill cancer patient with Wernicke encephalopathy has been reported.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041",
                    "text": "The syndrome can develop from unrecognized or undertreated Wernicke encephalopathy.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041",
                    "text": "Self-neglecting alcoholics who are bedridden may have severe illness and probably active Wernicke encephalopathy.",
                    "offsetInBeginSection": 915,
                    "offsetInEndSection": 1028,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041",
                    "text": "The intra-individual course of Wernicke-Korsakoff syndrome has not been studied extensively, nor has the temporal progression of gait disturbances and other symptoms of Wernicke encephalopathy.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 361,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16219837",
                    "text": "Wernicke encephalopathy is a neurologic disorder that results from thiamine deficiency.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293308",
                    "text": "Wernicke encephalopathy is rare and under-recognized in childhood and may be fatal.",
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293308",
                    "text": "Wernicke encephalopathy should be considered in all children with cancer presenting a neurologic deterioration, mainly in brain tumors.",
                    "offsetInBeginSection": 891,
                    "offsetInEndSection": 1026,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25856744",
                    "text": "Wernicke encephalopathy is an acute neuropsychiatric disease with heterogeneous symptoms, including changes in mental status, ataxia and ocular abnormalities; if left untreated, these symptoms can lead to morbidity and even to mortality.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9279523",
                    "text": "Both the thyrotoxicosis and a catabolic state due to the hyperemesis were thought to have induced a vitamin B1 deficiency, causing the Wernicke encephalopathy.",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 722,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d8d691d1251d03b000020",
            "body": "What is the association of the protein RAB10 and Alzheimers disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26082458",
                "http://www.ncbi.nlm.nih.gov/pubmed/19008234",
                "http://www.ncbi.nlm.nih.gov/pubmed/29127256"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458",
                    "text": "The target genes SEC22 vesicle trafficking protein homolog B (SEC22B) and SEC63 homolog (SEC63) regulated by miRNA-206, RAB10, member RAS oncogene family (RAB10) regulated by miRNA-655, and fms-related tyrosine kinase 1 (FLT1) regulated by miRNA-30e-3p and miRNA-369-3p were involved in the biological processes of protein transport and regulation of cell motion.",
                    "offsetInBeginSection": 678,
                    "offsetInEndSection": 1041,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458",
                    "text": "CONCLUSION The target genes SEC22B, RAB10, and FLT1 may be potential biomarkers of AD.",
                    "offsetInBeginSection": 1044,
                    "offsetInEndSection": 1130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234",
                    "text": "We have now determined that a related Rab protein, Rab10, can interact with myosin Va, myosin Vb, and myosin Vc.",
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 371,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234",
                    "text": "Interaction with Rab10 was dependent on the presence of the alternatively spliced exon D in myosin Va and myosin Vb and the homologous region in myosin Vc.",
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 730,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234",
                    "text": "Both Rab8a and Rab10 were mislocalized by the expression of dominant-negative myosin V tails.",
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 574,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234",
                    "text": "Rab10 localized to a system of tubules and vesicles that have partially overlapping localization with Rab8a.",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 480,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127256",
                    "text": "In this study, we analyse the selectivity and sensitivity of polyclonal and monoclonal phospho-specific antibodies raised against 9 different LRRK2 phosphorylated Rab proteins (Rab3A/3B/3C/3D, Rab5A/5B/5C, Rab8A/8B, Rab10, Rab12, Rab29[T71], Rab29[S72], Rab35 and Rab43).",
                    "offsetInBeginSection": 334,
                    "offsetInEndSection": 605,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127256",
                    "text": "Recent work has revealed that LRRK2 phosphorylates a subgroup of 14 Rab proteins, including Rab10, at a specific residue located at the centre of its effector binding Switch-II motif.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127256",
                    "text": "Mutations that activate the LRRK2 protein kinase, predispose to Parkinson's disease, suggesting that LRRK2 inhibitors might have therapeutic benefit.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127256",
                    "text": "We demonstrate that the MJFF-pRAB10 antibodies can be deployed to assess enhanced Rab10 phosphorylation resulting from pathogenic (R1441C/G or G2019S) LRRK2 knock-in mutations as well as the impact of LRRK2 inhibitor treatment.",
                    "offsetInBeginSection": 863,
                    "offsetInEndSection": 1090,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7379a83b9d13c70800000a",
            "body": "Is Rucaparib effective for ovarian cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29166829",
                "http://www.ncbi.nlm.nih.gov/pubmed/28790837",
                "http://www.ncbi.nlm.nih.gov/pubmed/28247266",
                "http://www.ncbi.nlm.nih.gov/pubmed/27002934",
                "http://www.ncbi.nlm.nih.gov/pubmed/29050241",
                "http://www.ncbi.nlm.nih.gov/pubmed/23729402",
                "http://www.ncbi.nlm.nih.gov/pubmed/28751443",
                "http://www.ncbi.nlm.nih.gov/pubmed/28057616"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829",
                    "text": "CONCLUSION Rucaparib appears to be a safe and effective new option in the treatment of relapsed, advanced BRCA1/2 mutant ovarian cancer.",
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 914,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829",
                    "text": "In patients with deleterious BRCA1/2 mutation, an overall response rate of 80% was achieved in the phase II trial Assessment of Rucaparib in Ovarian CancEr Trial 2 (ARIEL2).",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790837",
                    "text": "Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790837",
                    "text": "There is evidence to suggest that rucaparib has clinical efficacy against ovarian tumors with high HRD-LOH.",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28247266",
                    "text": "Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer.",
                    "offsetInBeginSection": 539,
                    "offsetInEndSection": 632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934",
                    "text": "METHODS Phase II, open-label, multicentre trial of rucaparib in proven BRCA-1/2 mutation carriers with advanced breast and or ovarian cancer, WHO PS 0-1 and normal organ function.",
                    "offsetInBeginSection": 413,
                    "offsetInEndSection": 592,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934",
                    "text": "We investigated the efficacy and safety of single-agent rucaparib in germline (g) BRCA mutation carriers with advanced breast and ovarian cancers.",
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 410,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402",
                    "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.",
                    "offsetInBeginSection": 1607,
                    "offsetInEndSection": 1773,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402",
                    "text": "Low expression of other genes involved in homologous repair (e.g., BCCIP, BRCC3, ATM, RAD51L1), amplification of AURKA or EMSY, and response to platinum-based chemotherapy was associated with sensitivity to rucaparib.",
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 1010,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057616",
                    "text": "The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation identified by an approved companion diagnostic test.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8b27e6fcd1d6a10c00001e",
            "body": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                "http://www.ncbi.nlm.nih.gov/pubmed/28449648",
                "http://www.ncbi.nlm.nih.gov/pubmed/25238658",
                "http://www.ncbi.nlm.nih.gov/pubmed/24927192"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                    "text": "RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package) is an easy-to-use open-source R package that implements several published NIPT analysis methods.",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                    "text": "UNLABELLED Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648",
                    "text": "BACKGROUND The availability of non-invasive prenatal testing (NIPT) for aneuploidies is expanding rapidly throughout the world.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648",
                    "text": "METHODS Training on NIPT was offered to health professionals, primarily midwives, involved in Down syndrome screening and testing in eight hospitals located in England and Scotland as part of a research study evaluating the implementation of NIPT in the UK National Health Service.",
                    "offsetInBeginSection": 400,
                    "offsetInEndSection": 681,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449648",
                    "text": "CONCLUSIONS Training materials, including a lesson plan, PowerPoint presentation and written factsheet on NIPT, have been developed and evaluated for use in educating midwives and supporting the introduction of NIPT.",
                    "offsetInBeginSection": 1484,
                    "offsetInEndSection": 1700,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25238658",
                    "text": "OBJECTIVE Non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal plasma has been developed for the detection of fetal aneuploidy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25238658",
                    "text": "Although its great potential for prenatal medicine is evident, more information regarding the consequences of implementing NIPT in a national programme for prenatal screening is required.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 466,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25238658",
                    "text": "STUDY DESIGN A decision-analytic model was developed to compare costs and outcomes of current clinical practice in The Netherlands using conventional screening only, with two alternatives: implementing NIPT as an optional secondary screening test for those pregnancies complicated by a high risk for T21, and implementing NIPT as primary screening test, replacing conventional screening.",
                    "offsetInBeginSection": 469,
                    "offsetInEndSection": 856,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24927192",
                    "text": "New technologies analyzing fetal DNA in maternal blood have led to the wide commercial availability of non-invasive prenatal testing (NIPT).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24927192",
                    "text": "Although NIPT presents opportunities for pregnant women, particularly women who are at increased risk of having a baby with an abnormality or who are otherwise likely to access invasive prenatal testing, NIPT brings significant ethics and policy challenges.",
                    "offsetInBeginSection": 242,
                    "offsetInEndSection": 499,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9acba61d1251d03b000014",
            "body": "Has intepirdine been evaluated in clinical trials? (November 2017)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                "http://www.ncbi.nlm.nih.gov/pubmed/29131320",
                "http://www.ncbi.nlm.nih.gov/pubmed/29151578",
                "http://www.ncbi.nlm.nih.gov/pubmed/25027481",
                "http://www.ncbi.nlm.nih.gov/pubmed/29155424",
                "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                "http://www.ncbi.nlm.nih.gov/pubmed/28591872",
                "http://www.ncbi.nlm.nih.gov/pubmed/29026293",
                "http://www.ncbi.nlm.nih.gov/pubmed/28985716",
                "http://www.ncbi.nlm.nih.gov/pubmed/29047408"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131320",
                    "text": "In November 2017, the Council of the European Society of Clinical Investigation (ESCI) evaluated all basic research articles published in the European Journal of Clinical Investigation (EJCI) from November 2016 to October 2017.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481",
                    "text": "The Biomet Nano (Biomet, Warsaw, IN, USA) clinical trial began in October 2013 and also has a tentative completion date of 2017.",
                    "offsetInBeginSection": 1067,
                    "offsetInEndSection": 1195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481",
                    "text": "The tentative study completion date is 2017.",
                    "offsetInBeginSection": 1022,
                    "offsetInEndSection": 1066,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                    "text": "RESULTS This study was started in June 2014 (registration period 2 years, survey period 3 years) and will end in May 2017.",
                    "offsetInBeginSection": 1392,
                    "offsetInEndSection": 1514,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                    "text": "METHODS This prospective survey will involve patients treated with landiolol for the treatment of tachyarrhythmia (AF/AFL) in cardiac dysfunction at Japanese medical facilities from June 2014 to May 2017.",
                    "offsetInBeginSection": 857,
                    "offsetInEndSection": 1061,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                    "text": "In November 2013, landiolol hydrochloride (Onoact(\u00ae) 50 for Injection, Ono Pharamaceutical, Osaka, Japan) was approved with the indication for \"tachyarrhythmia (AF/AFL) in patients with cardiac dysfunction.\"",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 517,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29026293",
                    "text": "The search was actualized in April 2017.",
                    "offsetInBeginSection": 736,
                    "offsetInEndSection": 776,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985716",
                    "text": "Between November 2014 and June 2017, an estimated 110 patients from two sites in Japan were randomized (1:1) to morphine or oxycodone in GG and non-GG groups.",
                    "offsetInBeginSection": 1850,
                    "offsetInEndSection": 2008,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047408",
                    "text": "From November 2014, a total of 60 patients will be recruited, and recruitment for the study is planned to be complete by October 2017.",
                    "offsetInBeginSection": 1420,
                    "offsetInEndSection": 1554,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047408",
                    "text": "TRIAL REGISTRATION Japan Pharmaceutical Information Center Clinical Trials Information (JAPIC CTI), trial registration: JAPIC CTI-142747 .",
                    "offsetInBeginSection": 1763,
                    "offsetInEndSection": 1901,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa3fa73d6d6b54f79000008",
            "body": "Is subacute sclerosing panencephalitis caused by the Measles vaccine?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                "http://www.ncbi.nlm.nih.gov/pubmed/850592",
                "http://www.ncbi.nlm.nih.gov/pubmed/3531224",
                "http://www.ncbi.nlm.nih.gov/pubmed/2019970",
                "http://www.ncbi.nlm.nih.gov/pubmed/2087249",
                "http://www.ncbi.nlm.nih.gov/pubmed/21311432",
                "http://www.ncbi.nlm.nih.gov/pubmed/1706253",
                "http://www.ncbi.nlm.nih.gov/pubmed/6685828",
                "http://www.ncbi.nlm.nih.gov/pubmed/2807674",
                "http://www.ncbi.nlm.nih.gov/pubmed/25802788"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                    "text": "UNLABELLED Subacute sclerosing panencephalitis (SSPE), in the majority of cases, is caused by the wild measles virus, although there are some reports relating SSPE to vaccination.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                    "text": "Subacute sclerosing panencephalitis is a fatal degenerative disease and, although it had largely disappeared because of nearly universal measles vaccination, it still remains a serious infection among children affected by human immunodeficiency virus (HIV).",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 663,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/850592",
                    "text": "Because live measles vaccine is highly effective in preventing measles illness and a high proportion of children in the United States have received measles vaccine, these data are consistent with the observed downward trend in SSPE incidence since 1969.",
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3531224",
                    "text": "Finally, persons with subacute sclerosing panencephalitis and atypical measles mounted abnormally high antibody responses to measles virus polypeptides, in particular the P protein.",
                    "offsetInBeginSection": 1005,
                    "offsetInEndSection": 1186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2019970",
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a progressive neurodegenerative disease caused by the measles (rubeola) virus and is most often seen in children.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2087249",
                    "text": "These results suggest that infection by measles virus is probably not the sole cause of MS and that, unlike subacute sclerosing panencephalitis and postmeasles encephalitis, MS may not be preventable by measles vaccination given at an appropriate age.",
                    "offsetInBeginSection": 300,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21311432",
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a progressive neurological disorder of childhood and early adolescence caused by persistent defective measles virus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1706253",
                    "text": "Subacute sclerosing panencephalitis (SSPE) has become rare since the widespread use of the measles vaccine.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6685828",
                    "text": "There was no indication that measles vaccine can induce SSPE.",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25802788",
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a devastating disease of the central nervous system (CNS) caused by persistent mutant measles virus infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d8ffe1d1251d03b000022",
            "body": "What are pQTLs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27532455",
                "http://www.ncbi.nlm.nih.gov/pubmed/27329291",
                "http://www.ncbi.nlm.nih.gov/pubmed/25087611",
                "http://www.ncbi.nlm.nih.gov/pubmed/23172855",
                "http://www.ncbi.nlm.nih.gov/pubmed/28129359",
                "http://www.ncbi.nlm.nih.gov/pubmed/25124843",
                "http://www.ncbi.nlm.nih.gov/pubmed/24823668",
                "http://www.ncbi.nlm.nih.gov/pubmed/28240269",
                "http://www.ncbi.nlm.nih.gov/pubmed/22595970",
                "http://www.ncbi.nlm.nih.gov/pubmed/21846806"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532455",
                    "text": "Some of these pQTLs [e.g., pQTLs for VDBP, sRAGE (gene = AGER), surfactant protein D (gene = SFTPD), and TNFRSF10C] have been previously associated with COPD phenotypes.",
                    "offsetInBeginSection": 1303,
                    "offsetInEndSection": 1472,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291",
                    "text": "cis-pQTLs for kallikrein and F12 also show trans associations for proteins (uPAR, kininogen) known to be cleaved by kallikrein and with NTproBNP.",
                    "offsetInBeginSection": 1168,
                    "offsetInEndSection": 1313,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291",
                    "text": "Here, we identify new common and rare genetic variants associated with cardiovascular-related protein levels (protein quantitative trait loci [pQTLs]).",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087611",
                    "text": "Our results suggest that protein-based mechanisms might functionally buffer genetic alterations that influence mRNA expression levels and that pQTLs might contribute phenotypic diversity to a human population independently of influences on mRNA expression.",
                    "offsetInBeginSection": 1296,
                    "offsetInEndSection": 1552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087611",
                    "text": "We collected more than 250,000 protein level measurements comprising 441 transcription factor and signaling protein isoforms across 68 Yoruba (YRI) HapMap lymphoblastoid cell lines (LCLs) and identified 12 cis and 160 trans protein level QTLs (pQTLs) at a false discovery rate (FDR) of 20%.",
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172855",
                    "text": "Analyses were confirmed by mechanistic studies and MALDI-TOF/TOF, liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses of the two strongest pQTLs: A pQTL for mass-to-charge ratio (m/z) 3494 (LOD 24.9, D11Mit151) was identified as the N-terminal 35 amino acids of hemoglobin subunit A (Hba) and caused by genetic variation in Hba.",
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 1154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129359",
                    "text": "In carrying out a genome wide genotype-protein association study (proteomic Quantitative Trait Loci, pQTL) within the CD patients, we identified 41 distinct proteomic traits influenced by cis pQTLs (underlying SNPs are referred to as pSNPs).",
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124843",
                    "text": "The objective of this study is to identify eQTL underlying expression of four gene families encoding isoflavone synthetic enzymes involved in the phenylpropanoid pathway, which are phenylalanine ammonia-lyase (PAL; EC 4.3.1.5), chalcone synthase (CHS; EC 2.3.1.74), 2-hydroxyisoflavanone synthase (IFS; EC1.14.13.136) and flavanone 3-hydroxylase (F3H; EC 1.14.11.9).",
                    "offsetInBeginSection": 285,
                    "offsetInEndSection": 651,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124843",
                    "text": "Overlapped loci of eQTLs and phenotypic QTLs (pQTLs) were analyzed to identify the potential candidate genes underlying the accumulation of isoflavone in soybean seed.",
                    "offsetInBeginSection": 900,
                    "offsetInEndSection": 1067,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21846806",
                    "text": "These colocalizing correlated cis-eQTLs (c3-eQTLs) are highly attractive as primary susceptibility loci for the colocalizing pQTLs.",
                    "offsetInBeginSection": 964,
                    "offsetInEndSection": 1095,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7428090384be9551000001",
            "body": "What can be predicted with the Wells criteria?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28260193",
                "http://www.ncbi.nlm.nih.gov/pubmed/23293869",
                "http://www.ncbi.nlm.nih.gov/pubmed/21610436",
                "http://www.ncbi.nlm.nih.gov/pubmed/17964711",
                "http://www.ncbi.nlm.nih.gov/pubmed/9447391",
                "http://www.ncbi.nlm.nih.gov/pubmed/28119448",
                "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                "http://www.ncbi.nlm.nih.gov/pubmed/12908858",
                "http://www.ncbi.nlm.nih.gov/pubmed/22653873",
                "http://www.ncbi.nlm.nih.gov/pubmed/20179688"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28260193",
                    "text": "CONCLUSIONS Wienecke criteria can be an appropriate points-scoring system to predict prognosis for adrenocortical tumors in children.",
                    "offsetInBeginSection": 1284,
                    "offsetInEndSection": 1417,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21610436",
                    "text": "CONCLUSIONS In patients with HGRT who had bleeding, a strategy of targeted angiography can be realized safely in using specific CT scan criteria that can predict with high accuracy and exclude the need for embolization, without reducing the success rate of CM.",
                    "offsetInBeginSection": 1525,
                    "offsetInEndSection": 1785,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21610436",
                    "text": "None of the CT criteria had a negative predictive value for renal embolization to 100%, only the absence of intravascular contrast extravasation associated with a perirenal hematoma rim distance<25 mm excludes an indication for embolization.",
                    "offsetInBeginSection": 1281,
                    "offsetInEndSection": 1522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9447391",
                    "text": "Specific research questions include: to what extent can consensus be achieved on definitions and accompanying rules of inference for criteria, the relationship of meta-analysis to the criterion of consistency, and the interrelationships of criteria such as consistency, strength of association, and biological plausibility.",
                    "offsetInBeginSection": 985,
                    "offsetInEndSection": 1308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "METHODS We assessed the sensitivity, specificity, and positive and negative predictive values of the clinical criteria of the Consortium on dementia with Lewy Bodies (CDLB) in 18 patients with autopsy-proven DLB and in 76 patients with dementia not associated with Lewy bodies, using postmortem diagnosis as a gold standard.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 437,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "OBJECTIVE To assess the clinical validity of clinical diagnostic criteria for dementia with Lewy bodies (DLB).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "Clinical criteria had higher predictive validity in patients with pure DLB than in patients with DLB and AD.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 710,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "CDLB criteria for probable DLB (two or more major criteria) distinguished DLB from AD with a sensitivity of 78% and a specificity of 64%.",
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "Positive predictive value of 75% can be achieved by a combination of any three major or minor criteria, providing the analysis is confined to patients with mild to moderate dementia.",
                    "offsetInBeginSection": 1264,
                    "offsetInEndSection": 1446,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20179688",
                    "text": "Two kinds of validations are reported: (i) studies testing whether symptom criteria discriminate patients with structural disease at colonoscopy from patients without structural disease; and (ii) studies testing whether symptom criteria discriminate patients presumed to have IBS by positive diagnosis from healthy subjects or patients with other functional and structural disorders.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8b292afcd1d6a10c00001f",
            "body": "Is there any role of interleukin-11 in cardiovascular fibrosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29160304",
                "http://www.ncbi.nlm.nih.gov/pubmed/20100971",
                "http://www.ncbi.nlm.nih.gov/pubmed/21646597",
                "http://www.ncbi.nlm.nih.gov/pubmed/23229370",
                "http://www.ncbi.nlm.nih.gov/pubmed/25304471"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29160304",
                    "text": "Fibrosis is a final common pathology in cardiovascular disease1.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100971",
                    "text": "CONCLUSIONS IL-11 attenuated cardiac fibrosis after MI through STAT3.",
                    "offsetInBeginSection": 1743,
                    "offsetInEndSection": 1812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597",
                    "text": "These results indicate that NF-\u03baB has an essential role in mediating the cardiovascular inflammatory response to angiotensin II and suggest that targeting the balance of I\u03baB\u03b1 and I\u03baB\u03b2 expression might be a novel therapeutic modality in preventing fibrosis in hypertensive cardiovascular disease.",
                    "offsetInBeginSection": 1620,
                    "offsetInEndSection": 1920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597",
                    "text": "The development of cardiovascular fibrosis is associated with chronic inflammation, where activation of nuclear factor \u03baB (NF-\u03baB) signaling may play a critical role.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597",
                    "text": "Replacement of I\u03baB\u03b1 with I\u03baB\u03b2 significantly attenuated angiotensin II infusion-induced expression of interleukin 1\u03b2, interleukin 6, monocyte chemotactic protein 1, collagen I and III, fibronectin, and tissue inhibitor of metalloproteinase 1 in the hearts.",
                    "offsetInBeginSection": 1027,
                    "offsetInEndSection": 1287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229370",
                    "text": "In addition to its potential as a biomarker for adverse cardiovascular events, ST2 is considered to play a causal role in chronic cardiovascular diseases such as atherosclerosis and heart failure.",
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 825,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25304471",
                    "text": "Here, we tested the hypothesis that deletion of interleukin-6 protects against the development of hypertension, cardiac inflammation, fibrosis, remodeling and dysfunction induced by high salt diet and angiotensin II (Ang II).",
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 516,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25304471",
                    "text": "CONCLUSION In conclusion, absence of interleukin -6 did not alter the development of Ang II-high salt-induced hypertension and cardiac hypertrophy, but it prevented the development of cardiac dysfunction, myocardial inflammation, and fibrosis.",
                    "offsetInBeginSection": 1345,
                    "offsetInEndSection": 1588,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25304471",
                    "text": "However, the role of the proinflammatory cytokine interleukin-6 in the chronic stage of hypertension is not well defined.",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 290,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25304471",
                    "text": "This indicates that interleukin-6 plays an important role in hypertensive heart damage but not in the development of hypertension.",
                    "offsetInBeginSection": 1589,
                    "offsetInEndSection": 1719,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9acc7b1d1251d03b000015",
            "body": "What is crenezumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27996029",
                "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                "http://www.ncbi.nlm.nih.gov/pubmed/24803227",
                "http://www.ncbi.nlm.nih.gov/pubmed/28924036",
                "http://www.ncbi.nlm.nih.gov/pubmed/25880481",
                "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
                "http://www.ncbi.nlm.nih.gov/pubmed/24445401"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27996029",
                    "text": "Crenezumab is a humanized anti-A\u03b2 monoclonal IgG4 that binds multiple forms of A\u03b2, with higher affinity for aggregated forms, and that blocks A\u03b2 aggregation, and promotes disaggregation.",
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                    "text": "In conclusion, the biosimilar antibodies Solanezumab, Crenezumab and Bapineuzumab strongly react with amyloid plaques, which are in contrast to the NT4X antibody that hardly recognizes plaques in human tissue.",
                    "offsetInBeginSection": 1742,
                    "offsetInEndSection": 1951,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                    "text": "In contrast to the biosimilar antibodies of Solanezumab, Crenezumab and Bapineuzumab, the murine NT4X antibody shows a unique target engagement.",
                    "offsetInBeginSection": 1350,
                    "offsetInEndSection": 1494,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                    "text": "Solanezumab and Crenezumab are two humanized antibodies targeting Amyloid-\u03b2 (A\u03b2) which are currently tested in multiple clinical trials for the prevention of Alzheimer's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24803227",
                    "text": "The most developed method for targeting A\u03b2 is the use of monoclonal antibodies including bapineuzumab, solanezumab and crenezumab.",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 302,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481",
                    "text": "Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-\u03b2 (A\u03b2) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                    "text": "Second-generation active A\u03b2 vaccines (CAD106, ACC-001, and Affitope AD02) and new passive anti-A\u03b2 immunotherapies (gantenerumab and crenezumab) have been developed and are under clinical testing.",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                    "text": "Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate AD patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of A\u03b2, were disappointing.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 369,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
                    "text": "Two other monoclonal antibodies, gantenerumab, which preferentially binds to fibrillar A\u03b2, and crenezumab, which preferentially binds to soluble, oligomeric and fibrillar A\u03b2 deposits, are being tested in secondary prevention trials in presymptomatic subjects with autosomal dominant AD mutations.",
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 1076,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
                    "text": "Second-generation active A\u03b2 vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-A\u03b2 immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer's disease patients, in presymptomatic individuals with Alzheimer's disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer's disease to definitely test the A\u03b2 cascade hypothesis of Alzheimer's disease.",
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa3fb7ad6d6b54f79000009",
            "body": "What drug cures hepatitis C?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22504355",
                "http://www.ncbi.nlm.nih.gov/pubmed/26043288",
                "http://www.ncbi.nlm.nih.gov/pubmed/21652618",
                "http://www.ncbi.nlm.nih.gov/pubmed/28644739",
                "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                "http://www.ncbi.nlm.nih.gov/pubmed/24782255",
                "http://www.ncbi.nlm.nih.gov/pubmed/21866039",
                "http://www.ncbi.nlm.nih.gov/pubmed/26666278",
                "http://www.ncbi.nlm.nih.gov/pubmed/26546955",
                "http://www.ncbi.nlm.nih.gov/pubmed/20039157"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043288",
                    "text": "Peginterferon combined with ribavirin and even the first-wave protease inhibitors telaprevir and boceprevir now belong to the milestones that had an important, although historical, role in the final conquest of hepatitis C.",
                    "offsetInBeginSection": 1364,
                    "offsetInEndSection": 1587,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21652618",
                    "text": "To maximize treatment success and reduce the likelihood of drug resistance selection, a proper individualization of hepatitis C therapy will be required, choosing the most convenient drugs and strategies according to distinct viral and host profiles.",
                    "offsetInBeginSection": 1256,
                    "offsetInEndSection": 1506,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644739",
                    "text": "The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                    "text": "INTRODUCTION The combination of pegylated interferon-\u03b1 plus ribavirin (pegIFN\u03b1-RBV) has been the only therapeutic option for patients with chronic hepatitis C virus (HCV) infection during the last decade.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                    "text": "The addition of any of the two recently approved HCV protease inhibitors, boceprevir or telaprevir, to pegIFN\u03b1-RBV results in the cure for two-thirds of HCV genotype 1, interferon-naive patients.",
                    "offsetInBeginSection": 454,
                    "offsetInEndSection": 650,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                    "text": "AREAS COVERED This paper reviews new antivirals for hepatitis C and HCV treatment failures, along with HCV drug resistance and rescue therapies.",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 797,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                    "text": "The recent introduction of new direct-acting antivirals (DAA) has revolutionized the hepatitis C field.",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24782255",
                    "text": "The development of new models and tools has led to the discovery and clinical development of a large number of new anti-hepatitis C virus (HCV) drugs, including direct-acting antivirals and host-targeted agents.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21866039",
                    "text": "As a result of using first-generation DAAs in HIV-HCV-co-infected patients, a growing proportion of the remaining hepatitis C individuals will be those harboring non-HCV 1 genotypes or drug-resistant HCV variants.",
                    "offsetInBeginSection": 600,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21866039",
                    "text": "The approval of the first direct-acting antivirals (DAAs) against the hepatitis C virus (HCV) has been eagerly expected for treating chronic hepatitis C in HIV individuals given that progression to cirrhosis and end-stage liver disease occurs faster in the co-infected population.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 280,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d96564e03427e73000001",
            "body": "List major risk factors for Alzheimer's disease. ",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16945215",
                "http://www.ncbi.nlm.nih.gov/pubmed/11884656",
                "http://www.ncbi.nlm.nih.gov/pubmed/10396132",
                "http://www.ncbi.nlm.nih.gov/pubmed/23375669",
                "http://www.ncbi.nlm.nih.gov/pubmed/27688858",
                "http://www.ncbi.nlm.nih.gov/pubmed/14710446",
                "http://www.ncbi.nlm.nih.gov/pubmed/16314757",
                "http://www.ncbi.nlm.nih.gov/pubmed/21655757",
                "http://www.ncbi.nlm.nih.gov/pubmed/20182020",
                "http://www.ncbi.nlm.nih.gov/pubmed/26993513"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215",
                    "text": "Apolipoprotein E is the major risk factor for Alzheimer's disease.",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 647,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11884656",
                    "text": "The apolipoprotein E E4 allele and a positive family history (FH) are both genetic risk factors for AD.",
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23375669",
                    "text": "The vestibular loss hypothesis is further supported by the vestibular symptoms found in Alzheimer's patients as well as in various diseases that are major risk factors for Alzheimer's disease.",
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 694,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27688858",
                    "text": "Three other important modifiable risk factors should also be added to this list: midlife hypercholesterolemia, late life atrial fibrillation, and chronic kidney disease.",
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1034,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27688858",
                    "text": "Among the 93 identified risk factors, seven major modifiable ones should be considered: low education, sedentary lifestyle, midlife obesity, midlife smoking, hypertension, diabetes, and midlife depression.",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 864,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14710446",
                    "text": "There is now strong epidemiologic evidence supporting an association between Alzheimer disease and two major vascular risk factors--blood pressure and diabetes.",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16314757",
                    "text": "The apolipoprotein gene E4 allele (APOE 4) is a major risk factor for the disease.",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 219,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20182020",
                    "text": "The major vascular risk factors such as diabetes and impaired glycemic control, hypertension, obesity, and hyper- or dyslipidemia have been associated both with Alzheimer's disease and vascular dementia.",
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 426,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20182020",
                    "text": "Midlife diabetes mellitus, hypertension, and obesity are established risk factors for clinically defined Alzheimer's disease as well as vascular dementia.",
                    "offsetInBeginSection": 838,
                    "offsetInEndSection": 992,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26993513",
                    "text": "These compounds are clinically effective against major risk factors for Alzheimer's disease: hypertension, stroke, chronic kidney disease, diabetes and metabolic syndrome, and ameliorate age-dependent cognitive loss.",
                    "offsetInBeginSection": 1034,
                    "offsetInEndSection": 1250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7486a90384be9551000003",
            "body": "Which molecules are inhibited by anticancer drug Dovitinib?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                "http://www.ncbi.nlm.nih.gov/pubmed/22674553"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Dovitinib inhibited the catalytic decatenation activity of topoisomerase II\u03b1.",
                    "offsetInBeginSection": 815,
                    "offsetInEndSection": 893,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Dovitinib (TKI258/CHIR258) is a multi-kinase inhibitor in phase III development for the treatment of several cancers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Finally, dovitinib inhibited the topoisomerase I-catalyzed relaxation of plasmid DNA and acted as a cellular topoisomerase I poison.",
                    "offsetInBeginSection": 1365,
                    "offsetInEndSection": 1497,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Dovitinib is a benzimidazole-quinolinone compound that structurally resembles the bisbenzimidazole minor groove binding dye Hoechst 33258.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Using isolated human topoisomerase II\u03b1, dovitinib stabilized the enzyme-cleavage complex and acted as a topoisomerase II\u03b1 poison.",
                    "offsetInBeginSection": 1036,
                    "offsetInEndSection": 1167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Because DNA binders are often topoisomerase I (EC 5.99.1.2) and topoisomerase II (EC 5.99.1.3) inhibitors, the ability of dovitinib to inhibit these DNA processing enzymes was also investigated.",
                    "offsetInBeginSection": 620,
                    "offsetInEndSection": 814,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Dovitinib was also found to be a cellular topoisomerase II poison in human leukemia K562 cells and induced double-strand DNA breaks in K562 cells as evidenced by increased phosphorylation of H2AX.",
                    "offsetInBeginSection": 1168,
                    "offsetInEndSection": 1364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Molecular modeling studies of the docking of dovitinib into an X-ray structure of a Hoechst 33258-DNA complex showed that dovitinib could reasonably be accommodated in the DNA minor groove.",
                    "offsetInBeginSection": 430,
                    "offsetInEndSection": 619,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "In conclusion, the cell growth inhibitory activity and the anticancer activity of dovitinib may result not only from its ability to inhibit multiple kinases, but also, in part, from its ability to target topoisomerase I and topoisomerase II.",
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1739,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22674553",
                    "text": "Dovitinib, a drug in clinical development, showed greater activity than sunitinib and sirolimus.",
                    "offsetInBeginSection": 1286,
                    "offsetInEndSection": 1382,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67c497b750ff4455000012",
            "body": "Which method is available for whole genome identification of pathogenic regulatory variants in mendelian disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27569544"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544",
                    "text": "Overall, Genomiser is able to identify causal regulatory variants as the\u00a0top candidate in 77% of simulated whole genomes, allowing effective detection and discovery of regulatory variants in Mendelian disease.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 929,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544",
                    "text": "Genomiser scores variants through either existing methods such as CADD or a bespoke machine learning method and combines these with allele frequency, regulatory sequences, chromosomal topological domains, and phenotypic relevance to\u00a0discover variants associated to specific Mendelian disorders.",
                    "offsetInBeginSection": 423,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544",
                    "text": "The interpretation of non-coding variants still constitutes a major challenge in the application of whole-genome sequencing in Mendelian disease, especially for single-nucleotide and other small non-coding variants.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544",
                    "text": "Here we present Genomiser, an analysis framework that is able not only to score the relevance of variation in the non-coding genome, but also to associate regulatory variants to specific Mendelian diseases.",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9acd921d1251d03b000016",
            "body": "In what phase of clinical trials is crenezumab? (November 2017)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25880481",
                "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
                "http://www.ncbi.nlm.nih.gov/pubmed/28760727",
                "http://www.ncbi.nlm.nih.gov/pubmed/24803227",
                "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                "http://www.ncbi.nlm.nih.gov/pubmed/28591872",
                "http://www.ncbi.nlm.nih.gov/pubmed/29099493",
                "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                "http://www.ncbi.nlm.nih.gov/pubmed/25027481",
                "http://www.ncbi.nlm.nih.gov/pubmed/29155424"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481",
                    "text": "Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-\u03b2 (A\u03b2) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
                    "text": "Second-generation active A\u03b2 vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-A\u03b2 immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer's disease patients, in presymptomatic individuals with Alzheimer's disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer's disease to definitely test the A\u03b2 cascade hypothesis of Alzheimer's disease.",
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
                    "text": "Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of A\u03b2, were disappointing.",
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 826,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28760727",
                    "text": "RESULTS Recruitment for the first phase of this project commenced in November 2016, and the phase will run from February to November 2017.",
                    "offsetInBeginSection": 2157,
                    "offsetInEndSection": 2295,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28760727",
                    "text": "TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12616001243404p; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371422 (Archived by WebCite at http://www.webcitation.org/ 6rmlEiM1L).",
                    "offsetInBeginSection": 2590,
                    "offsetInEndSection": 2823,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                    "text": "Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate AD patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of A\u03b2, were disappointing.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 369,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099493",
                    "text": "Peripheral blood samples from 21 patients with relapsed/refractory CLL in acalabrutinib phase I (100-400\u2009mg/day) and II (100\u2009mg BID) clinical trials were collected prior to and on days 8 and 28 after treatment initiation and evaluated for plasma chemokines, reverse phase protein array, immunoblotting, and pseudoemperipolesis.",
                    "offsetInBeginSection": 633,
                    "offsetInEndSection": 964,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Ongoing Phase III clinical trials via passive immunotherapy against A\u03b2 peptides (crenezumab, gantenerumab, and aducanumab) seem to be promising.",
                    "offsetInBeginSection": 1431,
                    "offsetInEndSection": 1576,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Using small molecules blocking 5-HT6 serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials.",
                    "offsetInBeginSection": 1577,
                    "offsetInEndSection": 1795,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027481",
                    "text": "The Biomet Nano (Biomet, Warsaw, IN, USA) clinical trial began in October 2013 and also has a tentative completion date of 2017.",
                    "offsetInBeginSection": 1067,
                    "offsetInEndSection": 1195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa55b45d6d6b54f7900000d",
            "body": "What organism causes scarlet fever also known as scarletina?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2772682",
                "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                "http://www.ncbi.nlm.nih.gov/pubmed/2045646",
                "http://www.ncbi.nlm.nih.gov/pubmed/8415304",
                "http://www.ncbi.nlm.nih.gov/pubmed/1432423",
                "http://www.ncbi.nlm.nih.gov/pubmed/19869456",
                "http://www.ncbi.nlm.nih.gov/pubmed/7405299",
                "http://www.ncbi.nlm.nih.gov/pubmed/125514",
                "http://www.ncbi.nlm.nih.gov/pubmed/12843042",
                "http://www.ncbi.nlm.nih.gov/pubmed/19869457"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2772682",
                    "text": "The severity of symptoms and the demonstration of scarlet fever developing from infection with this organism supports antibiotic treatment of patients with group C streptococcal pharyngitis.",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                    "text": "Scarlatinal antistreptococcic serum affords some degree of protection against virulent scarlet fever streptococci but has no protective power against hemolytic streptococci from other diseases.",
                    "offsetInBeginSection": 987,
                    "offsetInEndSection": 1180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                    "text": "In a small epidemic of scarlet fever a healthy carrier of hemolytic streptococcus was detected; the organism carried was identical in its serological reactions with strains of hemolytic streptococci isolated from active cases of scarlet fever.",
                    "offsetInBeginSection": 1184,
                    "offsetInEndSection": 1427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2045646",
                    "text": "We present a case that illustrates the distinctive clinical spectrum of A. hemolyticum infections that may be confused with drug allergy, group A streptococcal scarlet fever, diphtheria, and even toxic shock syndrome.",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 466,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8415304",
                    "text": "Other streptococcal and staphylococcal cutaneous infections may exhibit overlapping clinical features, including scarlet fever, impetigo, toxic shock syndrome, and cellulitis.",
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 554,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19869456",
                    "text": "The clinical and bacteriological findings in two cows the udders of which became infected under natural conditions with hemolytic streptococci of the scarlet fever type are discussed.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7405299",
                    "text": "More discussed are the infectious hospitalism, the salmonellial enteritis, the yersinioses, typhoid fever, paratyphoid fever, bacterial dysentery, scarlet fever, diphtheria, meningitis, brucelloses, leptospiroses, listerioses, pneumonias, bronchitis, obstructive diseases of the respiratory tract as well as pyelonephritis and bacterial carditis.",
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 945,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/125514",
                    "text": "Consequently, a higher immunological reactivity of the organism in children in Ashkhabad (promoting rapid formation of both the antitoxic and the antimicrobial immunity and limiting of the spread of marked scarlet fever affections) underlied the differences in the level of scarlet fever morbidity in different climatic zones.",
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 1136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19869457",
                    "text": "The streptococcus isolated from the udder of a cow on a farm where an outbreak of scarlet fever originated has been correlated with known scarlet fever strains.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19869457",
                    "text": "Skin tests indicate that the strain isolated from the milk of the cow in a herd to which the scarlet fever epidemic was attributed produced a toxin which was neutralized with scarlet fever antitoxin.",
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9da8df4e03427e73000006",
            "body": "What is emicizumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29042366",
                "http://www.ncbi.nlm.nih.gov/pubmed/28451690",
                "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
                "http://www.ncbi.nlm.nih.gov/pubmed/27384849",
                "http://www.ncbi.nlm.nih.gov/pubmed/27223146",
                "http://www.ncbi.nlm.nih.gov/pubmed/27795538",
                "http://www.ncbi.nlm.nih.gov/pubmed/27960628"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366",
                    "text": "FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, si-RNA to reduce antithrombin expression and the bispecific antibody ACE910/Emicizumab.",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366",
                    "text": "Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa (FIXa) and the substrate factor X (FX).",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28451690",
                    "text": "Emicizumab, a humanised bispecific antibody recognising factors (F) IX/IXa and X/Xa, can accelerate FIXa-catalysed FX activation by bridging FIXa and FX in a manner similar to FVIIIa.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
                    "text": "This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
                    "text": "BACKGROUND Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27384849",
                    "text": "Currently, the phase 1/2 extension study is ongoing.",
                    "offsetInBeginSection": 909,
                    "offsetInEndSection": 961,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27223146",
                    "text": "BACKGROUND In patients with severe hemophilia A, standard treatment is regular prophylactic and episodic intravenous infusions of factor VIII.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795538",
                    "text": "ACE910 (emicizumab) is a humanized bispecific antibody recognizing factor IXa and X mimicking factor VIII function.",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 465,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795538",
                    "text": "The principle of hemophilia treatment is replacement therapy with factor VIII and factor IX concentrates.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 105,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27960628",
                    "text": "Of these, 5 mAbs are for cancer (durvalumab, JNJ-56022473, ublituximab, anetumab ravtansine, glembatumumab vedotin) and 15 mAbs are for non-cancer indications (caplacizumab, lanadelumab, roledumab, tralokinumab, risankizumab, SA237, emapalumab, suptavumab, erenumab, eptinezumab, fremanezumab, fasinumab, tanezumab, lampalizumab, brolucizumab).",
                    "offsetInBeginSection": 1609,
                    "offsetInEndSection": 1953,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75df9883b0d9ea66000002",
            "body": "Which cancers compose Carney's triad?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19561114",
                "http://www.ncbi.nlm.nih.gov/pubmed/3827356",
                "http://www.ncbi.nlm.nih.gov/pubmed/22664948",
                "http://www.ncbi.nlm.nih.gov/pubmed/11878780",
                "http://www.ncbi.nlm.nih.gov/pubmed/12893072",
                "http://www.ncbi.nlm.nih.gov/pubmed/9591034",
                "http://www.ncbi.nlm.nih.gov/pubmed/8091266",
                "http://www.ncbi.nlm.nih.gov/pubmed/10468897",
                "http://www.ncbi.nlm.nih.gov/pubmed/24840526",
                "http://www.ncbi.nlm.nih.gov/pubmed/8272014"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356",
                    "text": "Carney's Triad comprises a triad of neoplasms: gastric stromal tumor, extra-adrenal paraganglioma (usually functional), and pulmonary chondroma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356",
                    "text": "Thus, the Triad may be a disorder of the autonomic nervous system rather than a multiple endocrine neoplasia syndrome or multiple hamartoma syndrome.",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 787,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11878780",
                    "text": "This report encourages clinicians to consider a diagnosis of Carney's triad in patients with multifocal gastric stromal sarcoma, extraadrenal paraganglioma (predominantly mediastinal), or pulmonary chondroma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12893072",
                    "text": "Carney's triad is a syndrome of unknown etiology, representing a combination of gastrointestinal stromal tumors, bronchial chondromas and vagal, adrenal or paraadrenal paragangliomas.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12893072",
                    "text": "Two of the Carney's triad components-the paragangliomas and the gastrointestinal stromal tumors-are potentially lethal.",
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8091266",
                    "text": "Carney's triad, a rare disorder affecting young females, is characterized by the presence of at least two of the three following neoplasms: gastric epithelioid leiomyosarcoma, extra-adrenal paraganglioma, and pulmonary chondroma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8091266",
                    "text": "MRI is as effective as MIBG scintigraphy in detecting functioning paragangliomas.",
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10468897",
                    "text": "The etiology of the Carney's triad (gastrointestinal stromal tumors, pulmonary chondromas, and paragangliomas) is unknown, and only 57 cases have been reported since its identification in 1977.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24840526",
                    "text": "New adrenal tumors have also been associated with nonhereditary Carney's triad.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 681,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8272014",
                    "text": "Carney's triad is defined by the coexistence of at least two of three rare disorders, including gastric epithelioid leiomyosarcoma (malignant leiomyoblastoma), pulmonary chondroma, and paraganglioma, most often extra-adrenal and functioning.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 241,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d28981d1251d03b000017",
            "body": "Does verubecestat activate BACE?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
                "http://www.ncbi.nlm.nih.gov/pubmed/27023706",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800329",
                "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
                "http://www.ncbi.nlm.nih.gov/pubmed/28749667"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
                    "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
                    "text": "The aspartyl protease \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) is required for the production of A\u03b2, and BACE1 inhibition is thus an attractive target for the treatment of AD.",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 304,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706",
                    "text": "The most progressed mechanism-based therapies to date consist of immunological interventions to clear A\u03b2 oligomers, and pharmacological drugs to inhibit the secretase enzymes that produce A\u03b2, namely \u03b2-site amyloid precursor-cleaving enzyme (BACE) and \u03b3-secretase.",
                    "offsetInBeginSection": 948,
                    "offsetInEndSection": 1215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28800329",
                    "text": "Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to-moderate and prodromal Alzheimer's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "These investigations include acetylcholinesterase inhibitors, agonists and antagonists of neurotransmitter receptors, \u03b2-secretase (BACE) or \u03b3-secretase inhibitors, vaccines or antibodies targeting A\u03b2 clearance or tau protein, as well as anti-inflammation compounds.",
                    "offsetInBeginSection": 1162,
                    "offsetInEndSection": 1430,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Using small molecules blocking 5-HT6 serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials.",
                    "offsetInBeginSection": 1577,
                    "offsetInEndSection": 1795,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Recent therapeutic approaches have been strongly influenced by five neuropathological hallmarks of AD: acetylcholine deficiency, glutamate excitotoxicity, extracellular deposition of amyloid-\u03b2 (A\u03b2 plague), formation of intraneuronal neurofibrillary tangles (NTFs), and neuroinflammation.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 549,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
                    "text": "Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the \u03b2-secretase cleaving enzyme (BACE) (verubecestat), three anti-A\u03b2 monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1).",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 891,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
                    "text": "Putative disease-modifying drugs are in development and target \u03b2-amyloid (A\u03b2) peptide and tau protein, the principal neurophatological hallmarks of the disease.",
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 327,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28749667",
                    "text": "One major target has been the \u03b2-site amyloid-precursor-protein-cleaving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BACE-1 inhibitors.",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 351,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9dad764e03427e73000007",
            "body": "What is the preDIVA clinical trial?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28596452"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "METHODS The preDIVA trial (Prevention of Dementia by Intensive Vascular Care) was an open-label, cluster-randomized controlled trial in community-dwelling individuals aged 70 to 78 years.",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 435,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "CLINICAL TRIAL INFORMATION URL: http://www.isrctn.com/ISRCTN29711771.",
                    "offsetInBeginSection": 1831,
                    "offsetInEndSection": 1900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "Of 3526 preDIVA participants, 195 nondemented participants with a systolic blood pressure \u2265140 mm\u2009Hg were consecutively recruited to undergo magnetic resonance imaging at 2 to 3 and 5 to 6 years after baseline.",
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 793,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "BACKGROUND AND PURPOSE This study aimed to evaluate the effect of a nurse-led multidomain cardiovascular intervention on white matter hyperintensity (WMH) progression and incident lacunar infarcts in community-dwelling elderly with hypertension.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "New lacunar infarcts developed in 6 (9%) intervention and 2 (3%) control participants (odds ratio, 2.2; 95% confidence interval, 0.4-12.1; P=0.36).",
                    "offsetInBeginSection": 1363,
                    "offsetInEndSection": 1510,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "However, our results do suggest this type of intervention could be effective in persons with high WMH volumes.",
                    "offsetInBeginSection": 1646,
                    "offsetInEndSection": 1756,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "Unique identifier: ISRCTN29711771.",
                    "offsetInBeginSection": 1901,
                    "offsetInEndSection": 1935,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "CONCLUSIONS Nurse-led vascular care in hypertensive community-dwelling older persons did not diminish WMH accumulation over 3 years.",
                    "offsetInBeginSection": 1513,
                    "offsetInEndSection": 1645,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "WMH volumes were measured automatically, lacunar infarcts assessed visually, blinded to treatment allocation.",
                    "offsetInBeginSection": 794,
                    "offsetInEndSection": 903,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "Analyses suggested greater intervention effects with increasing baseline WMH volumes (P for interaction=0.03).",
                    "offsetInBeginSection": 1252,
                    "offsetInEndSection": 1362,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76072283b0d9ea66000013",
            "body": "Does armodafinil improve fatigue of glioma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26902850"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "CONCLUSIONS While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.",
                    "offsetInBeginSection": 1326,
                    "offsetInEndSection": 1490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "Armodafinil did not significantly improve fatigue or QOL based on the 42-day change in FACIT-F fatigue subscale, FACT-G, CFS, or BFI.",
                    "offsetInBeginSection": 1008,
                    "offsetInEndSection": 1141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "BACKGROUND Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "Further studies are needed to determine whether pharmacologic treatment improves fatigue in glioma patients undergoing RT.",
                    "offsetInBeginSection": 1491,
                    "offsetInEndSection": 1613,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "Patients were randomized 1:1 to armodafinil or placebo for 8 weeks beginning within 10 days of starting RT.",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "Fatigue and QOL were assessed at baseline, day 22, day 43, and day 56 with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), the Functional Assessment of Cancer Therapy - General (FACT-G), the Brief Fatigue Inventory (BFI), and the Cancer Fatigue Scale (CFS).",
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 784,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "The primary aim was to detect a difference in the 42-day change in FACIT-F fatigue subscale between the 2 groups using a 2-sample Wilcoxon statistic.",
                    "offsetInBeginSection": 785,
                    "offsetInEndSection": 934,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "RESULTS We enrolled 81 patients total (42 armodafinil and 39 placebo).",
                    "offsetInBeginSection": 937,
                    "offsetInEndSection": 1007,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "Treatment was well tolerated with few grade 3 or 4 toxicities.",
                    "offsetInBeginSection": 1261,
                    "offsetInEndSection": 1323,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d29571d1251d03b000018",
            "body": "What effect does azeliragon have on RAGE?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27612394"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                    "text": "Blockade of RAGE by antibodies anti-RAGE, TTP488 (azeliragon), or rRAGE prevents or limits the deleterious effect of AGEs.",
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 738,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                    "text": "RAGE engagement by ligands AGE, \u03b2-amyloid peptide, and S100 calgranulin induces a stimulation of NADPH oxidase, reactive oxygen intermediate formation, NF\u03baB activation and gene transcription.",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 483,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                    "text": "Advanced glycation end products (AGE) resulted from a reaction between free amino group of proteins and carbohydrates.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                    "text": "AGEs bind to a cellular receptor RAGE.",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 289,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                    "text": "This cascade of reaction leads to an inflammatory reaction responsible for alteration of microvessels in the retina and the kidney.",
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 615,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                    "text": "Alternatively AGEs can be produced by glycolysis and oxidation.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                    "text": "This reaction is followed by oxidation and molecular rearrangement.",
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9e2386de7cb99d40000004",
            "body": "What is the drug forxiga used for?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                "http://www.ncbi.nlm.nih.gov/pubmed/24030968"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "This study explores the molecular interactions between AChE and SGLT2 with a new US Food and Drug Administration approved antidiabetic drug Forxiga (dapagliflozin) to explore a possible link between the treatments of AD and diabetes.",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "Hence, dapagliflozin might act as a potent dual inhibitor of SGLT2 and AChE.",
                    "offsetInBeginSection": 1088,
                    "offsetInEndSection": 1164,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "Sodium glucose co-transporter 2 (SGLT2) is one of the best targets in the treatment of diabetes, whereas acetylcholinesterase (AChE) has long been regarded as a therapeutic target for AD.",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 459,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "Hydrophobic and cation-\u03c0 interactions play an important role in the correct positioning of dapagliflozin within the catalytic site (CAS) of SGLT2 and AChE enzymes to permit docking.",
                    "offsetInBeginSection": 743,
                    "offsetInEndSection": 925,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "Numerous clinical and epidemiological studies have provided direct evidence to strengthen the link between type 2 diabetes (T2D) and Alzheimer's disease (AD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "The results described herein may form the basis of future dual therapy against diabetes-associated neurological disorders.",
                    "offsetInBeginSection": 1165,
                    "offsetInEndSection": 1287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968",
                    "text": "Dapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.",
                    "offsetInBeginSection": 601,
                    "offsetInEndSection": 742,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968",
                    "text": "Here, we review the evidence for the use of dapagliflozin in the management of type 2 diabetes mellitus.",
                    "offsetInBeginSection": 1241,
                    "offsetInEndSection": 1345,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968",
                    "text": "Management of diabetes includes patient support and education; addressing symptoms; lifestyle modification; targeting associated risk factors for cardiovascular disease; and surveillance for, and management of, complications including treatment-related hypoglycaemia.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 600,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968",
                    "text": "The company's advertising materials claim that dapagliflozin provides a \"novel method of controlling excess glucose\" with \"secondary benefit of weight loss\".",
                    "offsetInBeginSection": 1083,
                    "offsetInEndSection": 1240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a761ac3aacfb9cd4c000002",
            "body": "What is the most common feature of the Doege\u2013Potter syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17130256",
                "http://www.ncbi.nlm.nih.gov/pubmed/24793812",
                "http://www.ncbi.nlm.nih.gov/pubmed/7712654",
                "http://www.ncbi.nlm.nih.gov/pubmed/21510007",
                "http://www.ncbi.nlm.nih.gov/pubmed/23806618",
                "http://www.ncbi.nlm.nih.gov/pubmed/27197926",
                "http://www.ncbi.nlm.nih.gov/pubmed/17896212",
                "http://www.ncbi.nlm.nih.gov/pubmed/8745978",
                "http://www.ncbi.nlm.nih.gov/pubmed/24745007",
                "http://www.ncbi.nlm.nih.gov/pubmed/17159512"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256",
                    "text": "Metabolic syndrome, characterized by truncal obesity, hypertriglyceridemia, elevated BP, and insulin resistance, is recognized increasingly as a major risk factor for kidney disease and also is a common feature of patients who are on dialysis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 243,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256",
                    "text": "One feature that is common to patients with metabolic syndrome is an elevated uric acid.",
                    "offsetInBeginSection": 244,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17130256",
                    "text": "It is proposed that fructose- and purine-rich foods that have in common the raising of uric acid may have a role in the epidemic of metabolic syndrome and renal disease that is occurring throughout the world.",
                    "offsetInBeginSection": 812,
                    "offsetInEndSection": 1020,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24793812",
                    "text": "This review discusses the some of the more frequent, recurrent karyotypic abnormalities in which CDH is a feature, including 15q26, 8p23.1 and 4p16.3 deletions and tetrasomy 12p (Pallister-Killian syndrome), together with some of the syndromes in which CDH is a relatively common feature, including Fryns syndrome, Matthew-Wood syndrome, overgrowth syndromes and Donnai-Barrow syndrome.",
                    "offsetInBeginSection": 277,
                    "offsetInEndSection": 663,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7712654",
                    "text": "Malignant transformations are a common feature of this syndrome and have been reported in approximately 30% of reported cases, with chondrosarcomas being the most common.",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 362,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23806618",
                    "text": "Similar phenotypes result from mutation of oral-facial-digital syndrome 1 (Ofd1), suggesting that aberrant transcription of Fgf8 is a common feature of ciliopathies.",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 774,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27197926",
                    "text": "Chromosome 22q11.2 deletion syndrome is common and presents with a range of clinical features from cardiac malformations to hypocalcemia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27197926",
                    "text": "Laryngeal anomalies are not a common feature of this syndrome.",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17896212",
                    "text": "The study confirms that dysfluencies are a common feature of the speech of individuals with fragile X syndrome but also indicates that the dysfluency pattern displayed is not identical to developmental stuttering.",
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8745978",
                    "text": "Thrombocytopenia is a common feature in ICU patients which occurs usually in case of infection or septic shock.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d2a8f1d1251d03b000019",
            "body": "What is INCB3619?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16843264",
                "http://www.ncbi.nlm.nih.gov/pubmed/17363546",
                "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                "http://www.ncbi.nlm.nih.gov/pubmed/27489286"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264",
                    "text": "A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin.",
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 532,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264",
                    "text": "In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC.",
                    "offsetInBeginSection": 533,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264",
                    "text": "We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17363546",
                    "text": "RESULTS INCB3619 was identified as a representative selective, potent, orally bioavailable small-molecule inhibitor of a subset of ADAM proteases that block shedding of ErbB ligands.",
                    "offsetInBeginSection": 956,
                    "offsetInEndSection": 1138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17363546",
                    "text": "Further, INCB3619 synergized with clinically relevant cancer therapeutics and showed no overt or compounding toxicities, including fibroplasia, the dose-limiting toxicity associated with broad-spectrum matrix metalloprotease inhibitors.",
                    "offsetInBeginSection": 1334,
                    "offsetInEndSection": 1570,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells.",
                    "offsetInBeginSection": 1288,
                    "offsetInEndSection": 1483,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "Use of ErbB-specific antibodies to the receptors (Herceptin or Erbitux) or ErbB-specific small-molecule inhibitors of the receptor tyrosine kinase activity (Iressa or Tarceva) has shown clinical efficacy in several solid tumors.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "This study has shown that addition of INCB3619, a potent inhibitor of ADAM10 and ADAM17, reduces in vitro HER-2/neu and amphiregulin shedding, confirming that it interferes with both HER-2/neu and EGFR ligand cleavage.",
                    "offsetInBeginSection": 1069,
                    "offsetInEndSection": 1287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "ADAM 10 is the main sheddase of epidermal growth factor (EGF) and HER-2/neu cleavage, whereas ADAM17 is required for cleavage of additional EGF receptor (EGFR) ligands (transforming growth factor-alpha, amphiregulin, heregulin, heparin binding EGF-like ligand).",
                    "offsetInBeginSection": 807,
                    "offsetInEndSection": 1068,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "This sheddase activity is attributed to the ADAM (a disintegrin and metalloprotease) family of proteins.",
                    "offsetInBeginSection": 702,
                    "offsetInEndSection": 806,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa4faaed6d6b54f7900000b",
            "body": "Is Citrobacter rodentium pathogenic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19897651",
                "http://www.ncbi.nlm.nih.gov/pubmed/25088150",
                "http://www.ncbi.nlm.nih.gov/pubmed/16309456",
                "http://www.ncbi.nlm.nih.gov/pubmed/23462619",
                "http://www.ncbi.nlm.nih.gov/pubmed/24358033",
                "http://www.ncbi.nlm.nih.gov/pubmed/24831469",
                "http://www.ncbi.nlm.nih.gov/pubmed/11101562",
                "http://www.ncbi.nlm.nih.gov/pubmed/17557113",
                "http://www.ncbi.nlm.nih.gov/pubmed/22144475",
                "http://www.ncbi.nlm.nih.gov/pubmed/25624355"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651",
                    "text": "Citrobacter rodentium (formally Citrobacter freundii biotype 4280) is a highly infectious pathogen that causes colitis and transmissible colonic hyperplasia in mice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651",
                    "text": "In common with enteropathogenic and enterohemorrhagic Escherichia coli (EPEC and EHEC, respectively), C. rodentium exploits a type III secretion system (T3SS) to induce attaching and effacing (A/E) lesions that are essential for virulence.",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25088150",
                    "text": "Citrobacter rodentium is a mucosal pathogen of mice that shares several pathogenic mechanisms with enteropathogenic Escherichia coli (EPEC) and enterohaemorrhagic E. coli (EHEC), which are two clinically important human gastrointestinal pathogens.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16309456",
                    "text": "This classical genome organization is well illustrated by a group of extracellular enteric pathogens, which includes enteropathogenic Escherichia coli (EPEC), enterohaemorrhagic E. coli (EHEC) and Citrobacter rodentium, all of which use attaching and effacing (A/E) lesion formation as a major mechanism of tissue targeting and infection.",
                    "offsetInBeginSection": 420,
                    "offsetInEndSection": 758,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23462619",
                    "text": "C. rodentium is a gram negative, murine specific bacterial pathogen that is closely related to the clinically important human pathogens enteropathogenic E. coli and enterohemorrhagic E. coli.",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 379,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24358033",
                    "text": "Citrobacter rodentium (C. rodentium) is a member of the family of enteropathogens that provide an excellent in vivo model to investigate the host-pathogen interactions in real-time.",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24831469",
                    "text": "Citrobacter rodentium infection is a murine model of pathogenic Escherichia coli infection that allows investigation of the cellular and molecular mechanisms involved in host-protective immunity and bacterial-induced intestinal inflammation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 241,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557113",
                    "text": "The bacterial mouse pathogen Citrobacter rodentium causes attaching and effacing (AE) lesions in the same manner as pathogenic Escherichia coli, and is an important model for this mode of pathogenesis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22144475",
                    "text": "The attaching and effacing mouse pathogen Citrobacter rodentium associates intimately with the intestinal epithelium, and infections result in acute colitis.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 325,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624355",
                    "text": "A well-studied example is the RegA regulon of the enteric pathogen Citrobacter rodentium.",
                    "offsetInBeginSection": 207,
                    "offsetInEndSection": 296,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a679e8cb750ff4455000006",
            "body": "Milwaukee protocol was tested for treatment of which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18465396",
                "http://www.ncbi.nlm.nih.gov/pubmed/26639059",
                "http://www.ncbi.nlm.nih.gov/pubmed/21208030",
                "http://www.ncbi.nlm.nih.gov/pubmed/25956434",
                "http://www.ncbi.nlm.nih.gov/pubmed/18305449",
                "http://www.ncbi.nlm.nih.gov/pubmed/23369672",
                "http://www.ncbi.nlm.nih.gov/pubmed/19545499",
                "http://www.ncbi.nlm.nih.gov/pubmed/11890620",
                "http://www.ncbi.nlm.nih.gov/pubmed/20881935",
                "http://www.ncbi.nlm.nih.gov/pubmed/24708671"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396",
                    "text": "RESULTS Milwaukee brace 23-hours wearing protocol was most effective for the treatment of adolescent idiopathic scoliosis.",
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396",
                    "text": "CONCLUSION With part-time wearing protocol, the Milwaukee brace can survive today as a treatment option for idiopathic scoliosis with thoracic curve or double curve.",
                    "offsetInBeginSection": 808,
                    "offsetInEndSection": 973,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059",
                    "text": "Therapies suggested in the Milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 550,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208030",
                    "text": "Milwaukee brace 23-hours wearing protocol was most effective for the treatment of adolescent idiopathic scoliosis.",
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956434",
                    "text": "We report a case of a patient with paralytic rabies who survived after being treated with what is now known as Milwaukee protocol.",
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 220,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18305449",
                    "text": "This report summarizes the clinical course of disease in that patient, who was treated using the Milwaukee Protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 403,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20881935",
                    "text": "Earlier that day, an infectious disease physician in Virginia had contacted CDC requesting confirmatory diagnostic testing and reported initiating treatment with the Milwaukee protocol after consultation with staff at the Medical College of Wisconsin.",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 378,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24708671",
                    "text": "BACKGROUND Human rabies infection continues to be a significant public health burden globally, and is occasionally imported to high income settings where the Milwaukee Protocol for intensive care management has recently been employed, with limited success in improving survival.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24708671",
                    "text": "Access to molecular diagnostics, pre- and post-mortem, and documentation of pathophysiological responses while using the Milwaukee protocol, can add useful insights for the future of rabies management.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 480,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24708671",
                    "text": "Management guided by the Milwaukee protocol is feasible within well-resourced intensive care units, but its role in improving outcome for canine-derived rabies remains theoretical.",
                    "offsetInBeginSection": 2096,
                    "offsetInEndSection": 2276,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d2dd21d1251d03b00001a",
            "body": "What do the trispecific HIV antibodies target?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28931639",
                "http://www.ncbi.nlm.nih.gov/pubmed/26176328"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639",
                    "text": "We engineered trispecific antibodies (Abs) that allow a single molecule to interact with three independent HIV-1 envelope determinants: the CD4 binding site, the membrane-proximal external region (MPER), and the V1V2 glycan site.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 404,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639",
                    "text": "The development of an effective AIDS vaccine has been challenging because of viral genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639",
                    "text": "Trispecific Abs thus constitute a platform to engage multiple therapeutic targets through a single protein, and they may be applicable for treatment of diverse diseases, including infections, cancer, and autoimmunity.",
                    "offsetInBeginSection": 709,
                    "offsetInEndSection": 926,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639",
                    "text": "Trispecific Abs exhibited higher potency and breadth than any previously described single bnAb, showed pharmacokinetics similar to those of human bnAbs, and conferred complete immunity against a mixture of simian-human immunodeficiency\u00a0viruses (SHIVs) in nonhuman primates, in contrast to single bnAbs.",
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 708,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328",
                    "text": "To test whether simultaneous targeting of EphA2, EphA4, and EphB4 would be an effective approach to cancer therapy, we generated a recombinant trispecific antibody using the variable domain genes of anti-EphA2, anti-EphA4, and anti-EphB4 monoclonal antibodies.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328",
                    "text": "Targeting Eph (erythropoietin producing hepatoma) receptors with monoclonal antibodies is being explored as therapy for several types of cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328",
                    "text": "These results indicate that simultaneous blockade of EphA2, EphA4, and EphB4 could be an attractive approach to cancer therapy.",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328",
                    "text": "Here we demonstrate that the trispecific antibody is expressed at high levels by mammalian cells, monodispersed in solution, thermostable, capable of simultaneously binding the three receptors, and able to activate the three targets effectively as evidenced by receptor internalization and degradation both in vitro and in vivo.",
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 897,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328",
                    "text": "Furthermore, pharmacokinetic analysis using tumor-bearing nude mice showed that the trispecific antibody remains in the circulation similarly to its respective parental antibodies.",
                    "offsetInBeginSection": 898,
                    "offsetInEndSection": 1078,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328",
                    "text": "A multidisciplinary approach combining biochemical, biophysical, and cellular-based assays was used to characterize the trispecific antibody in vitro and in vivo.",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 568,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa6c800d6d6b54f79000012",
            "body": "What is liquid liquid phase transition?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16774199",
                "http://www.ncbi.nlm.nih.gov/pubmed/10646596",
                "http://www.ncbi.nlm.nih.gov/pubmed/26165855",
                "http://www.ncbi.nlm.nih.gov/pubmed/22069236",
                "http://www.ncbi.nlm.nih.gov/pubmed/16095377",
                "http://www.ncbi.nlm.nih.gov/pubmed/16942294",
                "http://www.ncbi.nlm.nih.gov/pubmed/21054046",
                "http://www.ncbi.nlm.nih.gov/pubmed/11497749",
                "http://www.ncbi.nlm.nih.gov/pubmed/11102052",
                "http://www.ncbi.nlm.nih.gov/pubmed/19566187"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774199",
                    "text": "Furthermore, liquid water has a liquid-liquid phase transition near the middle of the normal liquid range.",
                    "offsetInBeginSection": 1658,
                    "offsetInEndSection": 1764,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10646596",
                    "text": "These features are strongly suggestive of a first-order liquid-liquid phase transition.",
                    "offsetInBeginSection": 1086,
                    "offsetInEndSection": 1173,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26165855",
                    "text": "Liquid-liquid transition, a phase transition of one liquid phase to another with the same composition, provides a key opportunity for investigating the relationship between liquid structures and dynamics.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22069236",
                    "text": "The temperature of the solid-to-liquid-crystalline phase transition seems mostly unaffected by the confinement, whereas the temperature of the liquid-crystalline-to-liquid phase transition is depressed for smaller pore sizes.",
                    "offsetInBeginSection": 353,
                    "offsetInEndSection": 578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22069236",
                    "text": "The contact layer exhibits a phase transition at a temperature 30 K lower than the solid-to-liquid-crystalline phase transition observed for the neat ILC.",
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 802,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16942294",
                    "text": "As an example the glacial phase formation and the first-order liquid-liquid phase transition in triphenyl phosphate are considered and discussed.",
                    "offsetInBeginSection": 889,
                    "offsetInEndSection": 1034,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21054046",
                    "text": "We report the first observation of the liquid-glass transition by a first-order polyamorphous phase transition from the equilibrium stable liquid phase.",
                    "offsetInBeginSection": 341,
                    "offsetInEndSection": 493,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21054046",
                    "text": "Under cooling, a liquid can undergo a transition to the glassy state either as a result of a continuous slowing down or by a first-order polyamorphous phase transition.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11102052",
                    "text": "Our model suggests a new possibility that (i) even an ordinary molecular liquid can have a hidden liquid-liquid phase transition and (ii) it may be the origin of a second amorphous phase (e.g., \"glacial phase\") and critical-like, large-scale fluctuations (\"Fischer clusters\") observed in supercooled molecular liquids.",
                    "offsetInBeginSection": 626,
                    "offsetInEndSection": 944,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19566187",
                    "text": "Therefore, the inference that liquid-liquid phase transition in supercooled liquid Si is a fragile-to-strong transition is unjustifiable.",
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 736,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70ec6899e2c3af2600000c",
            "body": "Is pregabalin effective for sciatica?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23845078",
                "http://www.ncbi.nlm.nih.gov/pubmed/28328324",
                "http://www.ncbi.nlm.nih.gov/pubmed/26633090",
                "http://www.ncbi.nlm.nih.gov/pubmed/26818733",
                "http://www.ncbi.nlm.nih.gov/pubmed/15067505"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078",
                    "text": "The impact of this research may allow the future development of a cost-effective conservative treatment strategy for patients with sciatica.",
                    "offsetInBeginSection": 2042,
                    "offsetInEndSection": 2182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078",
                    "text": "DISCUSSION This study will establish the efficacy of pregabalin in reducing leg pain intensity in patients with sciatica and provide important information regarding the effect of pregabalin treatment on disability and quality of life.",
                    "offsetInBeginSection": 1807,
                    "offsetInEndSection": 2041,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078",
                    "text": "While this condition may cause significant suffering for the individual, the lack of evidence supporting effective treatments for sciatica makes clinical management difficult.",
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 365,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324",
                    "text": "Pregabalin is effective in the treatment of some types of neuropathic pain.",
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324",
                    "text": "CONCLUSIONS Treatment with pregabalin did not significantly reduce the intensity of leg pain associated with sciatica and did not significantly improve other outcomes, as compared with placebo, over the course of 8 weeks.",
                    "offsetInBeginSection": 1877,
                    "offsetInEndSection": 2098,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324",
                    "text": "METHODS We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in patients with sciatica.",
                    "offsetInBeginSection": 247,
                    "offsetInEndSection": 361,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26633090",
                    "text": "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26818733",
                    "text": "BACKGROUND Sciatica is a severe, disabling condition that lacks high quality evidence for effective treatment strategies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15067505",
                    "text": "In neuropathic pain, different therapeutic approaches are effective, i.e., antidepressants such as amitriptyline and anticonvulsants such as gabapentin, carbamazepine, and pregabalin.",
                    "offsetInBeginSection": 883,
                    "offsetInEndSection": 1066,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15067505",
                    "text": "Current analgesic therapeutic first-line strategies for chronic sciatica rely on NSAIDs that are known to relieve nociceptive pain only.",
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 882,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d30241d1251d03b00001b",
            "body": "Can gas vesicles be detected by ultrasound?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24633522",
                "http://www.ncbi.nlm.nih.gov/pubmed/27351374",
                "http://www.ncbi.nlm.nih.gov/pubmed/28880278",
                "http://www.ncbi.nlm.nih.gov/pubmed/28258771",
                "http://www.ncbi.nlm.nih.gov/pubmed/28889941"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522",
                    "text": "We show that gas vesicles produce stable ultrasound contrast that is readily detected in vitro and in vivo, that their genetically encoded physical properties enable multiple modes of imaging, and that contrast enhancement through aggregation permits their use as molecular biosensors.",
                    "offsetInBeginSection": 531,
                    "offsetInEndSection": 816,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522",
                    "text": "Gas vesicles are gas-filled protein-shelled compartments with typical widths of 45-250 nm and lengths of 100-600 nm that exclude water and are permeable to gas.",
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 530,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374",
                    "text": "Gas vesicles-genetically encoded protein nanostructures isolated from buoyant photosynthetic microbes-have recently been identified as nanoscale reporters for ultrasound.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 357,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374",
                    "text": "Here, we demonstrate that genetic engineering of gas vesicles results in nanostructures with new mechanical, acoustic, surface, and functional properties to enable harmonic, multiplexed, and multimodal ultrasound imaging as well as cell-specific molecular targeting.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 1040,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374",
                    "text": "Furthermore, as a genetically encoded material, gas vesicles present the possibility that the nanoscale mechanical, acoustic, and targeting properties of an imaging agent can be engineered at the level of its constituent proteins.",
                    "offsetInBeginSection": 543,
                    "offsetInEndSection": 773,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28880278",
                    "text": "Gas vesicles (GVs) are a unique class of gas-filled protein nanostructures that are detectable at subnanomolar concentrations and whose physical properties allow them to serve as highly sensitive imaging agents for ultrasound and MRI.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258771",
                    "text": "Gas vesicles (GVs) are a new and unique class of biologically derived ultrasound contrast agents with sub-micron size whose acoustic properties have not been fully elucidated.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258771",
                    "text": "We illustrate that gas vesicles behave non-linearly when exposed to ultrasound at incident pressure ranging from 160\u00a0kPa to the collapse pressure and generate second harmonic amplitudes of -2 to -6\u00a0dB below the fundamental in media with viscosities ranging from 0.89 to 8\u00a0mPa\u00b7s.",
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 801,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258771",
                    "text": "In this study, we investigated the acoustic collapse pressure and behavior of Halobacterium salinarum gas vesicles at transmit center frequencies ranging from 12.5 to 27.5\u00a0MHz.",
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 353,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28889941",
                    "text": "Recently, biogenic gas vesicles (GVs), naturally formed by cyanobacteria and haloarchaea, have exhibited great potential as an ultrasound molecular imaging probe with a much smaller size (\u223c100\u00a0nm) and improved imaging contrast.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa82388fcf4565872000001",
            "body": "Which proteins are regulated by Nrf2?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20399915",
                "http://www.ncbi.nlm.nih.gov/pubmed/15601839",
                "http://www.ncbi.nlm.nih.gov/pubmed/25827424",
                "http://www.ncbi.nlm.nih.gov/pubmed/20427290",
                "http://www.ncbi.nlm.nih.gov/pubmed/21812759",
                "http://www.ncbi.nlm.nih.gov/pubmed/22641035",
                "http://www.ncbi.nlm.nih.gov/pubmed/20410673",
                "http://www.ncbi.nlm.nih.gov/pubmed/27816475",
                "http://www.ncbi.nlm.nih.gov/pubmed/24859727",
                "http://www.ncbi.nlm.nih.gov/pubmed/22814021"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20399915",
                    "text": "Correlative network analysis (MetaCore) identified two predominant groups of Nrf2-regulated proteins.",
                    "offsetInBeginSection": 807,
                    "offsetInEndSection": 908,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15601839",
                    "text": "Here we report that the human BTB-Kelch protein Keap1, a negative regulator of the antioxidative transcription factor Nrf2, binds to CUL3 and Nrf2 via its BTB and Kelch domains, respectively.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 910,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827424",
                    "text": "One such master regulator, the redox sensitive transcription factor NF E2 Related Factor 2 (NRF2), controls the expression of cellular defense genes including those encoding intracellular redox-balancing proteins involved in glutathione (GSH) synthesis.",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427290",
                    "text": "Mammalian cells respond to this damage by increased transcription of cytoprotective phase II genes, which are regulated by NRF2.",
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759",
                    "text": "The ARE binds different bZIP (basic-region leucine zipper) transcription factors, most notably Nrf2 (nuclear factor-erythroid 2-related factor 2) that functions as a transcriptional activator via heterodimerization with small Maf proteins.",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 567,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759",
                    "text": "In the present study, we have demonstrated that BACH1 itself is regulated by Nrf2 as it is induced by Nrf2 overexpression and by Nrf2-activating agents in an Nrf2-dependent manner.",
                    "offsetInBeginSection": 991,
                    "offsetInEndSection": 1171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22641035",
                    "text": "As systems-level examples of NRF2-related signaling we identified regulatory loops of NRF2 interacting proteins (e.g., JNK1 and CBP) and a fine-tuned regulatory system, where 35 TFs regulated by NRF2 influence 63 miRNAs that down-regulate NRF2.",
                    "offsetInBeginSection": 404,
                    "offsetInEndSection": 648,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20410673",
                    "text": "The transcription factor nuclear erythroid-derived 2-related factor 2 (Nrf2) regulates expression of genes encoding antioxidant proteins involved in cellular redox homeostasis, while gamma-ray irradiation is known to induce reactive oxygen species in vivo.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859727",
                    "text": "Six proteins were regulated at both basal and inducible levels exhibiting the largest dynamic range of Nrf2 regulation: cytochrome P4502A5 (CYP2A5; 17.2-fold), glutathione-S-transferase-Mu 3 (GSTM3; 6.4-fold), glutathione-S-transferase Mu 1 (GSTM1; 5.9-fold), ectonucleoside-triphosphate diphosphohydrolase (ENTPD5; 4.6-fold), UDP-glucose-6-dehydrogenase (UDPGDH; 4.1-fold) and epoxide hydrolase (EPHX1; 3.0-fold).",
                    "offsetInBeginSection": 764,
                    "offsetInEndSection": 1178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24859727",
                    "text": "At a dose shown to evoke maximal Nrf2 induction in the liver, CDDO-me appeared highly selective for known Nrf2-regulated proteins.",
                    "offsetInBeginSection": 2531,
                    "offsetInEndSection": 2661,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d31711d1251d03b00001c",
            "body": "What is the approximate size of gas vesicles?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19007418",
                "http://www.ncbi.nlm.nih.gov/pubmed/807555",
                "http://www.ncbi.nlm.nih.gov/pubmed/3098234",
                "http://www.ncbi.nlm.nih.gov/pubmed/1956294",
                "http://www.ncbi.nlm.nih.gov/pubmed/9573198",
                "http://www.ncbi.nlm.nih.gov/pubmed/3091230",
                "http://www.ncbi.nlm.nih.gov/pubmed/19230840",
                "http://www.ncbi.nlm.nih.gov/pubmed/7683649",
                "http://www.ncbi.nlm.nih.gov/pubmed/26988462",
                "http://www.ncbi.nlm.nih.gov/pubmed/22846397"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418",
                    "text": "salinarum PHH1 and NRC-1 contained 5-20 small gas vesicles arranged in two to three aggregates per cell instead of the 30-80 gas vesicles present under oxic conditions.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418",
                    "text": "salinarum PHH1 and NRC-1 were grown with dimethyl sulphoxide or trimethylamine N-oxid under anoxic conditions the number but not the size of gas vesicles was reduced.",
                    "offsetInBeginSection": 1049,
                    "offsetInEndSection": 1215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3098234",
                    "text": "This corresponds to the size of the repeating unit cell demonstrated by X-ray crystallography of intact gas vesicles.",
                    "offsetInBeginSection": 222,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1956294",
                    "text": "The comparison of the three genomic regions encoding gas vesicles in Halobacterium halobium (p-vac- and c-vac-region) and Haloferax mediterranei (mc-vac-region) indicates high DNA sequence similarity throughout a contiguous sequence of 9 kbp.",
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3091230",
                    "text": "Individual platelet cells contained central spindle-shaped gas vesicles (which together constitute the cell's gas vacuole), intracytoplasmic membrane vesicles (chromatophores), and peripheral sulfur globules.",
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19230840",
                    "text": "The turgor pressure decreases, however, as gas vesicles collapse; this decrease is minimised by calculating the turgor pressure in samples with few of their gas vesicles collapsed.",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 467,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26988462",
                    "text": "At small and intermediate P\u00e9clet (Pe) numbers-the ratio between shear and Brownian forces-the competition between rearrangement, deformation, and break-up favors the growth of micelles and vesicles increasing mean cluster size, which is consistent with a previous numerical study of Janus particles under shear.",
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 745,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26988462",
                    "text": "After this growth micelles dissociate continuously to reach a dilute colloidal \"gas phase\" at Pe \u2248 10 while vesicles dissociate into micelles with high aspect ratio at Pe \u2248 10 and finally break-up into a gas phase at Pe \u2248 30.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26988462",
                    "text": "In the absence of flow, by varying the Janus patch size and the range and strength of the anisotropic interaction potential, Janus colloids form different aggregates such as micelles, wormlike clusters, vesicles and lamellae.",
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22846397",
                    "text": "Various size gene fragments coding for the major outer membrane protein (MOMP), outer membrane complex B (OmcB) and polymorphic outer membrane protein D (PompD) were integrated into and expressed as part of the gas vesicle protein C (gvpC) on the surface of these stable structures.",
                    "offsetInBeginSection": 540,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aacdcf1fcf4565872000009",
            "body": "List BET proteins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26137204"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "The bromodomain and extra-terminal (BET) proteins are epigenetic readers which utilize tandem bromodomains (BRD) modules to recognize and dock themselves on the acetylated lysine tails.",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 495,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "JQ1 is a prototype benzodiazepine molecule and a specific BET inhibitor with antineoplastic activity both in solid tumours and haematological malignancies.",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 982,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "I-BET762 is currently being tested in early phase clinical trials, along with a rapidly growing list of other BET inhibitors.",
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "The BET proteins act as scaffolds for the recruitment of transcription factors and chromatin organizers required in transcription initiation and elongation.",
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 652,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "Post-translational modifications of the nucleosomal histone proteins orchestrate chromatin organization and gene expression in normal and cancer cells.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "Among them, the acetylation of N-terminal histone tails represents the fundamental epigenetic mark of open structure chromatin and active gene transcription.",
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 309,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "Here, we review the development of this novel class of epigenetic drugs, the biology of BET protein inhibition, the emerging evidence from preclinical work and early phase clinical studies and we discuss their potential role in the treatment of haematological malignancies.",
                    "offsetInBeginSection": 1526,
                    "offsetInEndSection": 1799,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "Unlike older epigenetic therapies, the study of BET inhibitors has offered substantial, context-specific, mechanistic insights of their antitumour activity, which will facilitate optimal therapeutic targeting in future.",
                    "offsetInBeginSection": 1306,
                    "offsetInEndSection": 1525,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "The quinolone I-BET151 and the suitable for clinical development I-BET762 benzodiazepine were introduced in parallel with JQ1 and have also shown potent antitumour activity in preclinical studies.",
                    "offsetInBeginSection": 983,
                    "offsetInEndSection": 1179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "The recent discovery of small molecules capable of blocking their lysine-binding pocket is the first paradigm of successful pharmacological inhibition of epigenetic readers.",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 826,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa38f75d6d6b54f79000005",
            "body": "What is host induced gene silencing?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28856645",
                "http://www.ncbi.nlm.nih.gov/pubmed/21818318",
                "http://www.ncbi.nlm.nih.gov/pubmed/21112837",
                "http://www.ncbi.nlm.nih.gov/pubmed/19573239",
                "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                "http://www.ncbi.nlm.nih.gov/pubmed/22678572",
                "http://www.ncbi.nlm.nih.gov/pubmed/21533687",
                "http://www.ncbi.nlm.nih.gov/pubmed/19547658",
                "http://www.ncbi.nlm.nih.gov/pubmed/25057444",
                "http://www.ncbi.nlm.nih.gov/pubmed/22678574"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645",
                    "text": "We utilized Barley stripe mosaic virus-mediated virus induced gene silencing (BSMV-VIGS) to induce HIGS of candidate rust fungal genes in the wheat host to determine their role in plant-fungal interactions.",
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645",
                    "text": "Recently, Host-induced gene silencing (HIGS) has emerged as a useful tool to characterize gene function in rust fungi while infecting and growing in host plants.",
                    "offsetInBeginSection": 987,
                    "offsetInEndSection": 1148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19573239",
                    "text": "We demonstrate its ability to silence nuclear genes including ribulose bisphosphate carboxylase small subunit (rbcS), transketolase, the sulfur allele of magnesium chelatase (ChlI), and two homeotic transcription factors in spinach or tomato by generating gene-specific knock-down phenotypes.",
                    "offsetInBeginSection": 816,
                    "offsetInEndSection": 1108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                    "text": "Planta-generated silencing of targeted genes inside biotrophic pathogens can be achieved by expression of M.oryzae-derived gene fragments in the BMV-mediated gene silencing system, a technique termed host-induced gene silencing (HIGS).",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 746,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                    "text": "Brome mosaic virus (BMV)-induced RNA interference (RNAi) has emerged as a useful tool to study host-resistance genes for rice blast protection.",
                    "offsetInBeginSection": 367,
                    "offsetInEndSection": 510,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                    "text": "Systemic generation of fungal gene-specific small interfering RNA (siRNA) molecules induced by inoculation of BMV viral vectors inhibited disease development and reduced the transcription of targeted fungal genes after subsequent M.oryzae inoculation.",
                    "offsetInBeginSection": 902,
                    "offsetInEndSection": 1153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19547658",
                    "text": "Virus-induced gene silencing (VIGS) is one of the reverse genetics tools for analysis of gene function that uses viral vectors carrying a target gene fragment to produce dsRNA which trigger RNA-mediated gene silencing.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19547658",
                    "text": "For instance, Barley stripe mosaic virus (BSMV)-mediated VIGS allows silencing of barley and wheat genes.",
                    "offsetInBeginSection": 1249,
                    "offsetInEndSection": 1354,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678574",
                    "text": "When a recombinant viral vector (VIGS vector), carrying a host-derived target gene sequence, infects a plant, viral double-stranded RNAs are synthesized leading to the activation of the antiviral RNA silencing pathway and the subsequent knockdown of the endogenous host gene.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 727,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22678574",
                    "text": "One of the most efficient approaches of initiating PTGS is through virus-induced gene silencing (VIGS).",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 451,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aad4b37fcf456587200000a",
            "body": "What is the proteoform?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28968100",
                "http://www.ncbi.nlm.nih.gov/pubmed/27451424",
                "http://www.ncbi.nlm.nih.gov/pubmed/26941048",
                "http://www.ncbi.nlm.nih.gov/pubmed/27291504",
                "http://www.ncbi.nlm.nih.gov/pubmed/28003265",
                "http://www.ncbi.nlm.nih.gov/pubmed/24922115",
                "http://www.ncbi.nlm.nih.gov/pubmed/28453668",
                "http://www.ncbi.nlm.nih.gov/pubmed/26133526",
                "http://www.ncbi.nlm.nih.gov/pubmed/28491292",
                "http://www.ncbi.nlm.nih.gov/pubmed/29165996"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100",
                    "text": "A proteoform family is a group of related molecular forms of a protein (proteoforms) derived from the same gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100",
                    "text": "In the present study, this strategy is extended by utilizing a global PTM discovery database and is applied to the widely studied model organism Escherichia coli, providing the most comprehensive elucidation of E. coli proteoforms and proteoform families to date.",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 1136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451424",
                    "text": "Discovery of STAT1, WARS, MX1, and HSPB1 proteoform regulation by human respiratory syncytial virus highlighted the impact of the profiling strategy.",
                    "offsetInBeginSection": 1557,
                    "offsetInEndSection": 1706,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941048",
                    "text": "We present here a powerful new strategy for the identification of proteoforms and the elucidation of proteoform families (groups of related proteoforms) from the experimental determination of the accurate proteoform mass and number of lysine residues contained.",
                    "offsetInBeginSection": 381,
                    "offsetInEndSection": 642,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941048",
                    "text": "Accurate proteoform masses are determined by standard LC-MS analysis of undigested protein mixtures in an Orbitrap mass spectrometer, and the lysine count is determined using the NeuCode isotopic tagging method.",
                    "offsetInBeginSection": 643,
                    "offsetInEndSection": 854,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291504",
                    "text": "In top-down proteomics, proteoform identification is often performed by searching tandem mass spectra against a protein sequence database that contains only one reference protein sequence for each gene or transcript variant in a proteome.",
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291504",
                    "text": "Proteoform characterization is to identify and localize PSAs in a proteoform.",
                    "offsetInBeginSection": 752,
                    "offsetInEndSection": 829,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28003265",
                    "text": "We developed TopMG, a mass graph-based software tool for proteoform identification by top-down mass spectrometry.",
                    "offsetInBeginSection": 996,
                    "offsetInEndSection": 1109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28003265",
                    "text": "Proteoform identification is essential to mapping proteoforms to their biological functions as well as discovering novel proteoforms and new protein functions.",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 509,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453668",
                    "text": "We developed TopMG, a mass graph-based software tool for proteoform identification by top-down mass spectrometry.",
                    "offsetInBeginSection": 996,
                    "offsetInEndSection": 1109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa393b3d6d6b54f79000006",
            "body": "What does the Ribosome-bound Quality Control complex do?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28298488",
                "http://www.ncbi.nlm.nih.gov/pubmed/28528489",
                "http://www.ncbi.nlm.nih.gov/pubmed/23178123",
                "http://www.ncbi.nlm.nih.gov/pubmed/25578875",
                "http://www.ncbi.nlm.nih.gov/pubmed/23007158",
                "http://www.ncbi.nlm.nih.gov/pubmed/27129255"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488",
                    "text": "In eukaryotes, the ribosome-bound quality control (RQC) complex detects aberrant nascent peptides that remain stalled in 60S ribosomal particles due to a dysfunction in translation termination.",
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28528489",
                    "text": "Among these processes, translational protein quality control is performed by the Ribosome-bound Quality Control complex (RQC), which recognizes nascent peptides translated from aberrant mRNAs, polyubiquitylates these aberrant peptides, extracts them from the stalled 60S subunit and finally escorts them to the proteasome for degradation.",
                    "offsetInBeginSection": 226,
                    "offsetInEndSection": 564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23178123",
                    "text": "These included disruption of a ribosome-bound complex we named the Ribosome Quality Control Complex (RQC) comprising the Ltn1 E3 ubiquitin ligase, two highly conserved but poorly characterized proteins (Tae2 and Rqc1), and Cdc48 and its cofactors.",
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 586,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25578875",
                    "text": "Structural and mutational analyses showed that ribosome-bound NEMF recruits and stabilizes Listerin's N-terminal domain, while Listerin's C-terminal RWD domain directly contacts the ribosome to position the adjacent ligase domain near the nascent polypeptide exit tunnel.",
                    "offsetInBeginSection": 597,
                    "offsetInEndSection": 868,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25578875",
                    "text": "During ribosome-associated quality control, stalled ribosomes are split into subunits and the 60S-housed nascent polypeptides are poly-ubiquitinated by Listerin.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25578875",
                    "text": "The 3.6\u00a0\u00c5 cryo-EM structure of a nascent chain-containing 60S-Listerin-NEMF complex revealed that NEMF makes multiple simultaneous contacts with 60S and peptidyl-tRNA to sense nascent chain occupancy.",
                    "offsetInBeginSection": 394,
                    "offsetInEndSection": 596,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25578875",
                    "text": "Thus, highly specific nascent chain targeting by Listerin is imparted by the avidity gained from a multivalent network of context-specific individually weak interactions, highlighting a new principle of client recognition during protein quality control.",
                    "offsetInBeginSection": 869,
                    "offsetInEndSection": 1122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23007158",
                    "text": "Here we show that the ribosome-bound chaperone system consisting of the ribosome-associated complex (RAC) and the Hsp70 homolog Ssb is required to stabilize translationally repressed ribosome-polylysine protein complexes, without affecting the folding or the degradation of polylysine proteins.",
                    "offsetInBeginSection": 688,
                    "offsetInEndSection": 982,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23007158",
                    "text": "Nonstop mRNA degradation depends on Ski7 and the exosome; nonstop protein degradation depends on the ribosome-bound E3 ligase Ltn1 and the proteasome.",
                    "offsetInBeginSection": 425,
                    "offsetInEndSection": 575,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27129255",
                    "text": "Stalled ribosomes are dissociated, aberrant mRNAs are degraded by the cytoplasmic exosome, and the nascent peptides remaining in stalled 60S exit tunnels are detected by the ribosome-bound quality control complex (RQC) composed of Ltn1, Rqc1, Rqc2, and Cdc48.",
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 601,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}
